The role of Grb2 in FGFR2IIIc-mediated early signalling complexes by Lin, C.-C.
1 
 
 
UNIVERSITY COLLEGE LONDON 
Research Department of Structural and Molecular Biology 
 
 
 
 
 
 
The role of Grb2 in FGFR2IIIc-mediated 
early signalling complexes 
 
 
 
Chi-Chuan Lin 
 
 
September 2010 
 
 
 
 
 
Thesis submitted for award of the degree of Doctor of Philosophy by the 
University College London 
 
 
 
 
 
Supervisor: Professor John E. Ladbury 
 
2 
 
Abstract 
 
Receptor tyrosine kinases (RTKs) regulate cellular processes by undergoing 
autophosphorylation on their tyrosine residues upon ligand binding. Phosphotyrosine residues 
also provide binding sites for adaptor protein binding. Grb2 has been shown to play a role in 
RTK pathways by recruiting other signalling proteins. Previously we showed the direct 
binding of Grb2 SH3 domain to the last 15 residues of FGFR2 C-terminal tail. In the present 
study, it is demonstrated that the direct binding of full-length Grb2 to FGFR2 cytoplasmic 
domain is a 2:1 binding event. Importantly, the direct binding may induce an apparent 
FGFR2 conformational change and enhance the FGFR2 phosphorylation. It is also shown 
that the effect of Grb2 on FGFR2 phosphorylation is mediated by the Grb2 C-SH3 domain. In 
addition, both N-SH3 domain and SH2 domain of Grb2 may play a role in the enhancement 
of the C-SH3 domain-mediated FGFR2 phosphorylation by stabilising Grb2 polypeptide 
structure, thus increasing the binding affinity toward FGFR2.  
 
This study also shows Grb2 phosphorylation by FGFR2 mediated by the direct binding of 
Grb2 to the C-terminal of FGFR2. Three phosphorylation sites on Grb2 are identified; in 
vitro FGFR2 phosphorylation and ERK1/2 activation studies suggest that Grb2 
phosphorylation may play a role in regulating FGFR2-mediated signalling pathway. 
Moreover, the interactions between Grb2 and SHP2, as well as FGFR2 and SHP2 have been 
characterised. It is also demonstrated that the binding of Grb2 to FGFR2 can prevent SHP2 
binding to FGFR2, which is important in regulating FGFR2 activation. Finally, a model for 
the recruitment of FGFR2-Grb2-SHP2 signalling complex is proposed, in which Grb2 and 
SHP2 control FGFR2 early signalling complex formation. This study provides new insights 
into the role of Grb2 in the FGFR2-mediated signalling pathway.  
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1.1 Receptor Tyrosine Kinases (RTKs) 
1.1.1 General introduction  
Protein tyrosine kinases (PTKs) play critical roles in signal transduction cascades by 
catalysing the phosphorylation of the tyrosine residues of signalling proteins. Two 
types of protein tyrosine kinases have been identified: non-receptor tyrosine kinases 
and RTKs1, 2. Extracellular signalling molecules such as hormones, neurotransmitters, 
cytokines and growth factors modulate the activities of vertebrate cells (e.g., cell 
growth and differentiation). These extracellular signals are transmitted through a class 
of transmembrane proteins known as receptors. One type of transmembrane receptor 
is the receptor tyrosine kinase (RTK) family, which consists of PTKs that can transfer 
phosphate groups from ATP molecules to tyrosine residues3. The tyrosine kinase 
activity of a receptor is important for its ability to activate signal transduction 
pathways and achieve downstream regulation4 .  
 
1.1.2 Signalling by RTKs  
1.1.2.1 Cellular responses by RTKs 
Upon ligand binding, the tyrosine residues of RTKs undergo autophosphorylation. 
Phosphotyrosine residues in the cytoplasmic domains of the receptor are selective 
binding sites for downstream intracellular signalling proteins. The recognition and 
17 
 
specific binding of intracellular signalling proteins to RTKs result in the formation of 
a signalling complex and activation of the downstream signalling pathway, therefore 
inducing the cellular response to growth factors. The responses of any given receptor 
are usually cell-type specific. For example, activation of the FGF receptor in PC12 
cells leads to neurite outgrowth and cell differentiation, but in NIH3T3 cells, FGF 
receptor activation results in proliferation5. The following sections outline three major 
signalling pathways downstream of activated RTKs. 
 
1.1.2.2 The Ras/Raf/MEK/ERK pathway 
Activated RTKs recruit Grb2-Sos complexes to the plasma membrane. Sos acts as a 
guanine nucleotide exchange factor for Ras by promoting the exchange of GDP to 
GTP bound to Ras, leading to Ras activation. Ras is a critical mediator of RTK 
signalling and is responsible for the activation of downstream signalling. Activated 
Ras activates the protein kinase activity of Raf, the first component of the MAP 
kinase cascade. Activated Raf phosphorylates and activates MEK, and activated MEK 
then activates the extracellular regulated kinase 1/2 (ERK1/2) by phosphorylation. 
Activated ERK1/2 kinase then phosphorylates its downstream targets, leading to the 
regulation of various cellular functions6. Raf, MEK and ERK1/2 are all 
serine/threonine protein kinases. 
18 
 
           
Figure 1.1: The Ras/Raf/MEK/ERK pathway. Activated RTK recruits the Grb2-Sos complex 
and activates Ras. The GTP-bound (activated) Ras then activates the downstream 
Raf/MEK/ERK pathway. 
 
1.1.2.3 The PLCγ pathway 
PLCγ is a 150-kDa phosphoprotein that associates with activated RTKs upon ligand 
binding7. Activated PLCγ cleaves phosphatidyl-inositol-4,5-bisphosphate to inositol 
trisphosphate (IP3) and diacylglycerol (DAG); DAG remains on the membrane and 
IP3 is released into the cytosol. IP3 and DAG are important second messengers; IP3 
binds to the endoplasmic reticulum and releases Ca2+ into the cytosol, where Ca2+ 
activates various cellular processes. In the presence of Ca2+, DAG activates protein 
kinase C, which phosphorylates cellular proteins. 
 
19 
 
             
Figure 1.2: The PLCγ pathway. Activated RTK interacts with and activates PLCγ, which then 
catalyses the hydrolysis of inositol phospholipid to produce the second messengers IP3 and 
DAG. IP3 induces the release of calcium from the endoplasmic reticulum, thus allowing DAG 
to activate PKC. 
 
1.1.2.4 The phosphatidylinositol 3-kinase (PI3-kinase) pathway 
Phosphatidylinositol 3-kinases (PI3-kinases) are a family of enzymes involved in 
cellular functions such as cell growth and cell survival through inhibition of apoptosis. 
The PI3-kinase family can be divided into Class I, Class II and Class III according to 
their primary structure, regulation, and in vitro lipid substrate specificity. Only the 
Class I PI3-kinases can activate Akt in cells. PI3-kinase can be activated by RTKs, 
and active PI3-kinase phosphorylates the D-3 position of the inositol ring in inositol 
phospholipids to produce phosphatidylinositol 3-phosphate (PI(3)P), 
phosphatidylinositol (3,4)-bisphosphate (PI(3,4)P2) and phosphatidylinositol 
(3,4,5)-trisphosphate (PI(3,4,5)P3). PI(3,4)P2 and PI(3,4,5)P3 activate PDK1 by 
20 
 
binding to it, and activated PDK1 then phosphorylates Akt, thus activating the Akt 
pathway 8, 9.  
            
P
P
P
P
PIP2 PIP3
P
ATP
Other signalling pathways (Akt)
PDK1
 
Figure 1.3: The PI3 kinase pathway. Activated RTK recruits and activates PI3 kinase. The 
activated PI3-kinase phosphorylates the phospholipid PIP2 to form PIP3, which activates the 
protein-serine/threonine kinase Akt pathway. 
 
1.1.3 Structural Features of RTKs 
1.1.3.1 RTK families 
RTKs are found in all multicellular eukaryotic organisms, and 59 genes encoding 
different RTKs have been identified in the human genome. All RTKs have a similar 
architecture, with an extracellular domain, a single transmembrane region, and an 
intracellular region with protein tyrosine kinase activity and a C-terminal tail10. 
Human RTKs can be divided into 20 subfamilies according to their structural 
characteristics and the sequence homology in their extracellular domains, which are 
specific for their biological ligands (Figure 1.4). 
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Figure 1.4: Overview of RTK families. Human RTKs can be divided into 20 subfamilies 
according to the differences in their extracellular domain structures. Adapted from Lemmon 
and Schlessinger, Cell, 141, 1117-34 (2010)11. 
 
1.1.3.2 RTK domain composition and features 
The N-termini of RTKs have a signal peptide sequence that is followed by an 
extracellular domain. The signal peptide targets the protein to the secretory pathway. 
The signal peptide and the extracellular domain are secreted outside the cellular 
membrane, where the extracellular domain plays its role as the ligand-binding domain. 
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This N-terminal extracellular domain is usually glycosylated and contains a 
distinctive pattern of cysteines, which form structural motifs. Different receptors have 
different extracellular motifs. For example, the fibroblast growth factor receptor 
(FGFR) subfamily has two or three immunoglobulin domains, whereas the epidermal 
growth factor receptor (EGFR) subfamily has two cysteine-rich regions. The 
extracellular domains of the various receptors form binding pockets specific for their 
biological ligands12. Asides from providing the binding site for signalling molecules, 
the extracellular domain also functions as a point of adhesion with other cell surface 
proteins. Further, the extracellular domain plays a critical role in receptor dimerisation 
following ligand binding, which is necessary for RTK signalling13, 14.  
 
The transmembrane domain has hydrophobic and basic residues that function as a 
stop-transfer signal. The transmembrane domain anchors the receptor in the correct 
orientation, stabilises the dimeric conformation of activated receptors, and transmits 
biological signals to the plasma membrane upon receptor dimerisation. Studies have 
indicated that mutations in the transmembrane domains of FGFR and EGFR can cause 
ligand-independent RTK activation15, 16, 17. 
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Most RTKs share a highly conserved intracellular catalytic domain that consists of 
approximately 250 amino acids and has high sequence similarity among RTKs, 
including 13 conserved residues in all of the 59 human RTK sequences18, 19. The 
intracellular catalytic domain catalyses the phosphorylation reaction and interacts 
with and activates downstream signalling proteins. Moreover, structural studies 
focused on several protein kinases also provide evidence that the protein kinase 
catalytic domains have conserved architectures20-24. Although the catalytic domains of 
RTKs are highly conserved, there are differences between the intracellular sequences 
of various subfamilies. For example, platelet-derived growth factor receptor (PDGFR) 
and FGFR have an insertion region in their protein tyrosine kinase domains that splits 
this domain into two parts. Moreover, different RTK subfamilies use different sites to 
interact with docking proteins, essential components of the cellular signalling network 
that mediate the formation of the signalling complex. For example, a highly conserved 
sequence on the FGFR juxtamembrane region binds constitutively to the FRS2 PTB 
domain without FGFR activation. However, the NPQpY motif of nerve growth factor 
receptor (NGFR) binds to the FRS2 PTB domain only when NGFR is activated25.        
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1.1.4 Ligand binding and RTK activation 
Extracellular ligand binding is the first step in the activation of receptor signalling 
pathways. Ligand binding induces a conformational change in the extracellular 
domain, which in turn causes receptor dimerisation, resulting in the 
autophosphorylation or transphosphorylation of specific tyrosine residues in the 
cytoplasmic domain1, 26, 27. Different ligands use different mechanisms to induce 
receptor dimerisation. Dimeric growth factors such as vascular endothelial growth 
factor (VEGF) exist as homodimers and bind to their receptors in a 2:2 complex to 
induce receptor dimerisation. On the other hand, Cunningham et al. proposed a 
monomeric growth factor binding mechanism. Their study indicates that the binding 
of one molecule of human growth factor to one molecule of its receptor can promote 
the binding of the second receptor molecule to this complex and induce dimerisation 
of receptor extracellular domains28. Receptor dimerisation is further stabilised by 
additional interactions between the two receptors’ extracellular domains29-31.  
 
The dimerisation of receptors is important for the activation of the intrinsic catalytic 
activity and autophosphorylation of receptor protein tyrosine kinases32. The tyrosine 
kinase domain of all RTKs is highly conserved; this domain contains the ATP binding 
sequence GlyXGlyXXGlyX(15-20)Lys26, 33. Mutagenesis studies performed both in 
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vitro and in vivo demonstrate that the lysine residue in the EGF and PDGF receptors is 
necessary for ATP binding and kinase activity34-36. Sequence alignments also reveal a 
glutamate residue (E651 in PDGFR) conserved in all protein tyrosine kinases. This 
conserved glutamate residue is involved in coordinating ATP and forming a salt 
bridge to the lysine residue in the above sequence13. Another conserved sequence that 
is found in the catalytic loop of receptor protein tyrosine kinases is 
HisArgAspLeuAlaAlaArgAsn, in which the Asp residue is believed to be the catalytic 
base. This conserved sequence not only exists in protein tyrosine kinases but can also 
be found in protein serine/threonine kinases13. Finally, the kinase activity of the 
receptor protein tyrosine kinase is increased by dimerisation, causing 
transphosphorylation between the two receptor monomers37. The 
transphosphorylation within the receptor dimer results in the activation of the dimeric 
tyrosine kinase domain and causes the phosphorylation of cytoplasmic substrate 
proteins. A mutagenesis study demonstrated that transphosphorylation is necessary for 
the activation or phosphorylation of the downstream substrate proteins13. This 
suggests that the tyrosine autophosphorylation in receptor protein tyrosine kinases has 
two important roles: the stimulation of the intrinsic catalytic activity of the receptor 
and the creation of binding sites for downstream Src homology 2 (SH2) domain- or 
phosphotyrosine-binding (PTB) domain-containing signalling proteins38. Further 
26 
 
studies demonstrate that the phosphorylation of tyrosine residues on a receptor 
induces a conformational change that allows for the binding of signalling proteins 
containing SH2 or PTB domains39-41.  
 
1.1.5 The formation of early signalling complexes (ESCs) 
RTKs undergo phosphorylation at specific sites upon stimulation. This leads to the 
recruitment of signalling proteins such as Grb2 and Shc to the 
activated/phosphorylated RTKs via their SH2 or PTB domains. These recruited 
signalling proteins may be phosphorylated or may constitute platforms for other 
signalling proteins. To prevent incorrect crosstalk between different signalling 
pathways, the recruitment takes place among a defined group of proteins and in a 
precise order. 
 
1.1.5.1 Specificity of signal transduction 
One characteristic of signalling proteins involved in RTK signalling pathways is that 
they contain different types of domains, which means small protein modules with 
highly homologous primary and tertiary structures. Several different signalling 
domains have been reported, such as Src homology 2 (SH2), Src homology 3 (SH3), 
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and the phosphotyrosine-binding (PTB) domains42. These domains interact with other 
signalling proteins by recognising specific motifs on their targets. 
 
The original dogma described an RTK signal transduction process as a linear pathway 
that requires a series of protein-protein interactions43. However, it is not obvious how 
the signalling can be specific when individual proteins participate in a number of 
pathways and how different proteins sharing common signalling domains transmit 
signals in a pathway-specific manner. Thus, each protein-protein interaction must 
have a high level of specificity to ensure that the entire signalling pathway is secure 
and that there is no interruption between different signalling pathways. However, it 
remains unclear how these proteins can be specific for one pathway.  
 
The specificity of a domain-mediated protein-protein interaction is reflected as the 
binding affinity (KD) of the interaction compared with those of any other competing 
interactions. Ladbury et al. determined that at least a 1000-fold difference in binding 
affinity is required to distinguish a specific interaction from non-specific interactions 
because a cell can have hundreds of signalling proteins composed of the same 
homologous domains44, 45. To investigate the specificity with which each domain 
recognises its binding partner in an RTK signalling pathway, several binding studies 
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have been performed using SH2, PTB and SH3 domains with their corresponding 
peptides. The following sections outline several studies on the specificity of binding 
by these domains.   
 
1.1.5.2 Specificity in SH2 domains 
SH2 domains are ~100 amino acid-long sequences with a structure composed of an 
anti-propeller β-sheet flanked by two α-helices46. SH2 domains regulate signalling 
pathways by recognising and binding to phosphotyrosine residues on their target 
proteins39, 47-49. Approximately 110 signalling proteins that contain a total of 120 SH2 
domains are involved in controlling tyrosine kinase signalling pathways in 
humans50-55.  
 
Because cells possess many different proteins containing the SH2 domain, it is 
important to understand how SH2 domain-containing signalling proteins recognise 
their specific targets. Several groups have employed phosphopeptide library screens 
to study the sequence specificity of the phosphopeptide binding sites of SH2 domains 
(Table 1.1). For example, phosphopeptide screening results reported by Songyang et 
al. demonstrate that the SH2 domains from Src, Fyn, Lck, Abl, Crk and Sem5 have 
higher selectivities toward pY-X1-X2-I/P (X1 and X2 are hydrophilic residues) 
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compare with that of other phosphopeptides. The residues positioned from -2 to +4 
surrounding this sequence are important for determining the selectivity of given 
phosphopeptides to certain SH2 domains56. For instance, the Src SH2 domain 
recognises the sequence pYEEI, whereas the Sem5 SH2 domain recognises the 
sequence pYLNV/P. However, this study also revealed that some SH2 domains can 
also bind to degenerate sequences with similar specificities, e.g., the Src SH2 domain 
can also bind to pYDNI or pYTEM. 
 
Table 1.1: Amino acids preferentially selected by different SH2 domains at the pY+1, 
pY+2 or pY+3 positions. The numbers indicate the enrichment values of the residues 
selected. Adapted from Songyang, Cell, 1993, 72, 76756. 
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Structural studies demonstrate that the pY residue interacts with a positively charged 
pocket within the SH2 domain. This binding site involves charge-charge interactions 
and hydrogen-bonds42, 57. The C-terminal residues of pY are bound in three different 
ways (Figure 1.5). First, the pY+1 and pY+2 residues extend across the polar surface, 
and the pY+3 residue inserts into the left pocket46. Second, the C-terminal residues of 
the pY extension bend to interact with a hydrophobic BG loop formed between helix 
αB and strand βG58. Third, the pY+2 residue is forced to adopt a β-turn conformation, 
resulting in an interaction between the hydrophobic side chain and the SH2 binding 
site surface59.  
 
A B C
 
Figure 1.5: Structures of (A) the Src SH2 domain in complex with a phosphotyrosine peptide. 
Adapted from Waksman et al., Nature, 358, 646-53 (1992). PDB code: 1SHA. (B) The PLCγ 
SH2 domain in complex with a phosphotyrosine peptide. Adapted from Pascal et al., Cell, 
77,461-72 (1994). PDB code: 2PLE. (C) The Grb2 SH2 domain in complex with a 
phosphotyrosine peptide. Adapted from DeLorbe et al., J Am Chem Soc, 131, 16758-70 
(2009). PDB code: 3KFJ59. 
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However, these studies did not explain the specificity with which SH2 domains bind 
to phosphotyrosine-containing proteins. According to reports by Ladbury et al.8, 39, 
thermodynamic data from isothermal titration calorimetry (ITC) studies focusing on 
the interactions between phosphotyrosine-containing peptides and the Src SH2 
domain reveal a lack of specificity in SH2 domain-phosphopeptide binding (Table 
1.2). Different peptides with different residues at their pY+1, pY+2 or pY+3 positions 
have similar binding affinities, ranging from 0.18 to 6.25 µM, which are clearly not at 
the levels of affinity required for specific binding because the differences between 
these binding affinities are below 1000-fold60.   
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Table 1.2: Binding of phosphotyrosine peptides to the Src SH2 domain. ITC was used to 
measure the interactions of a series of phosphotyrosine peptides with different amino acids in 
their pY+1, pY+2 or pY+3 positions. Adapted from Ladbury, Acta Crystallogr D Biol Crystallogr, 
D63, 26-31 (2007)60.          
        
Binding of tyrosyl phosphopeptides to the Src SH2 domain
Peptide                                                    Kd (µM)
PQpYEEIPI
PQpYQEIPI
PQpYDEIPI
PQpYAEIPI
PQpYGEIPI
Peptides with substitution in pY+1 position
Peptides with substitution in pY+2 position
PQpYEYIPI
PQpYEQIPI
PQpYEDIPI
PQpYEAIPI
PQpYEGIPI
0.25
0.47
0.18
0.34
6.25
0.66
0.53
0.42
1.04
1.96
Peptides with substitution in pY+3 position
PQpYEELPI
PQpYEEVPI
PQpYEEAPI
PQpYEEGPI
0.43
0.46
1.75
0.39
 
 
In contrast, studies performed using phosphotyrosine peptides to explore the 
interactions between SH2 domains and phosphotyrosine may be oversimplified 
because screening short peptide cannot sufficiently represent native proteins45, 61, 62. 
An X-ray crystal structure of the FGFR1 cytoplasmic domain in complex with PLCγ 
SH2 domains is an ideal model to study interactions between SH2 domains and 
phosphotyrosine-containing proteins in their native states (Figure 1.6)62.  
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Figure 1.6: Crystal structure of the activated FGFR1-PLCγ SH2 domain complex. The 
structure of FGFR1 is shown in green, the N-SH2 domain of PLCγ is shown in cyan and the 
C-SH2 domain of PLCγ is shown in blue. The A-loop is shown in pale green, and the catalytic 
loop is shown in yellow. The ATP analogue, phosphotyrosines (pY653, pY654 and pY766) and 
the catalytic base (D623) are shown in stick representations. Taken from Bae et al., Cell, 138, 
514-24 (2009)62. 
 
The SH2-phosphorylation binding specificity is determined by the primary SH2 
domain binding site, i.e., the N-SH2 domain of PLCγ binding to the pYDLD motif of 
FGFR1 is a typical SH2 domain-phosphotyrosine interaction that involves a pY 
binding pocket and a hydrophobic binding pocket. Surprisingly, the structure suggests 
that asides from the canonical phosphorylation-dependent binding, the binding of the 
N-SH2 domain of PLCγ to activated FGFR1 is also controlled by a secondary binding 
site that contributes the “selectivity” to the interaction (Figure 1.7). The secondary 
binding site is divided into hydrophobic sub-site I and hydrophilic sub-site II based on 
the hydrophobic and hydrophilic characteristics of the binding sites. 
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Figure 1.7: Interactions between activated FGFR1 and PLCγ. Interactions mediated by the 
primary binding site (phosphotyrosine-dependent) are coloured red. Interactions mediated by 
the secondary binding site are coloured blue. Taken from Bae et al., Cell, 138, 514-24 
(2009)62.  
 
Sequence alignments of the N-SH2 and C-SH2 domains from different species reveal 
that the residues responsible for the phosphotyrosine-dependent primary binding site 
are conserved across species. However, the residues responsible for the secondary 
binding site can only be found in the N-SH2 domain. In vitro binding studies using 
ITC demonstrate that the N-SH2 and C-SH2 domains have similar binding affinities 
to a phosphopeptide derived from FGFR1 (0.43 µM for the N-SH2 domain and 1.87 
µM for the C-SH2 domain). However, when the native protein was used instead of the 
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phosphopeptide, the N-SH2 domain exhibited a higher binding affinity (0.03 µM) 
towards the native FGFR1 protein62.  
 
Although the difference in binding affinity is less than what Ladbury et al. suggested 
(i.e., that meaningful specificity requires at least a 1000-fold difference in affinity), 
this study provides new insight into studying the specificity of SH2 domain 
interactions. 
 
1.1.5.3 Specificity in PTB domains 
PTB domains also recognise and bind to phosphotyrosine-containing cellular 
signalling proteins. Common PTB domains have a structure of seven antiparallel 
β-strands, forming a central β-sandwich motif, as well as a C-terminal α-helix63. 
According to their structural differences, PTB domains can be divided into three 
families: IRS-1/Dok-like, Shc-like and Dab-like64. The first PTB domain was 
identified as a 186-residue module in Shc, a scaffold protein in signalling cascades. 
This domain can also bind to a conserved phosphotyrosine-containing sequence 
NPXpY or NXXpY (where X represents any residue) in activated receptor protein 
tyrosine kinases65, 66.  
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Ligand recognition of PTB domains is more diverse than that of SH2 domains. In 
contrast to SH2 domains, the presence of a phosphotyrosine is not required for PTB 
domain-mediated binding, and PTB binding is more dependent on the surrounding 
β-strand antiparallel motif67-69. PTB domains lack specificity. For example, the FRS2 
PTB domain can bind to both NPXpY and AVHKLAKSIPLRRQVYVS with similar 
binding affinities25, 70.  
 
1.1.5.4 Specificity in SH3 domains 
SH3 domains were first identified as a conserved sequence in the N-terminus of Src71. 
SH3 domains are small 55- to 70-amino acid domains that are found in many cellular 
signalling proteins, such as PLCγ and PI-3 kinase72-75. SH3 domains have a compact 
β-barrel structure76. An early study performed by Rodaway et al. indicates that most 
SH3 domain-containing proteins are membrane-associated, suggesting that SH3 
domain may be involved in subcellular localisation77. Further studies have 
demonstrated that SH3 domains play a role in the reorganisation of signalling proteins 
to their targets through interactions with proline-rich sequences78. Several structural 
studies reveal the molecular details of the SH3-proline-rich motif interaction. 
Interactions between SH3 domains and proline-rich motifs are mediated by 
hydrophobic interactions and are typically rather weak. The binding site within SH3 
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domain consists of conserved aromatic residues that form an exposed hydrophobic 
patch on the protein surface76, 79-81. SH3 domains also have preferences for arginine 
and leucine residues. Peptide library screens have found that the proline-rich peptides 
bound to SH3 domains can be divided into two classes. Class I has the consensus 
sequence RXLPP(L/R)P, whereas class II has the sequence XPPLPXR. Due to the 
conserved arginine residues located at the N-terminus of Class I peptides and the 
C-terminus of Class II peptides, it is proposed that peptides of these two classes bind 
to SH3 domains in reverse orientations82. Studies also indicate that SH3 domains may 
form a dimer when they bind to ligands. This ligand-mediated SH3 dimerisation is 
stabilised by the peptide ligand83-85.  
 
The specificity of SH3 domain binding has been addressed using peptide library 
screening. Although the C-terminal residues of the proline-rich motif do not provide 
additional specificity, the difference in binding affinities among different proline-rich 
peptides is clearly < 40-fold (Table 1.3)45, suggesting that no high level of specificity 
is achieved. For example, the Fyn SH3 domain has similar binding affinities towards 
the Sos and p85 peptides (20 and 16 µM, respectively); thus, the SH3 domain cannot 
distinguish between these different binding partners in cells.  
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Table 1.3: Binding of proline-rich peptides to SH3 domains. The differences in the affinities 
from these binding studies are < 100-fold, suggesting that SH3 domain binding is non-specific. 
Adapted from Ladbury and Arold, Chem Biol, 7, R3-8 (2000)45. 
       
Recognition specificities of SH3 domains 
SH3 domain              Peptides                      KD (µM)
Abl
Abl
Fyn
Fyn
Fyn
Fyn
Fyn
Fyn
Grb2
Grb2
p85
Src
Src
RAPTMPPPLPP (3BP-1)
PPAYPPPPVP (3BP-2)
PVRPQVPLRPPMT (Nef)
PPRPTPVAPGSSKT(p85)
HSIAGPPVPPR (Sos 1-4)
RAPTMPPPLPP (3BP-1)
PPAYPPPPVP (3BP-2)
PPRPTPVAPGSSKT(p85)
VPPPVPPRRR (Sos)
GTDEVPVPPPVPPRRRPESA (hSos)
RKLPPRPSK (peptide libraries)
RALPPLPRY (peptide libraries)
HSIAGPPVPPR (Sos 1-4)
34
5
202
50
20
34
34
16
5
21
9
8
26
 
 
1.1.5.5 Early signalling complexes (ESCs) provide specificity 
Meaningful specificities require at least a 1000-fold difference between a specific 
interaction and a non-specific interaction45. Linear processing of a signal that employs 
individual protein-protein interactions would require a high level of specificity to 
avoid any cross reaction between signalling pathways. However, as described above, 
binding studies of SH2, PTB and SH3 domains reveal that the differences in binding 
affinity are < 100-fold (i.e., all three domains lack the specificity required to prevent 
cross-talk between different cell signalling pathways). Thus, linear processing of 
signals is not sufficient to ensure mutually exclusive pathways.  
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It has become clear that the stimulation of RTKs results in the assembly of a number 
of signalling proteins at the membrane. This formation of signalling complexes 
requires multiple interactions, potentially increasing the interaction affinity between 
two interacting proteins by providing the correct positioning of binding sites, making 
the interaction specific with respect to other binding partners. This increase in affinity 
would reduce the chance of non-specific interactions with other competing proteins. 
The formation of ESCs both explains the specificity of a signalling pathway and 
provides several features for the control of signalling pathways43. 
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1.2 Fibroblast Growth Factor Receptor Signalling 
1.2.1 The FGFR family 
1.2.1.1 FGFR subfamilies and isoforms 
Different promoters and alternative splicing in cells result in the formation of different 
types of FGFRs. The FGFR family consists of at least four types: FGFR1 (flg)86, 87, 
FGFR2 (bek)88, FGFR389, and FGFR490, 91. Further, alternative splicing of FGFR 
mRNA results in the formation of three different isoforms of the Ig-like domain III in 
FGFRs, termed IIIa, IIIb, and IIIc (Figure 1.8)92-95, which confers ligand-binding 
specificities on the receptors. The b isoform is mainly expressed in epithelial lineages, 
whereas the c isoform is expressed in mesenchymal lineages96-99. 
IIIa IIIb IIIc IIIc IIIc IIIc IIIc IIIcIIIb IIIb
FGFR1 FGFR2 FGFR3 FGFR4
Ig I
Ig II
Ig III
Acidic 
region
Transmembrane 
domain
Kinase domain
C-tail
IIIb
 
Figure 1.8: Various FGFR isoforms. Numerous splicing forms of FGFR. Some isoforms have 
truncated extracellular domains (in particular, Ig I is often missing). Secreted forms lack the 
transmembrane domain. Adapted from Johnson and Williams, Adv. Cancer Res, 60, 1-41 
(1993)100.  
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1.2.1.2 Fibroblast growth factors 
In humans, 22 different FGFs have been identified to date (FGF15 is only known to 
exist in mice). FGF3, 4, 8, 17 and 19 are expressed during embryonic development, 
while FGF1, 2, 5, 6, 7, 9, 10, 11, 12, 13, 14, 16, 18, 20, 21, 22 and 23 are expressed in 
both embryonic and adult tissues101. FGFs play important roles in DNA synthesis, cell 
migration, the regulation of cell growth, embryogenesis, and angiogenesis100-102. In 
vertebrates, these 22 FGFs are highly conserved in gene structure and amino acid 
sequence. Most FGFs have peptide sequences that allow them to be secreted from 
cells. Although FGF9, 16, and 20 do not have these peptides, they are still found 
outside the cell. FGF1 and FGF2 are found on the cell surface and within the 
extracellular matrix, and FGF11-14 remain inside cells. While some FGFs contain 
nuclear localisation signals and can be found in the nucleus, the role of these nuclear 
FGFs remains unclear101.   
 
FGF9 was used in this PhD study. Previous studies by our group indicate that 
FGFR2IIIc is highly phosphorylated even in unstimulated cells, and the level of 
FGFR2IIIc phosphorylation can only be increased upon FGF9 stimulation103-105.  
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1.2.1.3 Heparin sulphate proteoglycans (HSPGs) 
Heparin, a highly sulphated glycosaminoglycan, is found in various mammalian 
tissues including the liver, lung and intestines. Heparins are glycosaminoglycan 
family carbohydrates and have molecular weights ranging from 3 to 40 kDa. The 
basic structure of heparin consists of repeating sulphated disaccharide units. The main 
disaccharide unit in the heparin backbone is O-sulphated and N-sulphated 
glucosamine; iduronate and glucuronate residues are also prominent106.   
 
Heparin can link to proteins after chain elongation and modification, creating 
complexes called HSPGs. These complexes are macromolecules located on the 
surface of vertebrate and invertebrate cells. HSPGs have several important biological 
functions in embryonic morphogenesis, angiogenesis and tissue repair106. 
 
1.2.1.4 The Interaction between FGF and heparin 
FGFs alone are unable to bind and activate FGFRs without heparin107. Indeed, HSPGs 
are necessary components of the FGF signalling pathway108, 109. FGFs have a strong 
affinity for heparin and HSPGs. FGF-heparin complexes can bind to FGFRs and 
initiate downstream signalling cascades affecting gene expression, thus regulating cell 
growth, development and migration.  
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HSPGs bind and activate cellular growth factors through their heparin sulphate 
chains110. Heparin forms very tight complexes with groups of mammalian cellular 
growth factors, including FGF107, 111, VEGF112 and heparin-binding EGF113. Studies 
performed by Mansukhani et al. indicate that cell surface HSPGs can also enhance the 
binding of several types of FGF to FGFR2114. According to this study, binding of FGF 
to FGFR2 induces the phosphorylation of FGFR2 and leads to a mitogenic response; 
the binding affinity of FGF to FGFR2 can be greatly enhanced by the addition of 
heparin. In addition to increasing the binding affinity of FGF to FGFR, heparins and 
cell surface HSPGs also play important roles in protecting FGF from heat inactivation 
and proteolysis115-119. The degree of sulphation and the length of heparin in HSPGs 
affects the ability of FGF2 to bind FGFR1 and heparin120. This study demonstrates 
that the binding of FGF2 to its receptor requires heparin molecules containing at least 
eight to 10 sugar units. Also, FGF bound to highly sulphated heparin-derived 
polysaccharides has a greater receptor binding ability than FGF bound to heparin with 
a low level of sulphation.  
 
FGF4 provides an excellent example of the regulation of FGF and FGFR binding by 
heparin. FGF4 is found in tumours and is related to limb development and 
embryogenesis121, 122. FGF4 is known to bind and activate FGFR2 rather than FGFR1 
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at low heparin concentrations123. However, the low binding affinity of FGF4 to 
FGFR1 can be increased using a higher concentration of heparin. This study supports 
the model that the activation of different types of FGF receptors by FGF may be 
determined by different concentrations of heparin at the cell surface. However, there 
is no significant difference between the binding of FGF1 to FGFR1 or FGFR2 at the 
same heparin concentration, and the increase in heparin concentration has no effect on 
the binding affinity of FGF1 to FGFR1123. Brickman et al. used peptides homologous 
to the heparin binding region of the receptor to investigate whether HSPGs with 
different specificities for FGF2 also have different affinities for different FGF 
receptors124. The results demonstrate that the basic residues of the Ig-like domain 2 of 
FGFR 1 can form a heparin-binding site. Peptides homologous to this region of 
FGFR1 inhibit mitogenesis in vivo, but FGFR2, 3 and 4 do not elicit the same 
response. These findings indicate that unique heparin sulphate domains interact with 
specific cell-surface receptors and direct different cellular responses. 
 
1.2.2 The cellular context of FGFRs 
FGFR signalling is important in the regulation of cellular functions, such as 
differentiation, survival and proliferation. FGFR1 signalling is the best-studied 
component of the FGFR signalling pathway, and the initial signalling events are quite 
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similar between FGFR1 and FGFR4 due to the highly conserved sequence homology 
in their RTK domains125.  
 
While many growth factors can bind to more than one receptor, the various roles of 
these receptors in signalling pathways remain unclear. A study comparing FGFR1 and 
FGFR4 signalling in BaF3 cells and L6 cells revealed that both FGFR1 and FGFR4 
have high binding affinities to FGF1, and both have similar degrees of receptor 
activation upon FGF1 stimulation. However, FGFR1 has a stronger downstream 
response: tyrosine phosphorylation of PLCγ and ERK2, and only FGFR1 activation 
induced the phosphorylation of an unidentified 80-kDa protein125. Another study 
using the chimeric receptor FGFR4/R1C, which contains the FGFR4 extracellular 
domain and the FGFR1 intracellular domain, demonstrates that this chimeric receptor 
exhibits the same FGF-induced proliferation response as FGFR1 upon FGF1 
stimulation. Therefore, this result suggests that the intracellular domains of FGFRs 
determine their functional capacities126. Moreover, a study performed by Raffioni 
using chimeric receptors in PC12 cells indicates that FGFR1, FGFR3 and FGFR4 
mainly use FRS2 and PLCγ but not Shc to transduce signals, and these FGFRs have 
similar signalling responses. This study demonstrates that the major difference 
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between FGFRs is the level of receptor autophosphorylation; specifically, FGFR1 and 
FGFR3 have higher phosphorylation levels compared to FGFR4127.  
 
Haugsten et al. transfected each of the FGFR1-4 proteins into HeLa cells to study the 
intracellular trafficking of FGF1 in an effort to understand the differences between 
FGFR1, FGFR2, FGFR3 and FGFR4. Their study revealed that FGF1 is slowly 
degraded in cells expressing FGFR4. FGFR1-3 are ubiquitinylated on several lysine 
residues, can be transported to lysosomes with their bound ligands and are degraded 
in the lysosomes after endocytosis. Thus, these data suggest that differences exist 
between various FGFRs128.  
 
1.2.3 General structural overview of FGFRs 
1.2.3.1 Extracellular domains 
FGFRs have common structural features: they have three Ig-like domains in their 
extracellular domain (D1~D3), a transmembrane domain and an intracellular domain 
containing a highly conserved PTK domain. The Ig-like domains 2 and 3 (D2 and D3) 
are necessary for ligand binding; an acidic box between D1 and D2 participates in the 
regulation of FGF binding to FGFR. Alternative exon splicing results in the 
expression of FGFR with or without the Ig-like domain 1. The FGFR α isoforms 
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possess three Ig-like domains (D1, D2, and D3), whereas the β isoforms contain two 
Ig-like domains (D2 and D3)129, 130. A study performed by Johnson et al. indicates that 
both isoforms can respond to FGF1 and FGF2. Furthermore, Wang et al. indicate that 
the lack of D1 can increase the binding affinity to both FGF and heparin130. A crystal 
structure of the FGFR3c-FGF 1 complex reported by Olsen et al. (2004) displays that 
D1 and the linker region between D1 and D2 are disordered, suggesting that D1 and 
the linker are not responsible for FGF ligand binding. However, real-time binding 
assay results also demonstrate that the FGFR3c with 3 Ig-like domains have a lower 
affinity for both FGF and heparin compared to the FGFR3c with two Ig-like domains. 
This study proposes that the FGFR with three Ig-like domains possesses an 
autoinhibition function131.   
 
Several groups have explored the interaction between FGF, heparin and FGFR from a 
structural perspective. In 1999, Plotnikov et al. determined the crystal structure of 
immunoglobulin-like domains 2 and 3 with their ligand, FGF2; two FGF2:FGFR1 
complexes form a twofold symmetric dimer via the binding of ligand to Ig-like 
domains 2 and 3 (D2 and D3) (Figure 1.9). They also investigated ligand-receptor and 
receptor-receptor interactions that stabilise dimerisation, though they did not find 
evidence of a direct FGF-FGFR interaction. Instead, they propose a positively 
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charged heparin-binding canyon within the FGF2-FGFR1 crystal structure. Although 
heparin is not present in this crystal structure, this model still provides detailed 
information on how a growth factor binds to an extracellular domain of a receptor and 
how dimerisation occurs between receptors132.  
                   
                 
Figure 1.9: Dimeric structure of FGF2-FGFR1. Monomers of the D2-D3 domain of FGFR1 
are shown in light and dark green, and FGF1 is shown in purple. This structure shows that two 
FGF2-FGFR1 complexes form a twofold FGF2-FGFR1 symmetric dimer. Adapted from 
Plotnikov et al., Cell, 98, 641-50 (1999). FGF2-FGFR1 structure PDB code: 1CVS132. 
 
Two crystal structures, FGF1-FGFR1 and FGF2-FGFR2, have been determined to 
study the interaction between FGF and FGFR (Figure 1.10). The FGF1-FGFR1 D2 
region and FGF2-FGFR2 D2 region interactions are very similar (mainly mediated by 
hydrophobic interactions), whereas the interactions of FGF ligands to D3 regions are 
mediated by hydrogen bonds. In the FGF2-FGFR2 structure, the interactions between 
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FGF2 and the D3 region are mediated by FGF2 making contact with the ordered 
βC′-βE loop via five hydrogen bonds. The FGF2-FGFR1 structure also displays the 
interaction between FGF2 and the ordered βC′-βE loop of the FGFR1 D3 region. 
However, in the FGF1-FGFR1 structure, the βC′-βE loop is disordered due to the lack 
of interaction between FGF1 and the FGFR1 D3 region. Gln-58 and Val-88 of FGF2 
contribute to the interactions between FGF2 and FGFR2 D3. Substituting Gln-58 and 
Val-88 with Ser-47 and Pro-79 in FGF1 prevents the interaction with the βC′-βE loop, 
therefore making this loop disordered. This structural information was used to explain 
the binding specificity of FGF-FGFR133.  
        
Figure 1.10: Structures of the FGF2-FGFR2 (left) and FGF1-FGFR1 (right) complexes. 
The D2 and D3 domains are coloured in green and blue, respectively. FGF1 and FGF2 are 
shown in orange. The ordered βC′-βE loop is shown in purple in the FGF2-FGFR2 complex 
structure. The βC′-βE loop in the FGF1-FGFR1 complex is disordered. Adapted from Plotnikov 
et al., Cell, 101, 413-24 (2000). FGF2-FGFR2 structure PDB code: 1EV2, FGF1-FGFR 
structure PDB code: 1EVT133. 
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Stauber et al. (2000) also published a crystal structure of the complex between FGF1 
and the Ig-like domains 2 and 3 of FGFR2; this crystal structure is also a dimeric 1:1 
ligand:receptor complex. Moreover, they produced a model of a 
ligand:heparin:receptor complex that provides fundamental information on the 
interaction between heparin, FGFs and FGF receptors134. A model of the 
FGF2-FGFR1-heparin-like glycosaminoglycan (HLGAG) complex was proposed in  
which the two domains of a single FGFR1 molecule wrap around a single FGF2 
protein, indicating a role for the HLGAG in the complex with FGF2 and FGFR1, 
suggesting HLGAG-mediated FGF dimerisation or oligomerisation135. The crystal 
structure of the dimeric FGF1-FGFR2-heparin complex was reported in 2000 (Figure 
1.11). This structural model provides clear information on the FGF1-FGFR2-heparin 
interaction. The complex is assembled by two FGF1 molecules linked to one heparin 
molecule in the centre that forms a bridge between two FGFR2 molecules (2:2:1 
FGF:FGFR:heparin)136. 
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Figure 1.11: Structure of the FGF1-FGFR2-heparin complex. The D2-D3 domains of 
FGFR2 are shown in green and blue. FGF1 is presented in purple, and heparin is depicted in a 
CPK representation. This structure shows that the dimeric form of FGFR2 is induced by two 
FGF1 molecules and one heparin. Adapted from Pellengrini et al., Nature, 407, 1029-34 
(2000). FGF1-FGFR2-heparin structure PDB code: 1E0O136. 
 
A crystal structure of a 2:2:2 FGF:FGFR:heparin complex has also been reported. In 
contrast to the heparin-mediated formation of the twofold symmetric dimer formed by 
two FGF-FGFR complexes, this structure shows that each FGF-FGFR complex 
contains one decasaccharide molecule. This structure is proposed to exist when 
shorter heparin molecules are used for FGF-stimulated FGFR activation137. 
 
1.2.3.2 FGFR tyrosine kinase domain structure 
The crystal structures of the FGFR1 tyrosine kinase domain in complex with an ATP 
analogue and in the unliganded form were solved by Mohammadi et al. Figure 1.12 
shows the overall structure of the FGFR1 tyrosine kinase domain. The N-terminal 
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lobe comprises five anti-parallel β strands (β1 – β5) and one α helix (αC), while the 
N-terminal lobe has the ATP binding site located in the loop between strands β1 and 
β2. The C-terminal lobe has two β strands (β7, β8) and seven α helices (α D, αE, αEF, 
αF, αG, αH, and αI). The catalytic loop located between αE and β7 contains an 
aspartic acid residue that functions as the catalytic base in the phosphotransfer 
reaction of FGFR1 tyrosine kinase. The activation loop (A-loop) that serves as the 
substrate binding site has two tyrosine autophosphorylation residues, Tyr653 and 
Tyr654, and these residues are conserved in all FGFRs.  
 
Phosphorylation of these tyrosine residues within the A-loop is critical for the 
activation of kinase activity and the biological control of the receptor in several 
different cellular receptors, such as the insulin receptor and FGFR138, 139. The crystal 
structure of the non-phosphorylated kinase domain of the insulin receptor suggests a 
molecular mechanism in which the receptor tyrosine kinase domain has a low activity 
before the autophosphorylation of the A-loop140. This significant activation of protein 
tyrosine kinase activity stimulated by A-loop phosphorylation is both important in 
receptor protein tyrosine kinases and plays a critical role in non-receptor protein 
tyrosine kinases such as Src and JAK2141, 142.  
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Moreover, comparing the FGFR1 kinase domain structure with the insulin receptor 
kinase domain structure indicates that the main difference between the kinase 
domains is in the conformation of their activation loops. Hubbard et al. provide 
evidence for the different conformations of the A-loop between the FGF and insulin 
receptors143. In the FGFR1 kinase domain, residues Arg-661 and Pro-663 in the 
A-loop have the ability to interfere with the binding of substrate peptides but not with 
the binding of ATP, whereas the critical residue in the activation loop that blocks the 
binding of substrate peptide in insulin receptor kinase is Tyr-1162. This finding 
suggests that FGFR1 kinase may also have an autoinhibitory mechanism. 
                 
Figure 1.12: FGFR1 kinase structure. The α-helices are coloured red, and the β-strands are 
green. The nucleotide-binding loop is shown in orange, the catalytic loop is shown in blue and 
the activation A-loop is shown in yellow. The side chains of Tyr-653 and Tyr-654 are shown in 
purple. Taken from Mohammadi et al., Cell, 86, 577-87 (1996)139.  
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Crystal structures of the non-phosphorylated FGFR2 kinase domain and A-loop 
phosphorylated FGFR2 kinase domain, together with an ATP analogue and a peptide 
substrate (FGFR2 C-terminal tail, residues 764-778), were solved (Figure 1.13). The 
overall architectures of nonphospho-FGFR2 kinase and phospho-FGFR2 kinase are 
bilobate like that of the FGFR1 kinase domain, the insulin receptor kinase domain and 
other protein serine/threonine kinases with known 3D structures139, 140, 143-145. Briefly, 
the N-terminal lobe of FGFR2 kinase, which has an ATP binding site, consists of one 
α-helix (αC) and a β-sheet comprised of five anti-parallel β-stands (β1-5). The 
C-terminal lobe, which is responsible for kinase activation, substrate binding and 
catalysis, contains seven α-helices (αD, αE, αF, αEF, αG, αH, and αI) and two 
β-strands (β7 and β8). Two major architectural changes can be detected when the 
A-loop of FGFR2 kinase is phosphorylated. First, the N-lobe moves towards the 
C-lobe. Second, the A-loop conformation is rearranged and makes contact with the 
RD pocket. Arginine and aspartate residues have been demonstrated to be important 
in regulating tyrosine kinase activity144, 146. These conformational changes are 
necessary for ATP and substrate binding and to increase kinase catalytic efficiency.  
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Figure 1.13: Structures of non-phosphorylated FGFR2 kinase domain and A-loop 
phosphorylated FGFR2 kinase domain. The α-helices are coloured red, and the β-strands 
are blue. The nucleotide-binding loop is shown in cyan, the catalytic loop is shown in yellow, 
the kinase hinge is shown in orange, and the activation A-loop is shown in magenta. In the 
A-loop phosphorylated structure, AMP-PCP and the substrate peptide are labelled. Taken from 
Chen et al., Mol Cell, 27,717-30 (2007)147. 
 
Importantly, this group also reported seven non-phosphorylated pathogenic FGFR2 
kinase domain structures (N549H: PDB code 2PWL; N549T: PDB code 2PZ5; 
E565G: PDB code 2PY3; E565A: PDB code 2QO8; K641R: PDB code 2PZR; 
K526E: PDB code 2PZP; and K659N: PDB code 2PVY). These pathogenic mutants 
result in constitutive kinase activation. Comparing these structures suggests the 
existence of an autoinhibitory mechanism regulated by a molecular brake in the 
kinase hinge region. These pathogenic mutants regulate the molecular brake through 
different mechanisms, such as directly or indirectly disengaging the molecular brake 
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or forcing the A-loop to adapt the active conformation, resulting in constitutive kinase 
activation147. 
 
1.2.4 Activation of FGFRs 
1.2.4.1 FGF binding and FGFR activation 
The activity of the FGF signalling pathway is regulated by the binding affinities of 
FGFs for FGFRs91, 95. Further, the binding specificities are determined by the 
alternative splicing in the ligand-binding domain of FGFRs, which results in a large 
combinatorial group of potential FGF-FGFR interactions.  
 
Early in vitro binding assays performed by Miki et al. demonstrate that FGFR2IIIb 
isoform binds to FGF7, while FGFR2IIIc does not. Furthermore, FGFR2IIIb has a 
lower binding affinity for FGF2 than FGFR2IIIc95. Later, Chellaiah et al. cloned an 
alternatively spliced form of FGFR3 corresponding to FGFR1IIIc and FGFR2IIIc, 
which has a restricted ligand-binding specificity. Compared to FGFR3, FGFR2IIIc 
has a higher binding affinity for both FGF2 and FGF7, though the splicing pattern of 
FGFR3 is similar to that of FGFR2. Additionally, chimeric FGFR3 carrying the exon 
domain III isoform b from FGFR2IIIb exhibits high binding affinities to FGF2 and 
FGF7. This suggests that the Ig-like domain III, which is generated by alternative 
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mRNA splicing, plays an important role in regulating FGF ligand specificity94. In 
contrast, Ornitz et al created mitogenically responsive cell lines that express all 
known FGFRs. Their study demonstrated that FGF1 is the only ligand that can 
activate all FGF splice variants (FGFR1IIIb, FGFR1IIIc, FGFR2IIIb, FGFR2IIIc, 
FGFR3IIIb, FGFR3IIIc and FGFR4). Using FGF1 as an internal standard, they also 
measured the relative activity of FGF2, 3, 4, 5, 6, 7, 8, and 9. Xu et al. also 
determined the relative activity of FGF 8, 17 and 18 compared with FGF1 mitogenetic 
activity as the internal standard. Moreover, Zhang et al. extended Ornitz’s study and 
determined the relative activities of FGF 10-23. These studies provide further 
evidence of the receptor specificity of FGFs148-150.                            
 
1.2.4.2 Dimerisation and phosphorylation of FGFR 
FGFs mediate their biological functions by binding to the Ig-like domains of FGFRs, 
resulting in dimerisation and phosphorylation of multiple tyrosine residues on the 
cytoplasmic domain of the receptors. Early studies indicate that FGF1 and FGF2 can 
dimerise when they bind to heparin molecules, thereby causing the dimerisation and 
activation of FGFR151, 152. This property is important in achieving the binding of 
growth factors to their cellular receptors and the formation of dimeric receptors14, 153. 
Unlike other dimeric growth factors, such as PDGF, FGFs are unable to induce the 
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activation of FGFRs without HSPGs. The binding of FGF2 to HSPGs is important for 
FGFR activation and the subsequent induction of biological responses. A study 
performed by Ornitz et al. indicates that FGF2 binding to its cellular receptor requires 
heparin, and the presence of heparin is important for the induction of mitogenesis in 
living cells154. This study also proposes that the binding of heparin to FGF can induce 
a conformational change in FGF, and this conformational change is involved in the 
dimerisation of FGFRs.  
 
Conversely, several studies also reveal that though heparin can increase the binding 
affinity of FGF2 to its receptor (Ig-like domain of FGFR1), heparin is not actually 
required for the binding of basic FGF to its receptor155. An in vitro study performed 
using the FGFR2 extracellular ligand-binding domain also indicate that heparin is not 
required for the ligand-receptor interaction. However, the addition of heparin can 
cause the oligomerisation of FGF1; this oligomerisation allows FGF1 to induce the 
dimerisation of FGFR via the FGF1-heparin complex152. 
 
Oligomeric receptors also have higher kinase activities and ligand binding affinities 
than monomeric receptors156. In vivo and in vitro research carried out by Bellot et al. 
has also indicated the mechanism of ligand-induced transphosphorylation between 
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different FGFR molecules. NIH3T3 cells co-transfected with kinase-negative 
full-length FGFR2 and the truncated kinase domain of FGFR2 have the ability to 
phosphorylate kinase-negative full-length FGFR2 when FGF1 is added157. This result 
provides evidence that the autophosphorylation of FGFR occurs via an intermolecular 
mechanism. Moreover, transphosphorylation also occurs between different types of 
FGFRs, i.e., both homologous transphosphorylation (FGFR2 to FGFR2) and 
heterologous transphosphorylation (FGFR2 to FGFR1 and FGFR1 to FGFR2) occur. 
This study provides strong evidence that the autophosphorylation of FGFR occurs via 
an intermolecular transphosphorylation mechanism, and because most cell types 
express more than one type of FGFR, the heterologous transphosphorylation of FGFR 
may have a role in signal transduction157. 
 
1.2.4.3 The phosphorylation of the intracellular region in FGFR1 is an ordered 
process 
The binding of FGF to its cellular receptor not only induces the activation of intrinsic 
protein tyrosine kinase activity and the autophosphorylation of the receptors but also 
induces the phosphorylation of substrate proteins158. PLCγ, which serves as the main 
target protein of several receptor tyrosine kinases, associates with the PDGFR159, 
EGFR160 and FGFR7 signalling pathways. Several studies indicate that the 
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autophosphorylation of receptor tyrosine kinase can induce the phosphorylation of 
PLCγ, the downstream signalling molecule of ligand-induced receptor signalling 
pathways158-160,7. Tyr-766 in the C-terminus of FGFR1 has been identified as the 
phosphorylated residue that provides the binding site for the SH2 domain of PLCγ161. 
A study performed by Mohammadi et al. (1992) explored the role of Tyr-766 in FGFR 
signalling. The mutant FGF receptor (Y766F) is unable to interact with PLCγ and 
cannot induce the hydrolysis of phosphatidylinositol. Moreover, the elimination of the 
hydrolysis of phosphatidylinositol does not affect FGF-induced mitogenesis. However, 
mutant Y766F FGFR can undergo an autophosphorylation reaction, and this mutant 
FGFR still has the ability to phosphorylate several cellular proteins and stimulate 
DNA synthesis162.  
 
Another six autophosphorylation sites of FGFR1 have been identified: Tyr-463, 
Tyr-583, Tyr-585, Tyr-653, Tyr-654, and Tyr-730139. Both Tyr-653 and Tyr-654 are 
important for the activation of FGFR1 tyrosine kinase activity in vitro and in vivo. 
Studies of FGFR1 mutants with phenylalanine substitutions Y653F, Y654F, and 
Y653/654F reveal that the phosphorylation level of FGFR1 and PLCγ makes no 
difference to the wild type FGFR1 and Y653F mutant. However, the phosphorylation 
of FGFR1 and PLCγ is very weak in the Y654F mutant, and no phosphorylated PLCγ 
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is detected in Y653/654F. Moreover, because Tyr-653 and Tyr-654 are conserved in 
all four FGF receptor types, the homologous regions appear to be important for 
receptor activation. 
 
Mohammadi et al. also show that the autophosphorylation of tyrosine residues on 
FGFR1 is an ordered event: tyrosine 653 is autophosphorylated prior to tyrosine 654, 
and tyrosine 583 is autophosphorylated prior to tyrosine 585139. Recently, Furdui et al. 
also indicated that tyrosine phosphorylation occurs in a sequential and ordered 
manner on FGFR1. The detailed phosphorylation order of the FGFR1 cytoplasmic 
domain has been identified as follows: 1) Y653 in the activation loop, 2) Y583 in the 
kinase insert domain, 3) Y463 in the juxtamembrane domain, 4) Y585 in the kinase 
insert domain, and 5) Y654 in the activation domain163. This precise sequential 
reaction suggests that correct signalling may result from the observed phosphorylation 
pattern. They also demonstrate that the rate of substrate catalysis increases greatly 
after the phosphorylation of Y653 (50 times) and Y654 (500 times). These data 
suggest that phosphorylation at different time points may activate different signalling 
pathways. 
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1.2.5 The formation of ESCs of FGFR 
The docking protein FRS2 constitutively interacts with FGFR1 through the binding of 
the FRS2 PTB domain to the juxtamembrane region25. Recruitment of FRS2 to 
activated FGFR2 also results in the phosphorylation of FRS2, which forms a complex 
with Grb2-Sos upon FGF stimulation, therefore connecting to the MAPK signalling 
cascade164, 165. It has been shown that four Grb2 molecules bind to one 
tyrosine-phosphorylated FRS2 directly via the Grb2 SH2 domain. The Grb2 C-SH3 
domain can also mediate the recruitment of Gab 1 to FRS2, followed by the 
recruitment of PI3-kinase and the activation of the Akt pathway165-167. 
 
Tyrosine-phosphorylated FRS2 also provides binding sites for the phosphatase SHP2. 
SHP2 also binds to phosphorylated FRS2 via the SHP2 N-SH2 domain168, 169. The 
binding of SHP2 to the FGFR-FRS2 complex leads to the tyrosine phosphorylation of 
SHP2 and the recruitment of Grb2 to the FGFR-FRS2-SHP2 complex through the 
interaction between Grb2 and phosphorylated SHP2164, 170, 171. Upon FGF stimulation, 
PLCγ interacts with activated FGFR at Tyr-766 via its SH2 domain, therefore 
activating the PLCγ pathway162, 172.  
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Previous studies performed by our group also indicate the indirect recruitment of Shc 
to FGFR104 and the direct interaction of Grb2 and FGFR2173. These results provide 
new insight into the regulation of the FGFR signalling pathway (Figure 1.14).   
 
Figure 1.14: Signal transduction from FGFR via the formation of multi-protein 
complexes. Formation of a multi-protein complex via multivalent interactions with various 
signalling proteins leads to the activation of additional receptor activation-specific pathways174. 
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1.3 The Signalling Adaptor Protein Grb2 
1.3.1 General introduction to Grb2 
The phosphorylation and activation of RTKs results in the recruitment of cellular 
signalling proteins that contain SH2 domains, which can recognise and bind to the 
phosphotyrosine residues of activated receptors175. Some of these proteins, such as 
PLCγ, SHP2 and PI3K, have enzymatic activities that can catalyse different reactions 
to maintain normal cell functions. However, other proteins such as Grb2 (growth 
factor receptor-bound protein) do not have any enzymatic activities. These proteins 
serve as adaptor proteins to link the activated RTKs to their downstream targets.  
 
Grb2 was first isolated and cloned in 199254; it contains an SH2 domain flanked by 
two SH3 domains. Mammalian Grb2 and its homologues have been isolated and 
identified, such as Sem-5 from Caenorhabditis elegans176 and Ash from rats177. Of the 
Grb2 amino acid sequence, 63% is similar to the C. elegans protein Sem-5, which is 
an important protein in vulval development and myoblast migration176.  
 
N-SH3 SH2 C-SH3Full-length Grb2
 
Figure 1.15: Diagram of Grb2 domains. Grb2 has an SH2 domain flanked by two SH3 
domains. 
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A spliced isoform of Grb2 named Grb3-3 has a deletion of the SH2 domain from 
residues 60 to 100. Grb3-3 retains SH3 domain functions but does not bind to 
phosphotyrosine-containing proteins. Therefore, Grb3-3 is thought to be a suppressor 
of Grb2 function and has been implicated in apoptosis178, 179.  
 
1.3.2 The role of Grb2 in RTK signalling 
1.3.2.1 Grb2 function 
Grb2 plays an important role in several RTK signalling pathways by interacting with 
other signalling receptors, enzymes or adaptor proteins via its SH2 or SH3 domains. 
For example, non-phosphorylated Grb2 interacts with PDGFR by recognising 
phosphotyrosine residues through its SH2 domain54, 180, 181. The SH2 domain of Grb2 
recognises and binds to the pYXNX motif with a preference for residues Q, V, and Y 
at the P+1 position and F, Q, and Y at the P+3 position56 . 
 
Microinjection studies performed by Lowenstein et al. indicate that injection of Grb2 
or H-Ras alone into quiescent rat embryo fibroblast cells has no effect on mitogenesis, 
while injecting both together stimulates DNA synthesis. This suggests that Grb2 has a 
positive effect on the Ras-mediated cell signalling pathway, and both the SH2 and 
SH3 domains are important for stimulating DNA synthesis54. Subsequent 
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microinjection experiments using an anti-Ash/Grb2 antibody revealed that the 
antibody can abrogate the cellular effects of EGF and PDGF, resulting in the 
inhibition of DNA synthesis and causing a reversion in Rac-regulated actin fibre 
assembly to the unstimulated level. These results led to a proposed role for Ash/Grb2 
in controlling RTK signalling transduction to Ras and Rac as a linker joining RTK 
activation to downstream signalling16, 180, 182-184. 
 
1.3.2.2 The Grb2-Sos interaction is SH3 domain-dependent  
Sos, the guanine nucleotide exchange factor of Ras to activated receptors, 
constitutively associates with Grb2 in mammalian cells185-187. Two different Sos 
proteins, Sos1 and Sos2, are found in mammalian cells. Sos1 and Sos2 share 65% 
similarity in their amino acid sequences, but their C-terminal regions are quite 
different, with the conserved region restricted only to the short proline-rich motif 185, 
188
. Both in vitro and in vivo studies performed by Yang et al. indicate that hSos1 and 
hSos2 have different binding affinities to Grb2, and the higher affinity of hSos2 for 
Grb2 may be due to the existence of an extra SH3 binding motif and the relative 
positions of the binding domains within the C-terminal domain of hSos2. Therefore, 
hSos1 and hSos2 are proposed to have different roles in receptor-mediated 
Ras-activation based on their interactions with Grb2. Moreover, this study also 
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demonstrates that both the N-SH3 and C-SH3 domains are involved in Grb2-Sos 
complex formation189. 
 
NMR structures reported by Goudreau et al. show that the Grb2 N-SH3 domain is 
highly similar to other human SH3 domain-containing proteins, such as Spectrin76, 190. 
The SH3 domains of these proteins have a compact β-barrel structure consisting of 
five to six antiparallel β-strands and a C-terminal α-helix. Further experiments have 
investigated the SH3 domain-mediated Grb2-Sos interaction at the molecular level. 
Studies have also revealed the NMR structure of the Grb2 N-SH3 domain with the 
proline-rich peptide derived from the hSos C-terminal proline-rich region. The SH3 
domain sequences form an exposed hydrophobic patch on the surface of the protein, 
and the peptide binds to the hydrophobic patch at the conserved aromatic 
residues191-194. 
 
1.3.2.3 The Grb2-Shc interaction is SH2 domain-dependent 
Another important cellular signalling protein involved in the receptor-Grb2 
interaction is Shc, which has a domain architecture consisting of a PTB domain, a 
collagen homology 1 (CH1) domain and an SH2 domain. The ShcA family has three 
isoforms: p46, p52 and p66. All three isoforms are known to serve as signalling 
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adaptors that can form complexes with activated EGFRs and therefore control their 
downstream signalling pathways, which regulates the proliferation of mammalian 
cells195. p52 and p46 Shc isoforms activate the Ras and MAP kinase pathway, while 
p66 participates in the regulation of the cellular response to oxidative stress and 
lifespan196.  
 
The Shc protein associates with activated EGFR on the cellular membrane following 
EGF stimulation197. An early study indicates that the Shc p46 and p52 isoforms are 
tyrosine phosphorylated in Rat-2 v-Src cells, and a Grb2-Shc complex can be 
immunoprecipitated in these cells. Additionally, phosphorylated Shc recruits and 
forms a stable complex with Grb2-Sos through the Grb2 SH2 domain in response to 
growth factor stimulation181, 198-200. Moreover, a short YV/IN motif has been identified 
on Shc as the binding site for the Grb2 SH2 domain181. 
 
1.3.2.4 The Grb2-Sos complex in RTK signalling  
The Grb2-Sos complex binds to activated growth factor receptors directly or 
indirectly via other proteins such as Shc adaptor protein, Syp or SHP254, 198, 201.  
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A study performed by Buday et al. indicates that the Grb2/Sos complex associates 
with activated EGFR through Grb2 upon EGF stimulation in Rat-1 fibroblast cells. 
The formation of the EGFR-Grb2-Sos complex also alters the subcellular localisation 
of Sos to the membrane. Furthermore, an earlier study demonstrates that the rate of 
GTP binding to Ras is increased when Rat-1 cells are stimulated with EGF. Therefore, 
the formation of activated EGFR-Grb2-Sos complexes in Rat-1 cells is believed to 
play a key role in Ras activation202. EGF-induced Ras and MAPK activation are also 
enhanced when Grb2 is overexpressed203. Further studies have identified the 
interaction between Grb2 and Sos; both in vivo and in vitro experiments performed by 
Chardin et al. reveal that downstream Ras signalling is mediated by Grb2 coupling the 
activated RTKs and the C-terminal region of Sos through its SH3 domain185.  
 
In contrast, insulin-stimulated ERK activation is mediated by the Grb2-Sos complex 
recruiting tyrosine phosphorylated Shc and IRS-1 via the Grb2 SH2 domain. However, 
there is no evidence of Grb2 phosphorylation by the activated insulin receptor181, 204. 
Several studies also suggest that the interaction of the Grb2-Sos complex with 
phosphorylated Shc in vitro can initiate GTP binding to Ras198, suggesting a 
mechanism by which the Grb2-Sos complex may regulate Ras activation198, 205. 
Moreover, Shc is also tyrosine-phosphorylated upon PDGF stimulation, and 
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tyrosine-phosphorylated Shc mediates the interaction between the Grb2-Sos complex 
and the activated PDGFR. The membrane-associated PDGFR-Shc-Grb2-Sos complex 
is important for proliferation in response to PDGF stimulation206.  
 
1.3.3 Grb2 structure 
The crystal structure of dimeric Grb2 was solved in 1995 (Figure 1.16). Both the SH2 
and SH3 domains of Grb2 have classic structures. The SH2 domain is composed of a 
central antiparallel β-sheet flanked by two α-helices, while both the N-SH3 and 
C-SH3 domains contain five antiparallel β-sheets207.  
         
Figure 1.16: Dimeric Grb2 structure. Two Grb2 molecules are shown. The N-SH3, SH2 and 
C-SH3 domains of Grb2 molecule A are shown in red, green and blue, respectively. The 
N-SH3, SH2 and C-SH3 domains of Grb2 molecule B are shown in pink, light green and purple, 
respectively. Adapted from Maignan et al., Science, 268, 291-3 (1995). PDB code: 1GRI207. 
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The SH3 domains are not in contact with the SH2 domain (Figure 1.17). The two SH3 
domains interact with each other via Van der Waals forces with five H-bonds within 
1000 Å2, which is weaker than typical protein-protein interactions. This unusually 
weak interaction suggests that the two SH3 domains of a Grb2 monomer can adopt 
different orientations, making Grb2 a flexible adaptor. A further NMR solution 
structure study of Grb2 performed by Yuzawa et al. also indicates that the Grb2 SH2 
domain is connected to the C-SH3 domain through a flexible linker, and at least 20 
different structures can be seen in solution. Moreover, the flexibility of Grb2 may be 
important for target recognition and binding208. 
                
Figure 1.17: Grb2 monomer structure. The N-SH3, SH2 and C-SH3 domains of the Grb2 
monomer are shown in red, green and blue, respectively. The structure shows that all three 
binding sites of Grb2 are fully accessible. Adapted from Maignan et al., Science, 268, 291-3 
(1995). PDB code: 1GRI207. 
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1.4 Protein Tyrosine Phosphatases (PTPs) and Signalling 
1.4.1 PTP, Protein tyrosine phosphatase 
1.4.1.1 Protein phosphatases 
In contrast to kinases, protein phosphatases function to dephosphorylate proteins. The 
coordinated action of the tyrosine phosphorylation and dephosphorylation processes 
of certain proteins in cells is the key to the regulation of cell signalling209. 
 
Protein phosphatases can be grouped into three main classes according to their 
sequences, structures and catalytic functions: 1) the phosphoprotein phosphatase (PPP) 
family (PP1, PP2A, PP2B, PP4, PP5, PP6, PP7, (2) the PTP super-family, and 3) the 
aspartate-based protein phosphatases210.  
 
1.4.1.2 PTP families 
The human genome encodes 107 PTPs that can be divided into four families 
according to the amino acid sequences of the catalytic domains: class I Cys-based 
PTPs (99 proteins), class II Cys-based PTPs (one protein), class III Cys-based PTPs 
(three proteins), and Asp-based PTPs (four proteins)211. 
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Among class I PTPs, 38 are considered “classical PTPs” and can be classified into 
two different groups: classical receptor PTPs (RPTPs, 21 proteins), which are 
transmembrane, receptor-like PTPs; and classical non-receptor PTPs (NRPTPs, 17 
proteins)211, 212.  
 
Receptor-like PTPs are transmembrane receptors that contain PTPase domains. All 
RPTPs have an extracellular domain followed by a transmembrane region and a 
C-terminal catalytic cytoplasmic domain. Some receptor-like PTPs contain the 
fibronectin type III (FN-III) repeat region, immunoglobulin-like domains, MAM 
domains or carbonic anhydrase (CA)-like domains in their extracellular regions. The 
cytoplasmic region generally contains two copies of the PTPase domain, though the 
second domain is usually inactive. All subclasses of RPTPs are expressed only in the 
nervous system, except for type I RPTPs. Although RPTPs are thought to be ligand 
receptors, their ligands are still largely unknown213.  
  
Non-receptor PTPs (intracellular PTPs) lack transmembrane regions and are targeted 
via their N- and/or C-terminal regulatory sequences to multiple intracellular locations. 
They can be divided into two groups according to their substrate specificities. The 
first group is phosphotyrosine-specific phosphatases, including PTP1B, STEP, 
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PTP-SL, and SH2 domain-containing phosphatases (SHP1 and SHP2). The second 
group contains phosphatases that can dephosphorylate both phosphotyrosines and 
phosphoserines/threonines, known as dual specificity phosphatases. 
 
1.4.2 Signalling by SHP2 
SHP2 is required for ERK/MAP kinase pathway activation in most RTK signalling 
pathways. However, the mechanism by which SHP2 mediates Ras/ERK activation is 
not completely understood.  
 
1.4.2.1 SHP2 as an adaptor protein 
Studies reveal that SHP2 can directly interact with activated EGFR and PDGFR or 
indirectly through binding to other tyrosine-phosphorylated adaptor proteins, such as 
FRS2 and Gab1, through SHP2 SH2 domains170, 214-216. Tyr 1009 of activated PDGFR 
is the binding site for SHP2, and both in vivo and in vitro binding studies carried out 
by Kazlauskas et al. demonstrate that the N-terminal SH2 domain directly binds to the 
activated growth factor receptor. Moreover, the research by Kazlauskas et al. also 
indicates that SHP2 is serine/threonine-phosphorylated and has trace tyrosine 
phosphorylation in A431 cells in the unstimulated state217. The presence of EGF 
significantly increases the tyrosine phosphorylation level of SHP2215. Several studies 
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propose that SHP2 functions as an adaptor protein. Stimulation by EGF or PDGF 
leads to SHP2 phosphorylation at Tyr 542 and Tyr 580, which can provide binding 
sites for the Grb2 SH2 domain, therefore recruiting the Grb2/Sos complex to the cell 
membrane and activating the Ras pathway201, 218, 201, 219. However, early studies reveal 
that tyrosine phosphorylation of SHP2 has no effect on EGF and PDGF signalling in 
293 cells or on FGF-induced ERK activation in Xenopus embryos220, 221. Surprisingly, 
Hadari et al170. indicate that SHP2 binds to tyrosine-phosphorylated FRS2 via the 
SHP2 N-SH2 domain in the FGF signalling pathway; this interaction leads to tyrosine 
phosphorylation of SHP2 and Grb2-SHP2 complex formation. The binding of 
tyrosine phosphorylated-SHP2 to tyrosine phosphorylated-FRS2 is necessary in 
FGF-induced MAP kinase activation and cell differentiation in PC12 cells. This result 
suggests that tyrosine phosphorylation of SHP2 may play a role in growth 
factor-induced MAP kinase activation. Tyrosine phosphorylation of SHP2 is required 
for FGF and PDGF-induced ERK activation but not for EGF signalling in fibroblasts. 
Additional data also show that Tyr 542 is the major Grb2 SH2 domain binding site in 
tyrosine-phosphorylated SHP2, though Grb2 binding to tyrosine 
phosphorylated-SHP2 is not necessary in SHP2-mediated Ras/ERK activation. It is 
proposed that tyrosine phosphorylation of SHP2 may be important in certain kinds of 
growth factor-induced Ras/ERK activation. However, it is also suggested that SHP2 
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may be important in regulating the MAP kinase pathway through PTP activity but not 
in acting as an adaptor protein for the Grb2/Sos complex222. 
 
1.4.2.2 SHP2-IRS1 interaction, SHP2 activation and signalling by SHP2 
Studies on the insulin receptor reveal that SHP2 does not bind to the tyrosine 
phosphorylated form of the receptor and is not tyrosine phosphorylated as part of the 
insulin response of 3T3-L1 adipocytes. Instead, upon insulin treatment, SHP2 
associates with the phosphotyrosine-containing sequence of IRS 1 (insulin stimulation 
results in at least 12 potential tyrosine phosphorylation sites in IRS1) on the YIDL 
motif via the SH2 domain of SHP2 in both in vitro and in vivo experiments214, 215, 223. 
These results suggest a model of insulin receptor-IRS1-SHP2 signalling complex 
formation214. To understand the role of IRS-1 in SHP2 activation, Sugimoto et al. 
performed in vitro binding experiments and SHP2 activity studies. Their surface 
plasmon resonance data suggest that the SH2 domains of SHP2 have different binding 
affinities towards IRS-1 phosphopeptides (N-SH2 prefers pY1172, whereas C-SH2 
prefers pY1222). In contrast, PTPase assay results also demonstrate that both pY1172 
and pY1222 have the ability to increase SHP2 activity, and pY1222 has a significant 
dose-dependence when compared with pY1172. This study proposes an allosteric 
activation mechanism in which SHP2 binds two individual 
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phosphotyrosine-containing motifs to its N-SH2 and C-SH2 domains, resulting in 
activation of the phosphatase domain and dephosphorylation of the third 
phosphotyrosine-containing motif224. SHP2 is also proposed to be a positive factor in 
growth factor-stimulated cell proliferation225. Noguchi et al. further identified that 
catalytically inactivated SHP2 (C459S) specifically inhibits insulin-stimulated 
Ras/MAP kinase activity in CHO cells, while insulin-stimulated PI3-kinase activity is 
not affected by catalytically inactive SHP2. Moreover, tyrosine phosphorylated-Shc 
binds to Grb2 and forms a complex with Grb2 and Sos. Grb2 also binds to IRS-1, 
linking IRS-1 to Sos and therefore leading to Ras activation in response to insulin 
stimulation181, 200, 204. However, catalytically inactivated SHP2 has no effect on the 
formation of Grb2-IRS-1 and Grb2-Shc complexes, suggesting that SHP2 regulates an 
upstream signalling protein that is necessary for insulin-induced Ras activation. 
Although it is indicated that the binding of SHP2 to IRS-1 plays a part in regulating 
Ras activation by controlling an unknown upstream element of the Grb2 and Shc 
pathways, the precise mechanism by which this occurs remains unclear226.  
 
An in vivo study reveals that the expression of the catalytically inactive mutant of 
SHP2 (C459S) has no effect on insulin receptor phosphorylation, Shc phosphorylation 
or IRS-1 phosphorylation but it does decrease insulin-induced MAPK activation and 
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reduces insulin-stimulated mitogenesis by suppressing DNA synthesis. Moreover, a 
120-kDa phosphoprotein that is suggested to be a potential insulin-induced MAPK 
activation regulator interacts with the SH2 domain of SHP2 upon insulin 
stimulation227. 
 
1.4.2.3 SHP2-Gab1 interaction, SHP2 activation and signalling by SHP2 
Deb et al. demonstrate that SHP2 activity is required for EGFR-induced MAPK 
activation in COS-7 cells overexpressing SHP2. Moreover, their results reveal that 
SHP2 has no effect on the Grb2-Shc, Shc-EGFR or Grb2-EGFR interactions, which 
also supports the idea that SHP2 regulates Ras/MAPK activation by controlling an 
upstream element of the Grb2 and Shc pathways228. 
 
SHP2-Gab1 interaction is important in epidermal proliferation. Studies focused on 
EGFR signalling pathways indicate that Gab1 Y627F and SHP2 C459S inhibit 
epidermal proliferation and enhance differentiation. Gab1, a member of a docking 
protein family that can bind to activated receptors and be tyrosine phosphorylated, 
recruits signalling proteins and plays a role in activating MAPK and PI3-kinase229-234. 
Gab1 is also the major binding protein for SHP2 in EGF-stimulated cells235. Cunnick 
et al. characterised the Gab1-SHP2 interaction to study the mechanism by which 
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SHP2 activation mediates MAPK activation. Western blotting results suggest that the 
N-SH2 and C-SH2 domains of SHP2 bind to pY627 and pY659 of Gab1, respectively, 
upon EGF stimulation, and binding both pY627 and pY659 is essential for SHP2 
PTPase activation. Gab1 mutants deficient in SHP2-binding have negative effects on 
Ras/ERK2 activation. Therefore, one possible mechanism is that activated SHP2 
mediates ERK2 activation via the binding of SHP2 to Gab1236, 237. Another study 
provides a more detailed mechanism for SHP2-mediated ERK activation, revealing 
that Gab1 PH domain and SHP2 binding residues (Y627 and Y659) are important for 
the Gab1-SHP2 interaction and are necessary for c-Src, Ras, MEK1 and ERK2 
activation. Therefore, Gab1 may serve as a carrier to target SHP2 to the membrane to 
activate a signalling step upstream of Src and Ras238. 
 
A possible molecular mechanism proposed by Yehenew et al. explains the positive 
role of SHP2 in growth factor-stimulated pathways. PTPase activity is necessary for 
EGF-induced Ras-ERK1/2 activation. SHP2 inhibits the translocation of Ras-GAP to 
the plasma membrane, and therefore, Ras-GAP cannot inactive Ras239. 
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1.4.3 SHP2 domain composition and structure 
1.4.3.1 SHP2 domain composition 
Two vertebrate SH2 domain-containing PTPs, SHP1 and SHP2, have been identified 
as the subfamily of NRPTPs. SHPs have two N-terminal SH2 domains (N-SH2 and 
C-SH2), a PTP domain and a C-terminal hydrophilic tail. The 240- to 250-amino acid 
PTP domain has a signature PTP motif ([I/V]HCxAGxxR[S/T]G, where the 
nucleophilic cysteine is essential for enzyme activity), is specific for hydrolysing 
phosphotyrosine, and is flanked by regulatory sequences. The C-terminal tail contains 
two tyrosine phosphorylation sites that can be variously phosphorylated by different 
protein tyrosine kinases. SHP2 also has proline-rich domains, and it is suggested that 
these act as binding sites for other SH3 domain-containing proteins. 
 
1.4.3.2 SHP2 structure and regulation 
The SHP2 crystal structure has been solved at 2.0-Å resolution (residues 1-527, 
C-terminally truncated). Both the N-SH2 and C-SH2 domains have the conserved 
SH2 fold, a large four-stranded-β-sheet flanked by two α-helices. The PTP domain 
has nine α-helices and 14 β-strands, and the signature PTP motif was found in βM and 
αG connected by loop MG. The signature motif and the other residues required for 
catalysis form a catalytic cleft at the phosphotyrosine binding pocket (Fig 1.18).  
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Figure 1.18: Structure of SHP2 (residues 1-527). The N-SH2 domain is shown in red, and 
the C-SH2 domain is shown in purple. The catalytic PTP is shown in green. Cys-459 is 
coloured blue. Adapted from Hof et al., Cell, 92, 441-50 (1998). PDB code: 2SHP240. 
 
It remains unclear why phosphotyrosine-containing proteins preferentially bind to the 
N-SH2 or C-SH2 domain of SHP2 (also SHP1). A study performed by Beebe et al. 
using a phosphotyrosine peptide library screen indicates that the N-SH2 domain of 
SHP1 selects for peptides with a leucine at the P-2 position; it recognises and binds to 
phosphopeptides with consensus sequences of LXpY(M/F)X(F/M) and LXpYAXL (X 
represents any amino acid). However, the C-SH2 domain almost exclusively selects 
phosphopeptides with (V/I/L)XpYAX(L/V) sequences, which are present in 
immuno-receptor tyrosine-based inhibitory motifs (ITIMs)241, 242.  
 
The SHP2 crystal structure also suggests an autoinhibition mechanism. In the absence 
of its phosphotyrosine target, the N-SH2 domain inserted into the catalytic cleft of the 
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PTP domain results in mutual allosteric inhibition and blocking of the catalytic site, 
converting the SHP2 into the inactive form.  
 
However, the phosphatase activity can be markedly increased using a 
phosphotyrosine peptide to compete with the N-SH2 domain for binding to the PTP 
domain. Moreover, using a peptide containing two phosphotyrosines that occupy both 
N-SH2 and C-SH2 domains can increase the phosphatase activity significantly more 
than the signal phosphotyrosine peptide does to the N-SH2 domain243.  
 
The C-terminal tail also plays an important role in the regulation of SHP1/SHP2 
function. An in vitro assay performed by Pei et al. demonstrates that the last 35 amino 
acids of SHP1 are important for phosphatase activity; the C-terminally truncated 
version has enhanced phosphatase activity244. Lu et al. suggest an intramolecular 
mechanism of regulation of SHP2; phospho-Tyr 542 and phospho-Tyr 580 can 
interact with the N-SH2 domain and C-SH2 domain, respectively, thereby inhibiting 
PTP activity245. Poole et al. also conclude that there are three possible mechanisms by 
which the C-terminal tail participated in SHP2 activity regulation: 1) Tyrosine 
phosphorylation of the C-terminal tail, as phosphorylated Tyr 542 and Tyr 580 at the 
SHP2 C-terminal tail have been suggested to function as the binding sites for the Grb2 
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SH2 domain, therefore connecting SHP2 to the MAP kinase pathway. However, the 
role of tyrosine phosphorylation of SHP2 in regulating signalling remains unclear. 
Tyrosine mutants of SHP2 have no effect on FGF signalling in Xenopus221. 2) Serine 
and threonine phosphorylation of SHP2 by PKC and MAP kinase has been reported in 
response to EGF stimulation both in vitro and in PC12 cells246, 247. Serine 
phosphorylation sites are located at Ser 576 and Ser 591, within the SHP2 C-terminal 
tail. The effect of serine and threonine phosphorylation on the activity of SHP2 
activity is not clear. Zhao’s result shows that serine phosphorylation has no effect on 
SHP2 activity246, whereas Peraldi’s data indicate that threonine phosphorylation may 
decrease SHP2 activity247. 3) The proline-rich motif may recruit SH3 domains. Only 
SHP2 (but not SHP1) has a proline-rich region. However, there is no direct evidence 
that this proline-rich motif interacts with any SH3 domains. Additionally, a study of 
FGF signalling in Xenopus reveals that the C-terminal tail of SHP2 has no effect on 
phosphatase activity221, 248. 
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1.5 Objectives 
1.5.1 The importance of precise protein recruitment in signalling 
pathways 
Cell signalling is initiated by external signals that are transduced into cells via 
membrane-bound receptors. To preserve the integrity of a signal transduction pathway 
without any corruption from other pathways, a critical step is the protein-protein 
interactions that mediate the formation of specific signalling complexes for each 
signalling pathway at the plasma membrane. The signalling complex is an assembly 
of multi-molecular protein complexes formed by sequential binding through 
domain-specific interactions. Schuller has shown the receptor type-specific 
recruitment of signalling complex formation in TrkA, EGFR and FGFR. Her study 
indicates that the differential recruitment of FRS2, Sos, Grb2 and Shc in these three 
different signalling pathways is an important mechanism of determining signalling 
specificity249.  
 
One of the questions regarding the FGFR2 signalling pathway that remains unclear is 
the molecular mechanism of the protein-protein interactions in the FGFR2 signalling 
complex. This study focuses on the roles of Grb2 in FGFR2 activation and in 
FGFR2-mediated formation of the early signalling complex. 
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1.5.2 Investigation of the regulation of Grb2 in FGFR2 signalling 
activation 
Grb2 mediates EGFR signalling by directly interacting with activated EGFR through 
the Grb2 SH2 domain. However, a study by our group revealed that the interaction 
between Grb2 and FGFR2 is SH3 domain-dependent, and the Grb2-FGFR2 
interaction is important in regulating SHP2 function173. Past studies of the biological 
function of Grb2 focused on the downstream responses of RTK signalling pathways. 
Grb2 is best known for its ability to link activated RTKs, such as EGFR or PDGFR, 
to the activation of Ras and its downstream signalling cascades such as the ERK1/2 
pathway16, 180, 182-184, 202, 203, 206. The first part of this study focuses on investigating the 
role of Grb2 in FGFR2 activation/phosphorylation in early signalling events.  
 
1.5.3 Investigation of the regulation of Grb2 recruitment to FGFR2  
Biophysical studies have investigated the direct binding of the Grb2 SH3 domain to 
FGFR2 using FGFR2 sequence-derived peptides173, but the molecular mechanism of 
the Grb2-FGFR2 interaction has not yet been elucidated. Therefore, the second part of 
the current study focuses on the molecular mechanism of FGFR2-mediated formation 
of the early signalling complex and the regulation of this process by Grb2. Because 
little is currently known about Grb2 phosphorylation and its role in the FGFR2 
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signalling pathway, this study also examines the ability of FGFR2 to induce tyrosine 
phosphorylation of Grb2 and the role of Grb2 tyrosine mutants in FGFR2 activation 
and downstream signalling.   
 
 
 
 
 
 
 
 
 
87 
 
 
 
Chapter 2 
 
 
Materials and Methods 
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2.1 Materials 
2.1.1Chemicals 
All chemicals used in this study were purchased from Sigma, Merck, Melford or 
Fisher unless otherwise stated. 
2.1.2 Enzymes and growth factor 
Enzymes and growth factor Supplier  
Vent DNA polymerase NEB 
T4 DNA polymerase NEB 
Calf intestinal phosphatase (CIP) NEB 
Restriction endonucleases NEB or Promega 
T4 DNA ligase NEB 
RNase Invitrogen  
Thrombin protease Sigma 
Recombinant human FGF9 R&D systems 
 
2.1.3 Kits and other materials 
Kits and other materials Supplier  
Talon superflow resin Clontech  
Glutathiones agarose Clontech or Sigma 
DEAE sepharose GE 
Superdex 75 GE 
Superdex 200 GE 
Protein A agarose Sigma 
Protein G agarose Sigma  
Protease inhibitor cocktail set III EMD 
Lipofectamine 2000 transfection reagent Invitrogen  
Genejuice transfection reagent EMD 
Immobilon-P PVDF membrane Millipore 
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QIAprep spin miniprep kit Qiagen 
QIAquick gel extraction kit Qiagen 
Enhanced chemiluminescence substrate Thermo Scientific 
X-ray film Kodak  
 
2.1.4 Bacterial cell culture reagents 
2.1.4.1 Bacterial growth media 
Luria-Bertani (LB) broth was used as the growth medium for E. coli culture.  
Luria-Bertani (LB) broth 
1.0% (w/v) tryptone 
0.5% (w/v) yeast extract 
0.5% (w/v) sodium chloride 
The medium was autoclaved and appropriate antibiotics were used for selection. 
 
Antibiotic working concentrations 
Ampicillin: 50 µg/ml (prerpared in H2O, following by 0.22 µm filtration) 
Carbenicillin : 250 µg/ml (prerpared in H2O, following by 0.22 µm filtration) 
Kanamycin: 50 µg/ml (prerpared in H2O, following by 0.22 µm filtration) 
Chlormphenicol: 50 µg/ml (prerpared in 100% ethanol) 
 
LB-Agar plates 
1.0% (w/v) agar powder was added to LB broth following by autoclaving. Plates 
containing appropriate antibiotic were prepared after the LB-agar was cooled to 50 oC. 
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2.1.4.2 E. coli glycerol stocks 
Glycerol stocks were prepared by mixing 400 µl 50% autoclaved glycerol and 600 µl 
E. coli overnight culture. Stocks were stored at -80 oC. 
 
2.1.5 Insect cell culture reagents 
Insect-Xpress Protein–Free Medium and Dulbecco’s PBS were purchased from Lonza. 
Fetal bovine serum was supplied by Biosera. Gentamycin sulphate and Pen/Strep 
Fungizone Mixture were purchased from Cambrex. Trypan blue solution was 
purchased from Novagen. 
 
2.1.6 Mammalian cell culture reagents 
HEK 293 complete growth medium  
Dulbecco’s modified Eagle’s Medium (DMEM) and Dulbecco’s PBS were purchased 
from Lonza. Fetal bovine serum was supplied by Biosera. Gentamycin sulphate and 
Pen/Strep Fungizone Mixture were purchased from Cambrex. 
Starvation medium 
DMEM medium without fetal bovine serum for HEK 293 cells. 
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2.1.7 Cell lines and Bacterial strains 
Cell lines and bacterial strains Use  
HEK 293 For transfection and protein production 
HEK 293 stable expressing WT-FGFR2 For transfection and protein production 
Sf9 For infection, virus production and protein production 
DH5α For plasmid DNA production and protein expression 
BL21 (DE3) For protein expression 
Rosetta 2 For protein expression 
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2.1.8 Antibodies 
 
Antibody Epitope Host species Supplier 
Bek antibody (C-8) C-terminus Mouse Santa Cruz 
Bek antibody (C-17) C-terminus Rabbit  Santa Cruz 
Grb2 antibody (F-3) 1-68 Mouse Santa Cruz 
Grb2 antibody (C-7) 54-164 Mouse Santa Cruz 
Grb2 antibody (C-23) C-terminus Rabbit Santa Cruz 
p-Tyr antibody N/A Mouse Santa Cruz 
p44/42 MAPK (ERK1/2) 
antibody 
C-terminus of rat p44 
MAP kinase 
Mouse Cell 
Signaling 
p44/42 MAPK (ERK1/2) 
antibody 
C-terminus of rat p44 
MAP kinase 
Rabbit Cell 
Signaling 
Phospho- p44/42 MAPK 
(ERK1/2) antibody 
Synthetic 
phosphopeptide 
corresponding to 
residues surrounding 
Thr202/Tyr204 of 
human p44 MAP 
kinase 
Mouse Cell 
Signaling 
Phospho- p44/42 MAPK 
(ERK1/2) antibody 
Synthetic 
phosphopeptide 
corresponding to 
residues surrounding 
Thr202/Tyr204 of 
human p44 MAP 
kinase 
Rabbit Cell 
Signaling 
GST antibody immunising animals 
with a GST fusion 
protein 
Rabbit  Cell 
Signaling 
Anti-mouse secondary 
antibody, HRP conjugated 
N/A Horse  Cell 
Signaling 
Anti-rabbit secondary 
antibody, HRP conjugated 
N/A Goat Cell 
Signaling 
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2.1.9 Plasmids 
Plasmid Characteristics   Source  
pcDNA6 Myc/His B Mammalian expression vector 
with a Myc tag and a His tag  
Invitrogen  
pcDNA-MBP Mammalian expression vector 
with a MBP tag 
This study 
pcDNA-Myc-MBP Mammalian expression vector 
with a Myc tag and a MBP tag 
This study 
pcDNA-Myc-Strep Mammalian expression vector 
with a Myc tag and a Strep tag 
This study 
pcDNA-Myc-MBP-WT-FGFR2 Mammalian expression vector 
that expresses C-terminal 
Myc-MBP-tagged wild-type 
full-length FGFR2 
This study 
pcDNA-Myc-Strep-WT-FGFR2 Mammalian expression vector 
that expresses C-terminal 
Myc-Strep-tagged wild-type 
full-length FGFR2 
This study 
pcDNA-Myc-MBP-WT-CYTO Mammalian expression vector 
that expresses C-terminal 
Myc-MBP-tagged FGFR2 
cytoplasmic domain 
This study 
pcDNA-Myc-Strep-WT-CYTO Mammalian expression vector 
that expresses C-terminal 
Myc-Strep-tagged FGFR2 
cytoplasmic domain 
This study 
pBAC4x1 Insect cell expression vector Novagen 
pBAC4x1- WT-FGFR2-MBP Insect cell expression vector that 
expresses C-terminal 
MBP-tagged wild-type full-length 
FGFR2 
This study 
pBAC4x1- WT-CYTO-MBP Insect cell expression vector that 
expresses C-terminal 
MBP-tagged FGFR2 cytoplasmic 
This study 
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domain 
pBAC4x1- WT-EX-MBP Insect cell expression vector that 
expresses C-terminal 
MBP-tagged FGFR2 extracellular 
domain 
This study 
pBAC4x1- WT-FGFR2-His Insect cell expression vector that 
expresses C-terminal His-tagged 
wild-type full-length FGFR2 
This study 
pBAC4x1- WT-CYTO-His Insect cell expression vector that 
expresses C-terminal His-tagged 
FGFR2 cytoplasmic domain 
This study 
pBAC4x1- WT-EX-His Insect cell expression vector that 
expresses C-terminal His-tagged 
FGFR2 extracellular domain 
This study 
pET28a His-tagged bacterial expression 
vector 
Novagen 
pET28a-Grb2 His-tagged bacterial expression 
vector that express wild type full 
length Grb2 
(173)  
pET33b His-tagged bacterial expression 
vector 
Novagen 
pET33b-CYTO Bacterial expression vector that 
expresses N-terminal His-tagged 
FGFR2 cytoplasmic domain 
This study 
pET33b-kinase Bacterial expression vector that 
expresses N-terminal His-tagged 
FGFR2 kinase domain 
This study 
pET33b-C58 Bacterial expression vector that 
expresses N-terminal His-tagged 
FGFR2 C-terminal 58 amino 
acids 
This study 
pGEX2T Bacterial expression vector that 
used for expression of GST-fused 
protein  
GE 
pGEX2T-Grb2 Bacterial expression vector that 
expresses GST-fused wild-type 
full-length Grb2 
(173) 
pGEX2T-N-SH3 Bacterial expression vector that (173) 
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expresses GST-fused Grb2 
N-SH3 domain 
pGEX2T-C-SH3 Bacterial expression vector that 
expresses GST-fused Grb2 
C-SH3 domain 
(173) 
pGEX2T-NSH3-SH2 Bacterial expression vector that 
expresses GST-fused Grb2 
Nsh3-SH2 domain 
(173) 
pGEX2T-SH2-CSH3 Bacterial expression vector that 
expresses GST-fused Grb2 
SH2-CSH3 domain 
(173) 
pGEX2T-Grb2 R/A Bacterial expression vector that 
expresses GST-fused full-length 
Grb2 R86A mutant 
(173) 
pGEX4T2-NSH3-CSH3 Bacterial expression vector that 
expresses GST-fused Grb2 
NSH3-CSH3 domain 
(173) 
pGEX4T2 Bacterial expression vector that 
used for expression of GST-fused 
protein 
GE 
pGEX4T2-2SH2 Bacterial expression vector that 
expresses GST-fused SHP2 
NSH2-CSH2 domain 
This study 
pGEX4T2-N-SH2 Bacterial expression vector that 
expresses GST-fused SHP2 
N-SH2 domain 
This study 
pGEX4T2-C-SH2 Bacterial expression vector that 
expresses GST-fused SHP2 
C-SH2 domain 
This study 
pGEX4T2-2SH2-R32A Bacterial expression vector that 
expresses GST-fused SHP2 
NSH2 R32A-CSH2 domain 
mutant 
This study 
pGEX4T2-2SH2-R138A Bacterial expression vector that 
expresses GST-fused SHP2 
NSH2-CSH2 R138A domain 
mutant 
This study 
pGEX4T2-2SH2-R32/138A Bacterial expression vector that This study 
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2.1.10 Stock solutions 
Coomassie blue stain solution 
0.2% (w/v) Coomassie brilliant blue R 
40% (w/v) methanol 
10% (w/v) acetic acid  
 
Coomassie blue destain solution 
40% (w/v) methanol 
10% (w/v) acetic acid 
 
Lysis buffer 
20 mM Tris-HCl pH 7.5 
138 mM NaCl 
1 mM EGTA 
20 mM β-glycerophosphate 
10% (w/v) glycerol 
1 mM sodium orthovanadate 
20 mM sodium fluoride 
1% (v/v) protease inhibitor cocktail set III 
 
Midiprep Solution I 
50 mM glucose 
25 mM Tris-HCl pH 8.0 
10 mM EDTA 
Autoclaved and stored at 4oC, add 4 µg/ml lysozyme before using. 
expresses GST-fused SHP2 
NSH2 R32A-CSH2 R138A 
domain mutant 
pGEX4T2-C58 Bacterial expression vector that 
expresses GST-fused FGFR2 
C-terminal 58 amino acids 
This study 
pET33b-SHP2 Bacterial expression vector that 
expresses N-terminal His-tagged 
wild-type full-length SHP2 
This study 
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Midiprep Solution II 
0.2 M NaOH 
1% (w/v) SDS 
Freshly prepared 
 
Midiprep Solution III 
8 M ammonium acetate 
Autoclaved and stored at room temperature. 
 
Native-PAGE running buffer (10x) 
1.9 M glycine 
250 mM Tris-base 
 
PBS (10x) 
80 g NaCl 
2 g KCl 
14.4 g Na2HPO4 
2.4 g KH2PO4 
Adjust pH to 7.4 with HCl. Bring volume to 1 litre, autoclave or sterilize by filtration. 
 
PBS (1x) 
137 mM NaCl 
2.7 mM KCl 
100 mM Na2HPO4 
2 mM KH2PO4 
pH 7.4 
 
Ponceau S stain buffer         
0.1% (w/v) Ponceau S   
5% (v/v) acetic acid 
 
Rapid screening buffer 
5 mM EDTA 
10% (w/v) sucrose 
0.25% (w/v) sodium lauryl sulphate (SDS) 
100 mM NaOH 
60 mM KCl 
0.05% (w/v) bromophenol blue  
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SDS-PAGE/Native-PAGE stacking gel buffer 
1.0 M Tris-HCl pH 6.8 
 
SDS-PAGE/Native-PAGE resolving gel buffer 
1.5 M Tris-HCl pH 8.8 
 
SDS-PAGE running buffer (10x) 
1.9 M glycine 
250 mM Tris-base 
10% (w/v) sodium lauryl sulphate (SDS) 
 
Silver stain fix solution    
40% (v/v) ethanol 
10% (v/v) acetic acid 
 
Silver stain sensitise solution  
0.005% (w/v) NN 
0.004% (w/v) sodium thiosulfate 
40% (v/v) ethanol 
10% (v/v) acetic acid 
 
Silver stain destain solution  
40% (v/v) ethanol 
10% (v/v) acetic acid 
 
Silver stain silver nitrate solution  
0.25% (w/v) silver nitrate 
0.03% (w/v) formaldehyde 
 
Silver stain develop solution  
3% (w/v) potassium carbonate 
0.03% (w/v) formaldehyde 
0.0004% (w/v) sodium thiosulfate 
 
Silver stain stop solution 
1.5% (w/v) EDTA  
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Stripping buffer 
62.5 mM Tris-HCl pH 6.7 
2% (w/v) SDS 
0.7% (V/V) β-mercaptoethanol 
 
TBE buffer (10x) 
890 mM Tris-base 
890 mM boric acid 
20 mM EDTA 
 
TBS (10x) 
500 mM Tris-HCl 
1.5 M sodium chloride 
pH 7.4 
 
TBS-T (1x) 
100 ml 10x stock solution 
1 mM EDTA 
0.01% (v/v) Tween-20 
 
Transfer buffer (10x) 
1.9 M glycine 
250 mM Tris-Base 
 
Transfer buffer (1x) 
100 ml 10x stock solution 
200 ml methanol 
700 ml ddH2O 
 
HBS (2x) 
42 mM HEPES pH 7.05 
274 mM NaCl 
10 mM KCl 
1.5 mM Na2HPO4 
2% (w/v) glucose 
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6x DNA loading dye 
0.25% (w/v) bromophenol blue  
0.25% (w/v) xylene xyanol  
30% (v/v) glycerol 
 
6x Native loading buffer 
300 mM Tris-HCl, pH 6.8 
60% (v/v) glycerol 
0.6% (w/v) bromophenol blue 
 
6x Laemmli loading buffer 
300 mM Tris-HCl pH 6.8 
12% (w/v) SDS 
60% (v/v) glycerol 
0.6% (w/v) bromophenol blue 
30 mM DTT (added before use) 
 
2.2 General Molecular Biological Protocols    
2.2.1 DNA manipulation 
2.2.1.1 DNA extraction 
Recombinant plasmids obtained from transformed E. coli DH5α cells were purified 
using the QIAprep Spin Miniprep Kit (Qiagen). Briefly, single colony from 
transformed E. coli DH5α culture was grown overnight in 5 ml LB media containing 
antibiotic at 37oC and 180 rpm. Purification was performed using a QIAprep Spin 
Miniprep Kit (Qiagen) according to the manufacture’s protocol. The bacterial cells 
were lysed using P1 alkaline buffer containing RNase, and the lysate was neutralised 
101 
 
and adjusted to high-salt binding condition using P2 and P3 buffer. Plasmid DNA was 
bound to silica spin column while remaining RNA, cellular proteins and salts were 
removed by spinning down and washing using ethanol containing PB buffer. The 
purified plasmid DNA was eluted from the QIAprep spin column using EB buffer 
(Tris containing buffer, pH 7.0 – 8.5). 
 
2.2.1.2 Agarose gel electrophoresis and DNA extraction from agarose gels 
Agarose gel electrophoresis was used to separate and confirm the size of PCR 
products and to separate restriction-enzyme digested DNA fragments. Agarose was 
dissolved in TAE buffer (40 mM 2-amino-2-hydroxymethyl-1,3-propanediol 
(Tris)-Acetate and 1 mM ethylene-diamine-tetraacetic acid (EDTA)). Gels were set in 
the apparatus provided. DNA samples were prepared by adding 1x DNA loading 
buffer (0.1% bromophenol blue, 20 mM Tris and 20% glycerol). The 100 bp or 1 kb 
ladders (New England Biolabs, NEB) were used as molecular weight standards. 
Electrophoresis was carried out in TAE buffer at a constant voltage of 60 V. Trace 
amount of ethidium bromide was added to the running buffer in order to visualise the 
DNA. The resolved DNA bands were visualised on UV-transilluminators. 
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DNA fragments were extracted from the gel using the QIAquick Gel Extraction Kit 
(Qiagen) according to the manufacturer’s protocol. Provided, agarose was dissolved 
using buffer QE. DNA was absorbed to the silica-membrane of the spin column. Salts 
were washed away by the ethanol-containing PE buffer. The DNA was subsequently 
eluted with buffer EB (10 mM Tris pH 8.5).  
 
2.2.1.3 Determination of DNA concentration 
Double strand DNA has an absorbance at a wavelength of 260 nm. An OD260=1 is 
equivalent to a DNA concentration of 50 µg/ml. The DNA concentration was 
measured using 1 µl of sample in a Nanodrop Spectrophotometer. 
 
2.2.1.4 Restriction enzyme digestion 
Restriction enzymes were purchased from NEB. Reactions were performed in 50 µl 
volumes using 
2 µg of DNA 
2 µl of each restriction enzyme  
5 µl of recommended buffer  
0.5 µl of 100x bovine serum albumin.  
Enzyme digestion reactions were incubated at 37oC for 2 hours or overnight according 
to manufacturer’s protocol. Digested products were then electrophoresed on an 
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agarose gel and subsequently extracted and purified using QIAquick Gel Extraction 
Kit (Qiagen). 
 
2.2.1.5 DNA ligation and transformation 
DNA ligations were set up in 10 µl volumes using  
3:1 molar ratio of insert to vector (~20 ng vector DNA) 
400 U of T4 DNA ligase (NEB) 
1x T4 DNA ligation buffer (NEB), containing 1 mM ATP 
Calculation of insert amount: 
Insert Mass (ng) = 3×[Insert Length (bp)/Vector Length (bp)]× Vector Mass (ng) 
The ligation mixture was mixed well and left overnight at room temperature. 
 
DNA was introduced into bacterial strain by chemical transformation. Method for 
competent cell preparation was described in section 2.2.3. For transformation, 
competent bacteria DH5α were thawed on ice for 12 minutes. 10 µl of ligation 
mixture was added and left on ice for 30 minutes. The cells were then heat shocked at 
42oC for 2 minutes and transferred to ice for another 5 minutes. 1 ml of LB broth was 
added to the cells which were then incubated at 37oC and 180 rpm for 45 minutes. 
Cells were then spun down at 4oC and 800 rpm for 1 minute. Culture medium was 
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discarded; 100 µl of LB was used to resuspend these cells and plated onto agar 
supplemented with the appropriate antibiotic and incubated overnight at 37oC. 
 
2.2.1.6 Rapid screening of plasmid DNA 
Plasmid DNA rapid screening was performed to check if the colonies contain inserts. 
The method involved in lysing bacteria and extract genomic DNA, plasmid DNA and 
RNA. The entire extraction product is subjected to agarose gel electrophoresis.  
 
Cells were picked and resuspended in 20 µl of rapid screen buffer and incubated on 
ice for five minutes followed by incubating at 37oC for 5 minutes. The reactions were 
pelleted by centrifugation at 13,000 rpm for 10 minutes and the samples were run on 
agarose gels. The sizes of the plasmids were compared with the original plasmid 
without insert. 
 
2.2.1.7 DNA sequencing 
All DNA constructs created by molecular cloning were sequenced with appropriate 
primers to make sure the gene sequence is correct and the open reading frame was 
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intact. Purified plasmid DNA and primers were sent to the sequencing facility of 
Wolfson Institute of Biomedical Research for sequencing. 
 
2.2.2 DNA amplification  
2.2.2.1 Polymerase chain reaction 
Oligonucleotide primers were synthesised (Sigma) in order to amplify various genes 
by polymerase chain reaction (PCR). PCR amplification was performed in 50 µl 
reaction volumes; the reaction mixture is listed follow: 
 1x ThermoPol Reaction Buffer (20 mM Tris-HCl, 10 mM (NH4)2SO4, 
10 mM KCl, 2 mM MgSO4 and 0.1 % Triton X-100, pH 8.8 at 25°C) 
 0.2 mM of each deoxynucleoside triphosphates  
 0.4 µM of upstream primer 
 0.4 µM of downstream primer 
 25 ng of DNA template 
 2 units (U) of Vent polymerase  
 5% DMSO 
Thermo cycles (35 cycles of melting step-annealing step-extension step): 
Initial melting step:    95oC, 5 minutes  
Melting step:         95oC, 1 minute                   
Annealing step:       appropriate temperature, 1 minute     
Extension step:       72oC, 1 minute/ kbp               
Final extension step:   72oC, 10 minutes 
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Different annealing temperatures were used according to the Tm values of primers. 
The PCR amplified products were analysed on an agarose gel and purified using 
QIAquick Gel Extraction Kit (Qiagen). 
 
2.2.2.2 Mutagenesis 
Oligonucleotide primers were synthesised (Sigma) in order to perform site-directed 
mutagenesis by polymerase chain reaction (PCR) as in section 2.2.2.1.   
Thermo cycles (18 cycles of melting step-annealing step-extension step): 
Initial melting step:    95oC, 5 minutes  
Melting step:         95oC, 1 minute   
Annealing step:       55 oC, 1 minute    
Extension step:       68oC, 1 minute/ kbp               
Final extension step:   68oC, 10 minutes 
The PCR products were further incubated with 1 µl of DpnI (20,000U/ml) at 37oC for 
one hour in order to digest the parental plasmid DNA since DpnI only recognises its 
restriction site when methylated. Following by clean-up the digestion product, 20 µl 
of the reaction were transformed into DH5α competent cells (transformation: 2.2.1.5). 
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2.2.3 Preparation of competent cells 
The bacterial strains used in this study are E. coli DH5α for cloning of microbacterial 
DNA and expression of proteins, and E. coli BL21 (DE3) for the expression of 
proteins. 
 
Competent DH5α cells or BL21(DE3) were made by rubidium chloride methods; 1 ml 
overnight culture was seeded into 100 ml LB, and incubated at 180 rpm, 37ºC until 
OD600 reaches 0.35. Cells were pelleted at 3500g at 4ºC for 15 min. After discarding 
the supernatant, 0.4x original culture volume of TFB I solution was used to resuspend 
the cell pellet. After 30 min of incubation on ice, pelleted cells again at 3500g at 4ºC 
for 15 min, and 0.04x volume of TFB II solution was added to resuspend the cell 
pellet. Competent cells for transformation were aliquoted and stored at -80ºC. 
 
• TFB I Solution  
Potassium acetate: 30 mM 
Rubidium chloride: 100 mM 
Calcium chloride: 10 mM 
Manganese chloride: 50 mM 
Glycerol: 15% 
pH value was adjusted to 5.8 with dilute acetic acid 
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• TFB II Solution 
MOPS: 10 mM 
Rubidium chloride: 10 mM 
Calcium chloride: 75 mM 
Glycerol: 15% 
pH value was adjusted to 6.5 with 1 M NaOH 
 
2.3 Cell Biological Methods 
2.3.1 HEK 293 cells 
Human Embryonic Kidney 293 (HEK 293) cells were used were from regular 
laboratory stock. Cells were maintained and grown in Dulbecco's Modified Eagle's 
Medium (DMEM) containing 4.5 g/L glucose, 4 mM L-glutamine, 10% fetal calf 
serum (FCS), 0.05 mg/ml gentamycin sulphate (Cambrex), and 1x Pen/Strep 
Fungizone Mixture (Cambrex) at 37°C in a 5% CO2 humidified incubator. The cells 
were split and the culture medium was changed every three to five days when the cell 
density reached 80%. Cell stocks were frozen in DMEM medium containing 20% 
FCS and 10% DMSO and stored in liquid nitrogen. All cell culture work was carried 
out in a tissue culture hood (HeraSafe, Heraeus) 
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2.3.2 Sf9 cells 
Sf9 cells were purchased from Novagen. Cells were maintained and grown in 
Insect-Xpress Protein–Free Medium (Lonza) containing 10% fetal bovine serum 
(FBS), 0.05 mg/ml gentamycin sulphate (Cambrex), and 1x Pen/Strep Fungizone 
Mixture (Cambrex). The Sf9 cell culture was maintained and grown in a 
temperature-controlled orbital shaker at 170 rpm and 27ºC. Cells were passaged every 
3-4 days to ensure the cell density was below 4×106 cells/ml and cell viability was 
higher than 95%. Cell number and viability were checked using Trypan Blue 
Exclusion Method. Briefly, cells and trypan blue solution (Novagen) were mixed 1:1 
and then applied immediately to a hemocytometer. Cells were counted using a light 
microscopic; trypan blue solution stains dead cells only, therefore both cell number 
and cell viability were calculated. 
 
A 35×10 mm culture dish (Sarstedt) was used for co-transfection. 0.5×106 cells/dish 
of Sf9 cells was seeded in 1 ml BacVector Insect Cell Medium 1 hour before 
co-transfection. Dishes were incubated at 27ºC for 1 hour to allow cells to attach to 
the plates. 
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2.3.3 Mammalian cell transfection 
2.3.3.1 Preparation of DNA for transfection 
Large amounts of highly concentrated DNA were required for efficient transfection. A 
single bacterial colony transformed with appropriate plasmid was grown at 37oC and 
180 rpm with appropriate antibiotic. The cells were pelleted by centrifugation at 4,000 
rpm for 20 minutes at 4oC. Cells were resuspended in 5 ml of solution I containing 4 
µg/ml of lysozyme and incubated on ice for 5 minutes. 10 ml of freshly prepared 
solution II was added and mixed by inverting gently four to six times. The insoluble 
cell components were precipitated by adding 5 ml of solution III, followed by 
spinning down at 18,000rpm for 10 minutes at 20oC. 0.7x volume of isopropanol was 
added to precipitated plasmid DNA; precipitated plasmid DNA was pelleted by 
centrifugation at 18,000rpm for 60 minutes at 20oC. Plasmid DNA pellet was washed 
using 70% ice-cold ethanol. Pelleted DNA was dissolved using appropriate volume of 
EB. In order to remove RNA, the DNA solution was treated with 10 µg/ml RNase A 
and incubated at 37oC for 20 minutes. The RNase and trace amount of cellular 
proteins were removed by adding equal volume of phenol/chloroform. The two layers 
were separated by centrifugation at 13,000rpm at 20oC for 3 minutes. The top layer 
containing DNA was transferred to a new tube. 2.5x volume of 100% ice-cold ethanol 
was added to precipitate plasmid DNA. The DNA was pelleted by centrifugation at 
111 
 
18,000 rpm at 4oC for 30 minutes, followed by washing with 70% ice-cold ethanol. 
The plasmid DNA was dried at room temperature and resuspended in 500 µl EB. 
 
      Solution I: 50 mM glucose, 10 mM EDTA and 25 mM Tris-HCl pH 8.0  
      Solution II: 0.2 M NaOH, 1% (w/v) SDS 
      Solution III: 8 M ammonium acetate 
 
2.3.3.2 Transfection 
Transfection was done using calcium phosphate transfection method in 10 ml medium 
in a 10 cm-dish. One day prior to transfection, the cells were plated to less than 50% 
confluence, in order to reach 70-75% confluence the next day. Before transfection, 
prepare two sets of 1.5 ml tubes. 0.5 ml 2x HBS (280 mM NaCl, 10 mM KCl, 1.5 mM 
Na2HPO4, 12 mM dextrose and 50 mM HEPES pH 7.5) was pipetted in one tube. 10 
µg of DNA in 438 µl volume was mixed with 62 µl 2M CaCl2 by drawing up and 
down in a 1 ml pipet and add dropwise to the 2X HBS and incubate at room temperature 
for 20 minutes. The DNA-CaPO4 coprecipitate was added dropwise to the surface of 
the media containing the cells, and swirled to mix. After overnight incubation at 37°C 
in a 5% CO2 incubator, the CaPO4 containing medium was removed and the cell 
monolayer was washed twice with PBS. Normal culture medium was added and the 
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cells were incubated at 37°C in a 5% CO2 incubator. Transient gene expression assays 
in transfected cells were performed 48 hours post transfection.  
 
2.3.3.3 Generation of stable transfected cell lines 
To obtain stable transfected cell line, MfeI (NEB) was used to linerised vectors to 
increase the chances that the vectors do not integrate in a way that disrupt the target 
genes. 293T cell kill curve was determined in order to obtain the minimum 
concentration of blasticidin required to kill untransfected cells. Briefly, 2×105 cells 
were seeded in 6 cm-dishes and incubated overnight. Medium containing different 
concentrations of blasticidin (1 µg/ml, 3 µg/ml, 5 µg/ml, 10 µg/ml, 15 µg/ml, 20 
µg/ml, 25 µg/ml, 30 µg/ml, 35 µg/ml, 40 µg/ml and 45 µg/ml) was used to substitute 
culture medium. The selective medium was replenished every 3 days until the 
appropriate concentration of blasticidin that prevented cell growth could be 
determined. Cells were grown in 96-well plates for a few days until single colonies 
could be observed. The individual colonies were picked, expanded in 25T flasks, and 
protein expression levels were compared by western blotting.  
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2.3.3.4 Preparation of frozen cell stocks 
Cells were centrifuged for 10 minutes and resuspend in freezing medium (10% 
DMSO, 20% FCS and 70% DMEM medium) at a concentration of 2 X 106 cells/0.5 
mL freezing medium. Cells with freezing medium were aliquoted and placed in a 
styrofoam box and covered. Cell stocks were kept at -70°C for 24 hours. After 24 
hours, cells were transferred into a liquid nitrogen container.  
 
2.3.4 Insect cell transfection 
2.3.4.1 Preparation of DNA and transfection 
DNA preparing procedure was described in section 2.3.3.1. Transfection of transfer 
plasmids with lineraized virus DNA (BacMagic DNA) for the production of 
recombinant baculovirus was done using the liposome-mediated transfection method. 
For each transfection, the following co-transfection mixture was mixed in a sterile 
tube and incubated at room temperature for 30 min to allow the formation of 
transfection complexes. 
 0.5 ml BacVector Insect Cell Medium 
 2.5 µl Insect GeneJuice 
 50 ng BacMagic DNA  
 250 ng transfer vector DNA carrying target gene 
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Prior to the end of incubation, culture medium was removed carefully and the 
transfection mixture was added immediately. After an overnight incubation at 27ºC, 
0.5 ml medium was added to each dish and kept for another 4 days. After incubation, 
the culture medium that contains recombinant baculovirus was harvested and filtered; 
the initial recombinant baculovirus generated was covered to avoid from light and 
stored at 4ºC. 
 
2.3.4.2 Virus titer 
Virus titer was determined using the FastPlaxTM Titer Kit (Novagen) according to the 
user manual. This method is based on the determination of the AcNPV gp64 
glycoprotein on the cell surface after 24 hours post-infection. 1×106 cells/well was 
seeded on 6-well plate with 2 ml of cell culture medium. Virus series dilutions (10-2, 
10-4, 10-5, 10-6 and 10-7) were prepared for titer determination. After the cells attached 
to the plate, the culture medium was aspirated and virus dilutions (10-5, 10-6 and 10-7) 
were added drop by drop to avoid disturbing the cell monolayer. The plate was 
incubated at room temperature for 60 minutes with gentle rocking every 10 minutes. 
At the end of incubation, 2 ml of medium was added to each well followed by 
incubating for 24 hours in a humid incubator. Medium containing infectious virus was 
aspirated after 24 hours post-infection. Cells were washed with PBS and fixed with 
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3.7% formaldehyde solution at room temperature for 15 minutes. Blocking was done 
using 1% gelatin in TBST with gentle rocking. After blocking and washing with PBS, 
1 ml/well of FastPlax antibody (1:10,000 in TBST) was added and incubated for 60 
minutes, followed by washing with TBST three times. 1 ml/well of Goat Anti-Mouse 
β-gal Conjugate (1:100 in TBST) was added and incubated for 60 minutes, followed 
by washing with TBST three times. During the last wash, developing solution was 
prepared by mixing 60 µl X-Gal and 60 µl NBT to 15 ml PBS plus 5 mM MgCl2. 
Infected cells were stained after developing solution was added and incubated at 37ºC 
within 60 minutes.  
 
Virus titer could be calculated by the formula: 
Pfu/ml = 5 × (number of infected cells and foci) × (dilution factor) 
 
2.3.4.3 Virus amplification and storage 
A 200 ml culture of Sf9 cells at density of 2×106 cells/ml was prepared in a 500 ml 
shaking flask. Cells were infected at a multiplicity of infection (MOI) of 0.1 and 
incubated with shaking at 170 rpm, 27ºC for 4-5 days. When the cells appeared to be 
well infected with recombinant virus, cells were harvested by centrifugation at 4000 × 
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g for 20 min at 4ºC. Culture medium containing the amplified recombinant 
baculoviurs was filtered using 0.22 µm filter (Millipore), and stored in dark at 4ºC. 
The titer of the amplified recombinant baculoviurs was determined according the 
above description. 
 
2.4 Protein Expression 
2.4.1 Construction of the mammalian cell expression vectors 
2.4.1.1 MBP-tagged mammalian cell expression vector 
Gene that encodes maltose binding protein was amplified from pMAL2t1 vector 
(NEB) using PCR reaction. The pcDNA6 Myc/His B plasmid and the amplified MBP 
DNA fragment were digested using XbaI and PmeI (NEB), followed by DNA ligation 
and transformation. Methods for restriction enzyme digestion, DNA ligation, and 
plasmid DNA transformation to generate the expression vector are described in 
sections 2.2.1.4 and 2.2.1.5. The plasmid DNA that expresses the MBP tag was 
named pcDNA-MBP.  
 
A Myc tag was also introduced into the pcDNA-MBP vector in order to introduce an 
antibody recognition site. The Myc tag fragment containing TEV protease cleavage 
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site and thrombin protease cleavage site was amplified from pcDNA6 Myc/His B 
plasmid. The pcDNA-MBP plasmid and the amplified Myc tag fragment were 
digested using HindIII and XbaI (NEB), followed by DNA ligation and plasmid DNA 
transformation. The plasmid DNA for mammalian cell expression that expresses both 
Myc tag and MBP tag containing TEV protease cleavage site and thrombin protease 
cleavage site was named pcDNA-Myc-MBP. 
 
2.4.1.2 Strep-tagged mammalian cell expression vector 
Another affinity tag for protein purification was chosen in order to produce protein of 
high purity. Strep II tag, an eight amino acid tag, based on the specific interaction 
between streptavidin and biotin, was generated using two complementary primers that 
encode Strep II tag, followed by XbaI and PmeI restriction enzyme digestion. 
pcDNA6-Myc-MBP expression vectors that carries either full-length FGFR2 or 
cytoplasmic domain of FGFR2 were also digested using XbaI and PmeI. This resulted 
in removal of the MBP tag which was replaced by the Strep II tag. Methods for 
restriction enzyme digestion, DNA ligation, and plasmid DNA transformation to 
generate the expression vector are described in sections 2.2.1.4 and 2.2.1.5. 
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2.4.2 Constructions of the insect cell expression vectors 
BacMagicTM DNA System (Novagen) was used in this study to generate recombinant 
baculovirus, eliminating the time-consuming steps of plaque purification. Plasmid 
DNA used for insect cell expression was generated using maltose binding protein 
(MBP) tagged pcDNA6.1 carrying different parts of the FGFR2 genes used in the 
mammalian cell expression system. 2 µg of mammalian expression plasmids were 
digested at 37ºC overnight using HindIII and PmeI in a total volume of 50 µl. The 
pBAC4x1 transfer vector (Novagen) was digested at 37ºC for overnight using AvrII. 
All restriction enzyme digested DNA fragments were purified using QIAquick Gel 
Extraction Kit (Qiagen) according to the user manual. AvrII digested pBAC4x1 
transfer vector was purified to remove trace amount of protein and salts, and treated 
by T4 DNA polymerase (NEB) and 100 µM dNTPs at 12ºC for 15 min to blunt the 
digested DNA fragment. After stopping the T4 polymerase filling up reaction by 
adding 10 mM EDTA and heating to 72ºC for 2 minutes, the DNA was purified and 
digested using HindIII at 37ºC for overnight. Ligation and transformation were 
carried out as above. 
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2.4.3 Small scale protein expression tests 
In order to find out the ideal condition for protein expression in Sf9 cell, tests were 
performed using 2×106 cells/ml in 50 ml medium. Different amounts of baculovirus 
(MOI 2, 5 and 10) were used to infect individual culture. 1 ml culture from each 
culture was taken every 24, 48, 72 and 96 hours after infection. Infected cells were 
pelleted at 1,500 rpm, 4ºC for 10 min, and lysed using 100 µl ice-cold lysis buffer 
(200 mM NaCl, 20 mM HEPES pH7.5, 1% Triton X-100 and 10% glycerol). Samples 
were run on a SDS-PAGE to test for protein expression; recombinant proteins were 
confirmed by western blotting. 
 
2.4.4 Large scale protein expression 
Large scale protein expression was performed using 2×106 cells/ml in 1 litre medium. 
Cells were infected at a MOI of 5, and incubated with shaking at 170 rpm and 27ºC 
for 2 days. Infected cells were pelleted at 1,500 rpm, 4ºC for 20 min, and lysed using 
suitable amount of ice-cold lysis buffer (200 mM NaCl, 20 mM HEPES pH7.5 and 
10% glycerol) containing protease inhibitors (AEBSF, aprotinin, bestatin, E-64, 
leupeptin, pepatatin A and PMSF). After lysing, the lysate was either frozen at -80ºC 
or used directly for protein purification.  
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2.4.5 Constructions of the bacterial expression vectors 
pET28a, pET33b, pGEX2T and pGEX4T2 were used to construct the expression 
vectors according to different requirement. Oligonucleotide primers were designed 
and synthesised in order to amplify various gene fragments by polymerase chain 
reaction (PCR). Methods for PCR amplification are described in section 2.2.2.1. 
Methods for restriction enzyme digestion, DNA ligation and plasmid DNA 
transformation to generate the expression vector are described in sections 2.2.1.4 and 
2.2.1.5.  
 
2.4.6 Bacterial culture and protein production 
Luria Bertani (LB) Broth was used to grow bacterial culture. Protein expression was 
carried out in appropriate amount of LB medium. Individual colonies were grown 
overnight in 5 ml of LB broth supplemented with appropriate antibiotic at 37oC and 
200 rpm. The cultures were then transferred to fresh medium supplemented with 
appropriated antibiotic. The cells were grown at 37ºC and 180 rpm until the optical 
density (OD) of the larger culture reached OD600nm = 0.6-0.8. The expression of 
protein was induced for 4 hours at 37ºC, or overnight at 20ºC with the addition of 
isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 0.1 mM. After 
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the expression period the cells were pelleted at 4,000 rpm for 20 minutes and frozen at 
-20ºC until further use.  
 
2.5 Protein Purification 
2.5.1 Protein purification by affinity chromatography   
2.5.1.1 Maltose binding protein (MBP) fused protein purification 
Amylose resin (NEB) was stored in 20% filtered ethanol. Before using, amylose resin 
was washed with 10 column volumes of filtered water, and equilibrated with 10 times 
column volume of MBP wash buffer (200 mM NaCl and 20 mM HEPES pH7.5). 
Transfected mammalian cells or infected insect cells that expressed the MBP fused 
receptor proteins were lysed using suitable amount of ice-cold lysis buffer (200 mM 
NaCl, 20 mM HEPES pH7.5 and 10% glycerol). Cell lysate was spun at 18,000 rpm 
at 4ºC for 60 min. The supernatant was applied to the amylose resin. In order to 
remove nonspecific binding proteins, amylose resin was washed with 20 column 
volumes of MBP wash buffer (200 mM NaCl and 20 mM HEPES pH7.5). MBP fused 
receptor proteins were eluted with MBP elution buffer (20 mM maltose, 200 mM 
NaCl and 20 mM HEPES pH7.5). The protein identity and purity were confirmed by 
western blotting and silver staining. Amylose resin was regenerated using 5 column 
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volumes of 0.1% SDS, followed by washing with 5 column volumes of MBP wash 
buffer (200 mM NaCl and 20 mM HEPES pH7.5), 5 column volumes of filtered H2O, 
and stored in 20% filtered ethanol at 4ºC. 
 
2.5.1.2 Strep•Tag II -tagged protein purification 
Strep•Tactin Superflow Agarose (Novagen) was stored in 20% filtered ethanol. 
Before using, Strep•Tactin Superflow Agarose was washed with 10 column volumes 
of filtered water, and equilibrated with 10 column volumes of Strep•Tactin wash 
buffer (150 mM NaCl, 1 mM EDTA and 100 mM Tris-HCl pH 8.0). Transfected 
mammalian cells that expressed the Strep•Tactin fused receptor proteins were lysed 
using suitable amount of ice-cold lysis buffer (200 mM NaCl, 20 mM HEPES pH7.5 
and 10% glycerol). Cell lysate was spun at 18,000 rpm at 4ºC for 60 min. The 
supernatant was applied to Strep•Tactin resin. In order to remove nonspecific binding 
proteins, Strep•Tactin resin was washed with 20 column volumes of Strep•Tactin 
wash buffer (150 mM NaCl, 1 mM EDTA and 100 mM Tris-HCl pH 8.0). 
Strep•Tactin fused receptor proteins were eluted with Strep•Tactin elution buffer (2.5 
mM desthiobiotin, 150 mM NaCl, 1 mM EDTA and 100 mM Tris-HCl pH 8.0). The 
protein identity and purity were confirmed using western blot. Strep•Tactin Superflow 
Agarose was regenerated using 5 column volumes of regeneration buffer (1 mM 
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HABA (2-[4'-hydroxy-benzeneazo]benzoic acid), 150 mM NaCl, 1 mM EDTA and 
100 mM Tris-HCl pH 8.0), followed by washing with 5 column volumes of 
Strep•Tactin wash buffer (150 mM NaCl, 1 mM EDTA and 100 mM Tris-HCl pH 
8.0), 5 column volumes of filtered H2O, and stored in 20% filtered ethanol at 4ºC. 
 
2.5.1.3 Proteins purification by hydroxyapatite 
The MBP-fused receptor proteins were further purified using type II CHT ceramic 
hydroxyapatite (Biorad). Protein samples were changed into HAP wash buffer A (150 
mM KCl and 10 mM potassium phosphate pH 6.8) by dialysis. Hydroxyapatite was 
equilibrated using HAP wash buffer A (150 mM KCl and 10 mM potassium 
phosphate pH 6.8). After loading and washing the column with 20 column volumes of 
HAP buffer A, proteins were eluted with a gradient of increasing concentration of 
potassium phosphate buffer at a flow rate of 0.5 ml/minute with 7 ml fractions 
collected (10 mM-600 mM; ÄKTA FPLC system was used to set up the gradient 
elution by mixing HAP wash buffer A and HAP elution buffer B (150 mM KCl and 
1000 mM potassium phosphate pH 6.8). The eluted proteins were detected using UV 
absorbance at 280 nm and verified by SDS-PAGE analysis. Hydroxyapatite was 
regenerated using 5 column volumes of HAP regeneration buffer (400 mM tri-sodium 
phosphate pH 11), following by washing with 5 column volumes of HAP storage 
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buffer (10 mM potassium phosphate pH 6.8 and 0.1% sodium azide), and stored at 
4ºC. This step of purification can also remove the strong binding of maltose on 
maltose binding protein.  
 
2.5.1.4 Protein purification by immobilized metal ion affinity chromatography 
6x histidine-tagged fusion protein (TEV-His, Grb2-His and FGF9-His) used in this 
study were purified as following: 
 
All protein purification procedures were carried out at 4oC. The cells were defrosted 
on ice and resuspended in Talon wash buffer A (250 mM NaCl, 1 mM 
β-mercaptoehanol and 50 mM potassium phosphate pH 8.0) and then lysed by 
sonication (20 x 10 sec bursts with 10 sec intervals). The lysate was centrifuged at 
13,000 g for 1 hour. The supernatant was injected into the equilibrated column at a 
flow rate of 0.5 ml/minute. The talon column was washed with 10 column volumes of 
25 mM imidazole wash buffer (25 mM imidazole, 250 mM NaCl, 1 mM 
β-mercaptoehanol and 50 mM potassium phosphate pH 8.0), followed by eluting with 
10 column volumes of Talon elution buffer B (200 mM imidazole, 250 mM NaCl, 1 
mM β-mercaptoehanol and 50 mM potassium phosphate pH 8.0) with 7 ml fractions 
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collected. After purification, the talon resin should be the resin should be washed with 
10 column volumes of 2-(N-morpholine)-ethanesulfonic acid (MES) buffer (50 mM 
MES pH 5.0), followed by washing with 5 column volumes of filtered H2O, and 
stored in 20% filtered ethanol at 4ºC. The eluted proteins were detected using UV 
absorbance at 280 nm and verified by SDS-PAGE analysis.  
 
2.5.1.5 GST-tagged protein purification 
Glutathione S-transferase-tagged (GST) fusion protein (FGF9-GST) used in this study 
was purified as following: 
 
All protein purification procedures were carried out at 4oC. The cells were defrosted 
on ice and resuspended in GST wash buffer A (PBS) and then lysed by sonication (20 
x 10 sec bursts with 10 sec intervals). The lysate was centrifuged at 13,000 g for 1 
hour. The supernatant was injected into the equilibrated column at a flow rate of 0.5 
ml/minute. The GST column was washed with 10 column volumes of PBS, followed 
by eluting with 10 column volumes of GST elution buffer B (10 mM reduced 
glutathione and 50 mM Tris-HCl pH 8) with 7 ml fractions collected. The eluted 
proteins were detected using UV absorbance at 280 nm and verified by SDS-PAGE 
126 
 
analysis. The GST resin can be regenerated by washing with the following buffers 
sequentially: 10 column volumes of wash buffer A (1x PBS and 300 mM NaCl), 10 
column volumes of wash buffer B (0.5 M NaCl and 0.1 M NaOAc pH 4.5), and 10 
column volumes of wash buffer C (1x PBS and 0.5 % Triton X-100), followed by 
washing with 5 column volumes of filtered H2O, and stored in 20% filtered ethanol at 
4ºC. 
 
2.5.2 TEV protease cleavage and removal 
The purified MBP-fused receptor proteins were treated with TEV protease in order to 
cut the MBP tag. Briefly, 1 µg of TEV was used to cut 5 µg of MBP-fused receptor 
proteins at 4ºC for overnight. The TEV protease was removed by passing through 
Talon superflow agarose (Clontech). The binding flow-through, containing receptor 
proteins and MBP tag, was further passed through amylose resin (NEB) in order to 
remove the released MBP tag. The binding flow-through, containing receptor proteins, 
was collected and concentrated using Millipore amicon centrifugal concentrator 
(Millipore). 
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2.5.3 Thrombin protease cleavage and removal 
The purified GST-fused receptor proteins were treated with thrombin protease in 
order to cut the GST tag. Briefly, 1 unit of thrombin was used to cut 1 mg of 
MBP-fused receptor proteins at 4ºC for overnight. The thrombin protease was 
removed by passing through Benzamidine Sepharose. The binding flow-through, 
containing GST tag and target proteins, was collected and passed through glutathione 
agarose beads to remove the GST tag and the flow-through containing target protein 
was concentrated using Millipore amicon centrifugal concentrator (Millipore).  
 
2.5.4 Protein purification by ion-exchange chromatography 
The receptor proteins were further purified using DEAE (GE Helthcare Life Sciences). 
Protein samples were changed into DEAE wash buffer A (20 mM NaCl and 20 mM 
HEPES pH 7.5) by dialysis. DEAE column was equilibrated using DEAE wash buffer 
A. After loading and washing the column with 20 column volumes of DEAE wash 
buffer A, proteins were eluted with a gradient of increasing concentration of 
potassium phosphate buffer at a flow rate of 0.5 ml/minute with 3 ml fractions 
collected (20 mM-600 mM NaCl; ÄKTA FPLC system was used to set up the 
gradient elution by mixing DEAE wash buffer A and DEAE elution buffer B (1000 
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mM NaCl and 20 mM HEPES pH 7.5). The eluted proteins were detected using UV 
absorbance at 280 nm and verified by SDS-PAGE and western blot analysis. DEAE 
column was regenerated using 5 column volumes of DEAE elution buffer B, followed 
by washing with 5 column volumes of filtered H2O, and stored in 20% filtered ethanol 
at 4ºC. 
 
2.5.5 Protein purification by size exclusion chromatography 
Proteins were further purified using either a Superdex 75, or Superdex 200 
pre-packaged size-exclusion chromatography column and ÄKTA FPLC system 
(Amersham Biosciences) at 4oC. The column was equilibrated with 5 time column 
volume of gel filtration buffer (200 mM NaCl and 20 mM HEPES pH7.5). Protein 
samples were concentrated to less than 5 ml and injected into the equilibrated column 
at a flow rate of 0.5 ml/minute with 0.5-1 ml fractions collected. The eluted proteins 
were detected using UV absorbance at 280 nm and verified by SDS-PAGE analysis. 
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2.6 Protein Gel Electrophoresis 
2.6.1 Sodium Dodecyl Sulphate–Polyacrylamide Gel (SDS-PAGE) 
SDS-PAGE was used to separate protein samples. The gels were composed of a 5% 
stacking layer and different percentage of resolving layer determined by the target 
protein sizes. Electrophoresis was carried out using the Biorad Mini-PROTEAN II 
System (Biorad). Protein samples were mixed with 1x SDS loading dye (Laemmli 
loading dye) (100 mM Tris-HCl pH 6.8, 0.1 % bromophenol blue, 2% SDS, 5% 
β-mercaptoethanol and 10% glycerol) and denatured at 95oC for 4 minutes. 
Pre-stained or Unstained Precision Plus Protein standards (Biorad) were used as 
molecular weight markers. Polyacrylamide gels were electrophoresed using 1X 
Running Buffer (0.025 M Tris, 0.192 M glycine and 0.1% SDS) at a constant voltage 
of 90 V through the stacking layer and 130 V through the resolving layer. Gels were 
stained in a staining solution (0.025% Coomassie Brilliant blue R 250, 40% methanol 
and 7% acetic acid). Protein bands were visualised by destaining gels in a destaining 
solution (40 % (v/v) methanol, 10 % (v/v) acetic acid and 50 % (v/v) H2O). 
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Gel Recipes and Solutions: 
 Stacking  Resolving  
Gel Percentage (%) 5 Gel Percentage (%) 7.5 10 
30% Polyacrylamide (mL) 1.7 30% Polyacrylamide (mL) 2.5 3.33 
1M Tris (pH6.8) (mL) 1.25 1.5M Tris (pH8.8) (mL) 2.5 2.5 
10% Ammonium persulfate 
(mL) 
0.1 10% Ammonium persulfate (mL) 0.1 0.1 
10% SDS (mL) 0.1 10% SDS (mL) 0.1 0.1 
TEMED (mL) 0.01 TEMED (mL) 0.008 0.004 
H2O (mL) 6.8 H2O (mL) 4.8 3.96 
 
2.6.2 Native gel 
Native polyacrylamide gels were used to measure the size of protein complexes or 
separate proteins with different phosphorylation levels. The gels were run using 1x 
Native Running Buffer (0.025 M Tris and 0.192 M glycine) at a constant voltage 
(120V), and followed by coomassie blue staining, silver staining or western blotting 
analysis.  
Gel Recipes and Solutions: 
 Stacking  Separating  
Gel Percentage (%) 5 Gel Percentage (%) 7.5 10 
30% Polyacrylamide (mL) 1.7 30% Polyacrylamide (mL) 2.5 3.33 
1M Tris (pH6.8) (mL) 1.25 1.5M Tris (pH8.8) (mL) 2.5 2.5 
10% Ammonium persulfate 
(mL) 
0.1 10% Ammonium persulfate (mL) 0.1 0.1 
TEMED (mL) 0.01 TEMED (mL) 0.008 0.004 
H2O (mL) 6.9 H2O (mL) 4.9 4.06 
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2.6.3 Coommassie blue staining 
After electrophoresis, gels were placed in stain solution for 60 minutes with gentle 
agitation. To remove non-specifically bound dye from the gels, destain solution was 
used to soak the gels with gentle sgitation until proteins bands could be visualised 
clearly. 
 
2.6.4 Silver staining 
After electrophoresis, gels were fixed in 100 mL fixing solution for 2 hours. Gels 
were sensitized with sensitize solution by shaking for 5 min. Upon completion of the 
staining, gels were destained twice, 3 minutes each using fixing solution, following by 
washing with water twice, 2 min each. Gels were incubated in silver solution for 20 
min to form silver-dye complexes on protein. Gels were washed with water twice, 20 
seconds each. Gels were soaked in the developing solution for suitable time to 
develop the color. EDTA stop solution was used to terminate the development. 
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2.6.5 Western Blot 
2.6.5.1 Transfer  
Proteins were separated with a 7.5% or 10% polyacrylamide gel and Prestained 
Precision Plus Protein standards (Biorad) or Nativemark unstained protein standard 
(Invitrogen) were used for molecular weight comparison. Polyvinylidene Difluoride 
(PVDF) membrane (Millipore) was soaked in methanol for 10 minutes before using. 
Following equilibration, proteins were transferred to a PVDF membrane in Mini 
Protean II (Bio-Rad) by electroblotting in transfer buffer (48 mM Tris, 39 mM glycine, 
0.037% SDS and 20% methanol) with a constant voltage of 250 milliamps (mA) for 2 
hours.  
 
2.6.5.2 Ponceau S staining  
0.1% (w/v) Ponceau S in 5% acetic acid was used to either confirm successful transfer 
of protein onto the PVDF membrane or to stain the protein bands for ease of 
manipulation. Ponceau staining is a rapid reversible detection of protein bands on 
membranes, the dye can be removed by washing with ddH2O or TBS-T buffer.  
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2.6.5.3 Immunoblotting 
Membranes were then incubated for 30 minutes in blocking buffer (5% BSA in 
TBS-T (140 mM NaCl, 3 mM KCl, 0.05% Tween-20 and 25 mM Tris pH 8.0) or 5% 
milk in TBS-T) to block the remaining protein binding sites on the membrane.   
 
The primary antibodies were added at a dilution of 1:1000 to blocking buffer. Upon 
incubation for 2 hours with primary antibody, membranes were washed 3 times with 
TBS-T buffer. The membrane was then incubated in TBS-T buffer with 1:1000 
Horseradish Peroxidase-Conjugated Immunoglobulin G antibody for 1 hour, and the 
membrane was subsequently washed three times in TBS-T. The membrane was 
incubated with Pierce ECL Western Blotting Substrate for 2 minutes. Detection was 
carried out using X-ray film in a dark room. 
 
2.7 Protein Concentration Determination 
2.7.1 Bradford protein assay  
Protein concentrations were determined using the BioRad protein assay kit (BioRad) 
following the manufacturer’s protocol. This method is based on the colour change of 
Coomassie Brilliant Blue G-250 dye, when bound to the protein residues arginine, 
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tryptophan, tyrosine, histidine and phenylalanine, and has an absorption maximum at 
595 nm. The protein concentrations can be determined by comparing with the 
absorbance of the BSA standard. 
 
2.7.2 Protein determination using absorbance at 280 nm  
Proteins in solution absorb ultraviolet light with maximum absorbance at 280 nm due 
to the aromatic rings. Secondary, tertiary, and quaternary structure, also pH, ionic 
strength, etc. can affect the absorbance at 280 nm. 
 
The protein extinction coefficient at 280nm was calculated using the equation: 
Ε280nm (cm-1 M-1) = (number of Trp)*(5500)+(number of Tyr)*(1490)+(number of 
Cys)*(125) 
Protein concentration can be calculated using following equation:  
Concentration (molarity) = Absorbance at 280 nm /extinction coefficient  
 
2.8 Immunoprecipitation 
Whole cell lysate were used for immunoprecipitation wih selected primary antibodies 
to identify the presence and phosphorylation states of proteins. Generally, 1 mg of 
whole cell lysate was prepared in 1 ml volume for immunoprecipitation. 1 µg of the 
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chosen antibody was added and incubated at 4 oC for overnight with gentle rotation. 
After incubation, 50 µl of 50% protein A or protein G agarose beads were added and 
incubated for an additional four hours. The beads were spun down at 13,000 rmp for 3 
minutes, supernatant was removed and the beads were washed 1 ml lysis buffer.  
This washing procedure was repeated for five times in order to remove non-specific 
binding. After the last wash, 50 µl of 2x Laemmli sample buffer were added, the 
sample were boiled and subjected to SDS-PAGE and western blot assay. 
 
2.9 GST pulldown 
Purified protein or total E. coli lysate were prepared in 1 ml volume for GST 
pulldown. 50 µl of 50% glutathione beads were added and incubated for overnight. 
The beads were spun down at 13,000 rmp for 3 minutes, supernatant was removed 
and the beads were washed with 1 ml lysis buffer. This washing procedure was 
repeated for five times in order to remove non-specific binding. After the last wash, 
50 µl of 2x Laemmli sample buffer were added, the sample were boiled and subjected 
to SDS-PAGE and western blot assay. 
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2.10 In vitro Phosphorylation of Purified Receptor Proteins 
Purified receptor proteins were phosphorylated by adding ATP and MgCl2 (5 mM, 
and 10 mM, respectively) and incubated on ice for varied times. The phosphorylation 
reactions were quenched by adding EDTA (prepared in 10 mM HEPES pH 7.5) to a 
final concentration of 25 mM. Proteins were analysed by either SDS-PAGE, native 
PAGE or western blot to study the protein phosphorylation.  
 
2.11 Isothermal Titration Calorimetry (ITC)  
ITC experiments were carried out using a VP Microcal instrument (Northampton, MA) 
and data were analysed using ORIGIN software. All measurements were repeated at 
least three times. The experiments were initiated by injecting protein sample from the 
syringe into the calorimetry cell containing 1.8 ml of another protein sample, used a 
fixed temperature in a range 15 to 25oC. The change in heat of each injection was 
recorded automatically using ORIGIN software.  
 
2.12 Surface Plasmon Resonance (SPR) Analysis 
Protein-protein interactions were analysed using a BIAcore T100 instrument (GE 
Healthcare). Dephosphorylated and phosphorylated FGFR2 cytoplasmic domain, 
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phosphorylated FGFR2 kinase domain and phosphorylated FGFR2 C-terminal tail 
were immobilized on CM 5 chips according to the standard amine coupling protocol. 
Briefly, carboxymethyl groups on the chip surface were activated with a 1:1 mixture 
of N-ethyl-N-(dimethyaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide 
(NHS). Proteins were diluted in 20 mM HEPES, pH 6.5 and injected over the 
activated chip surface. The unbound chip surface was blocked using ethanolamine. 
Proteins were immobilized to approximately 700 or 300 response units. Different 
concentrations of analytes were injected over the immobilized chips at a flow rate of 
30 µl/min for 60 aeconds, 120 seconds or 150 seconds to obtain kinetic data. 
Following 180 seconds of dissociation, the sensor surface was regenerated by 
injection of 30 µl of 0.1% SDS and 60 µl of 500 mM NaCl. Reference responses were 
substrated from flow cells for each analyte injection using BiaEvaluation software. 
The resulting sensorgrams were anaylsed to determine the kinetic parameters. 
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Chapter 3 
 
 
The effect of Grb2 binding on 
FGFR2 phosphorylation  
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3.1 Introduction 
FGFs mediate their biological functions by binding to the Ig-like domains of FGFRs, 
resulting in the dimerisation and phosphorylation of multiple tyrosine residues on the 
cytoplasmic domain of the receptors. The phosphorylated tyrosine residues have two 
important roles: activating the tyrosine kinase activity and providing binding sites for 
other signalling proteins. Mohammadi et al. identified six important tyrosine 
phosphorylation sites on the cytoplasmic domain of FGFR1139. Moreover, Furdui et al. 
indicated that tyrosine phosphorylation occurs in a sequential manner in FGFR1163. 
This precise sequential reaction suggests that correct downstream signalling may be a 
consequence of the proposed phosphorylation pattern.  
 
Previously, we showed the direct interaction between the Grb2 C-SH3 domain and 
FGFR2173. In this chapter, the role of Grb2 in FGFR2 phosphorylation is explored. In 
vitro studies using dot blot indicate that Grb2 binding may induce a conformational 
change of FGFR2, resulting in the exposure of pre-phosphorylated tyrosine residue(s). 
In vitro FGFR2 phosphorylation immunoblotting studies also suggest that the 
Grb2-mediated FGFR2 conformational change leads to increased FGFR2 
phosphorylation. The positive regulatory effect of Grb2 on FGFR2 phosphorylation is 
Grb2 concentration–dependent. Isothermal titration calorimetry determinations 
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revealed a two-site binding model of Grb2 binding to inactivated FGFR2. Therefore, 
Grb2 may be involved in enhancing FGFR2 phosphorylation. Moreover, we show that 
Grb2 regulation of FGFR2 phosphorylation is mediated by direct binding through the 
C-SH3 domain. Grb2 has several flexible structures in solution, which may be 
important for recognising and binding to its targets208. Here, we show that either the 
N-SH3 domain or SH2 domain alone has no effect on the regulation of FGFR2 
phosphorylation, but they may be important in coordinating the role of the C-SH3 
domain in FGFR2 activation. 
 
These results provide new insight into the function of Grb2. We determined that Grb2 
not only may act as an adaptor protein that recruits downstream signalling proteins 
but may also play an important role in regulating FGFR2 signalling activity. 
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3.2 Results 
3.2.1 Expression and purification of the functional FGFR2 
cytoplasmic domain in mammalian cells, insect cells and E. coli  
Both eukaryotic and prokaryotic protein expression systems were used in this study.  
The C-terminal MBP-tagged FGFR2 cytoplasmic domain (residues 309–821) was 
expressed and purified from stably transfected HEK 293 cells to produce proteins 
with post-translational modifications. Silver staining was used to confirm the purity of 
the samples by PAGE after eluting from amylase beads with 10 mM maltose. Figure 
3.1 (A) shows the quality of the purified recombinant protein. The expected molecular 
weight of recombinant MBP-fused FGFR2 cytoplasmic domain is 91 kDa, and 
multiple bands can be seen on the silver stain gel. These additional bands were likely 
due to post-translational modifications, such as phosphorylation or glycosylation, of 
the receptor proteins in HEK 293 cells. To confirm the phosphorylation states of the 
recombinant cytoplasmic domain and to test if the protein was functional after 
purification, 10 ng of the recombinant cytoplasmic domain was incubated at 4°C with 
5 mM ATP and 10 mM MgCl2. Then, 50 mM EDTA was added to stop the 
phosphorylation reactions at various time points. SDS-PAGE and 
anti-phosphotyrosine blotting were used to determine the phosphorylation level of 
each reaction. The recombinant cytoplasmic domain had a basal level of 
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phosphorylation, indicating that it was tyrosine-phosphorylated in HEK 293 cells 
(Figure 3.1 B, 0 sec). The phosphorylation levels increased as the incubation time 
increased, indicating that the FGFR2 cytoplasmic domain can autophosphorylate 
(Figure 3.1 B, 0-300 sec). Therefore, we concluded that the purified recombinant 
cytoplasmic domain retains its tyrosine kinase activity. Because the purified domain 
was tyrosine-phosphorylated in HEK 293 cells, the protein was treated with CIP to 
remove phosphate groups to ensure a uniformly unphosphorylated sample as the 
starting material for further experiments (Figure 3.1 C). However, CIP treatment did 
not remove all of the phosphate groups, and a trace amount of a tyrosine 
phosphorylation signal could still be seen on western blots after extended exposure. 
These results suggest that some of the phosphotyrosines are buried within the 
cytoplasmic domain and are shielded from phosphatases, which may be important in 
maintaining signalling complexes and signal transduction in vivo43. 
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Figure 3.1: Purification and characterisation of the FGFR2 cytoplasmic domain from 
HEK 293 cells. The plasmid containing the FGFR2 cytoplasmic domain was transfected into 
HEK 293 cells by the calcium phosphate precipitation method. Cells were harvested and lysed 
48 hours post-transfection. The supernatant was incubated with amylose resin for 2 hours. 
The beads were washed with buffer five times, and the bound MBP-fused FGFR2 cytoplasmic 
domain was eluted with 10 mM maltose. The purified FGFR2 cytoplasmic domain was then 
subject to SDS-PAGE to analyse its purity (A), activity (B) and phosphatase-treatment 
response (C). (A) Silver stain was used to confirm the purity of the purified receptor protein. M, 
protein marker; lane 1, total cell lysate; lane 2, amylase bead binding flow-through; lane 3, 
purified cytoplasmic domain; lane 4, elution buffer as the negative control for silver staining. (B) 
Tyrosine phosphorylation of recombinant FGFR2 cytoplasmic domain in vitro. Individual 
protein samples were incubated with 5 mM ATP and 10 mM MgCl2, and the phosphorylation 
reactions were quenched by addition of 50 mM EDTA
 
at various time points (0, 10, 30, 60, 180 
and 300 sec). Samples were denatured, separated by SDS-PAGE, and immunoblotted for 
phosphotyrosine. (C) Dephosphorylation of the purified cytoplasmic domain. 
Anti-phosphotyrosine blot showing the phosphorylation states of the purified cytoplasmic 
domain and the CIP-treated cytoplasmic domain (upper blot); an anti-FGFR2 antibody was 
used to confirm equal loading in each lane (lower blot). M, protein marker; lane 1, purified 
cytoplasmic domain; lane 2, phosphatase-treated cytoplasmic domain. The results are 
representative of three independent experiments. 
 
The C-terminal tail (last 58 residues of FGFR2) of FGFR2 has five tyrosine residues.  
Previous studies in our group indicate that the C-terminal tail can be 
tyrosine-phosphorylated and that C-terminal tyrosine-to-phenylalanine mutants cause 
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different FGFR2 phosphorylation patterns, suggesting a potential role for the 
C-terminal tail in the FGFR2-mediated signalling pathway. Therefore, constructs of 
the cytoplasmic domain including the C-terminal tail of FGFR2 were used to study 
the phosphorylation sequence of the FGFR2 cytoplasmic domain. 
 
Native gels (5%) were used to separate FGFR2 cytoplasmic domains with different 
phosphorylation states. Proteins with more phosphate groups have a higher 
charge/mass ratio and can migrate faster in a native gel than those with lower 
charge/mass ratios. Purified protein (10 µg) was incubated with ATP and MgCl2 in 
100 µl buffer to phosphorylate receptor proteins. The reactions were quenched at 
different time points. Native gels were run at 35 V for 48 hours. Despite the long 
running time, the protein samples did not enter the separating gel. However, 
cytoplasmic domains with different phosphorylation levels were separated in the 
sample wells (Figure 3.2 A, indicated by red arrows). The gels were then run for an 
additional 24 hours at 150 V, and silver stain was used to detect proteins in the native 
gel. Two bands can be seen in lane 1 (Figure 3.2 B), indicating that proteins with two 
different states, both unphosphorylated and phosphorylated, were present in the 
sample. This result is consistent with the earlier experimental result that a trace 
amount of phosphorylation remained, possibly due to phosphotyrosines being buried 
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within the protein molecule. Surprisingly, the band pattern after 1 hour suggested that 
a dephosphorylation process occurred after 1-hour incubation. According to Bae et al., 
the tyrosine kinase domain of FGFR may also have phosphatase activity. When a 
large amount of ADP is built up in solution, the kinase domain can function as a 
phosphatase and dephosphorylate itself250. A similar experiment was carried out using 
a dephosphorylated FGFR2 kinase domain (residues 412–760, without the C-terminal 
tail). The dephosphorylated FGFR2 kinase protein samples were incubated with ATP 
and MgCl2 and then quenched with EDTA after 5 or 10 minutes. The FGFR2 kinase 
domains with different phosphorylation levels were separated in a 6% native gel 
(Figure 3.2 C), suggesting that the C-terminus of the FGFR2 cytoplasmic domain may 
affect protein migration in native gels.  
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Figure 3.2: Phosphorylation order of the FGFR2 cytoplasmic domain. Native gels were 
used to separate the FGFR2 cytoplasmic and kinase domains with different phosphorylation 
states. Proteins with different phosphorylation levels can be separated according to their 
charge/mass ratio. Purified FGFR2 cytoplasmic domain was treated with CIP, then incubated 
with ATP/MgCl2 and quenched with EDTA at different time points (from 10 seconds to 
overnight). Purified FGFR2 kinase domain was treated with CIP, then incubated with 
ATP/MgCl2 and quenched with EDTA at 5 and 10 minutes. All protein samples were kept in 
their native states and subjected to native gel electrophoresis analysis. (A) Receptor protein 
with different phosphorylation levels was separated in the liquid phase in the sample wells. 
Dephosphorylation can be seen after a one-hour incubation. (B) After 120 hours of running 
time, receptor proteins remained at the interface of the stacking gel and separating gel. Two 
bands are observed in lane 1 (time 0), suggesting at least two different phosphorylation states 
of the protein (phosphorylated and unphosphorylated). (C) Different phosphorylation states of 
the FGFR2 kinase domain separated in the native gel. The results are representative of three 
independent experiments. 
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An insect cell expression system was also used to produce recombinant FGFR2 
proteins. Methods for soluble protein extraction from infected insect cells are 
described in Chapter 2. The soluble fraction from the cells (100 µg) was used in 
SDS-PAGE and immunoblot experiments to confirm the presence of the receptor 
protein (Figure 3.3 A). The expected molecular weights of the wild-type full-length 
FGFR2 (C-terminal MBP/Myc-fused), cytoplasmic domain (C-terminal 
MBP/Myc-fused), and extracellular domain (C-terminal MBP/Myc-fused) are 124 
kDa, 91 kDa and 68 kDa, respectively. A western blot of recombinant wild-type 
full-length FGFR2 showed multiple bands in the molecular weight range between 250 
kDa and 95 kDa, which was likely due to post-translational modifications on the 
receptor proteins (either glycosylation or phosphorylation). The recombinant 
cytoplasmic domain has an expected molecular weight of 91 kDa, but it appeared to 
have a molecular weight around 100 kDa on the western blot, likely because of 
post-translational modifications on the receptor proteins (phosphorylation). The 
recombinant extracellular domain has an expected molecular weight at 68 kDa, but it 
appeared to have multiple bands in the molecular weight range between 130 kDa and 
55 kDa on the western blot, which was also likely due to post-translational 
modifications on the receptor proteins (glycosylation). A general 
anti-phosphotyrosine antibody was used to study the post-translational modification 
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(phosphorylation) of these purified proteins. The recombinant wild-type full-length 
FGFR2 was highly tyrosine-phosphorylated (Figure 3.3 A, lower panel). This result 
suggests that the receptor is activated after production in the cells, which is likely due 
to the presence of growth factors in the culture medium that activate the wild-type 
full-length receptor and in turn induce the phosphorylation reaction of tyrosine 
residues in the cytoplasmic domain. The recombinant cytoplasmic domain showed a 
very low level of phosphorylation, which may have been due to the kinase domain 
using cellular free ATP to enable the autophosphorylation reaction. As expected, the 
extracellular domain showed no tyrosine phosphorylation. The cytoplasmic domain 
purification from insect cells was based on amylose and hydroxyapatite 
chromatographies. The MBP/Myc-tagged cytoplasmic domain was eluted from 
amylose resin using 10 mM maltose, followed by hydroxyapatite column 
chromatography (Figure 3.3 B). 
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Figure 3.3: Recombinant FGFR2 protein expression and purification in insect Sf9 cells. 
Wild-type full-length FGFR2 plasmid, FGFR2 cytoplasmic domain plasmid and FGFR2 
extracellular domain plasmid were transfected into Sf9 cells to generate recombinant viruses. 
After 4 days of incubation, culture media containing recombinant viruses were collected, and 
the virus titre was calculated. To produce recombinant proteins, Sf9 cells were infected with 
recombinant viruses at MOI=5. The infected cells were grown for 2 days, the cells were 
harvested and lysed, and the total cell lysate was used for protein expression tests. The 
supernatant was subjected to protein purification. (A) Expression of recombinant FGFR2 
proteins in Sf9 cells. Protein expression and phosphorylation states were confirmed using an 
anti-Myc antibody and an anti-phosphotyrosine antibody. (B) Purification of recombinant 
FGFR2 cytoplasmic domain in Sf9 cells. High-purity protein was obtained after amylose and 
hydroxyapatite chromatographies.  
 
Although the expression and purification of the functional recombinant FGFR2 
cytoplasmic domain from eukaryotic protein expression systems (HEK 293 and Sf9 
cells) was successful, only 3 µg and 700 µg of recombinant proteins could be 
extracted from 1 L of HEK 293 cell culture and Sf9 cell cultures, respectively. We 
decided that these systems do not yield enough protein for biophysical studies. 
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To maximise protein production, a prokaryotic protein expression system was chosen 
to carry out large-scale recombinant protein expression and purification. Expression 
and purification were performed as described in Chapter 2. The recombinant FGFR2 
cytoplasmic domain was fused with a C-terminal His-tag. The purity and 
phosphorylation states of the purified protein were verified by SDS-PAGE and 
western blots (Figure 3.4). The expected molecular weight of the recombinant 
His-tagged FGFR2 cytoplasmic domain is 48.8 kDa, but the purified protein appeared 
to have a molecular weight slightly above 50 kDa, suggesting that the recombinant 
protein used free ATP and phosphorylated itself in E. coli. Western blots also showed 
that the purified protein had a low level of tyrosine phosphorylation during expression 
or purification from E. coli (Figure 3.4 B). Recombinant cytoplasmic domain (10 ng) 
was incubated at 4°C with 5 mM ATP and 10 mM MgCl2 in a final volume of 50 µl. 
Then, 50 mM EDTA was added to stop the phosphorylation reactions at different time 
points. Samples were denatured and analysed to confirm the tyrosine kinase function. 
As shown in Figure 3.4 B, the phosphorylation levels of purified proteins increased as 
the incubation time increased. Thus, the prokaryotically expressed protein retains its 
tyrosine kinase function. 
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Figure 3.4: Production and characterisation of recombinant FGFR2 cytoplasmic domain 
in E. coli. The FGFR2 cytoplasmic domain plasmid was transformed into Rosetta strain E. coli 
cells to produce recombinant protein by inducing with 0.1 mM IPTG at 20°C for 16 hours. Cells 
were harvested and lysed, followed by protein purification. The purified recombinant protein 
was subjected to SDS-PAGE and silver staining to check its purity. The activity of the protein 
was determined by incubating the protein with ATP/MgCl2 for various times, and the 
phosphorylation states were confirmed using anti-phosphotyrosine immunoblot. (A) 
Coomassie blue staining revealed above 95% purity of the purified protein. (B) 
Time-dependent tyrosine phosphorylation of purified FGFR2 cytoplasmic domain in vitro. 
Phosphorylation level was determined using an anti-phosphorylation antibody (upper blot); gel 
loading consistency was checked using an anti-FGFR2 antibody (lower blot). The results are 
representative of three independent experiments. 
 
3.2.2 In vitro phosphorylation of the FGFR2 cytoplasmic domain is 
enhanced by Grb2 
Previous studies in our group have demonstrated that the Grb2 adaptor protein binds 
to the FGFR2 C-terminal tail directly via its C-SH3 domain; moreover, the binding of 
Grb2 to FGFR2 prevents site-specific dephosphorylation of FGFR2 by SHP2173. 
However, the role of Grb2 in FGFR2 activation still lacks mechanistic details. The 
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effect of Grb2 on the FGFR2 cytoplasmic domain phosphorylation was therefore 
examined using proteins from both insect cells and E. coli. 
 
Receptor proteins purified from eukaryotic and prokaryotic cells had low levels of 
tyrosine phosphorylation (Figure 3.1, 3.2 and 3.4). However, when Grb2 was not 
present, only a very weak phosphotyrosine signals could be detected when the 
purified FGFR2 cytoplasmic domain was in its native state on the dot blot (Figure 3.5 
A, lane 2). The phosphotyrosine signal could be detected when the purified receptor 
protein was denatured and probed with an anti-phosphorylation antibody in the 
absence of Grb2 (Figure 3.5 B, first panel, lane 2). When Grb2 was added to the dot 
blot, a stronger phosphotyrosine signal could be detected using an 
anti-phosphotyrosine antibody (Figure 3.5 A, lane 3). Because purified Grb2 is not 
tyrosine-phosphorylated in the absence of tyrosine kinase and free ATP/MgCl2 
(Figure 3.5 B, lane 1), the dot blot suggests that the native FGFR2 cytoplasmic 
domain may have a conformation that buries endogenous phosphotyrosine(s) within 
itself. The phosphotyrosine can only access the antibody when either the protein is 
denatured or Grb2 is bound to it, altering its conformation and resulting in exposure 
of the phosphotyrosine residue(s). However, the receptor protein mixed with Grb2 
showed no increase in FGFR2 tyrosine phosphorylation, i.e., Grb2 does not enable 
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cis/trans phosphorylation of the receptor proteins (Figure 3.5 B, first panel, lane 2 and 
3). These results suggest a potential role for Grb2 in changing the FGFR2 
conformation, but this hypothesis still needs to be investigated thoroughly. 
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Figure 3.5: Grb2 exposes buried phosphotyrosine(s) of the FGFR2 cytoplasmic domain. 
Purified FGFR2 cytoplasmic domain was added onto a nitrocellulose membrane, and Grb2 
protein was added to the same dot immediately. The effect of Grb2 in exposing 
phosphotyrosine residue(s) was examined using an anti-phosphotyrosine antibody. (A) A very 
weak tyrosine phosphorylation signal could be detected on the FGFR2 cytoplasmic domain 
without adding Grb2. However, a stronger phosphotyrosine signal could be detected when 
Grb2 was mixed with FGFR2 cytoplasmic domain protein. (B) Denaturing gels and 
anti-phosphotyrosine blots were used to examine the phosphorylation state of the purified 
receptor with/without the presence of Grb2. This experiment suggests that the 
phosphotyrosine signals seen on the dot blot may have been due to exposure of the buried 
phosphotyrosine(s) of the FGFR2 cytoplasmic domain by Grb2. The results are representative 
of two independent experiments. 
154 
 
The dot blot results suggest that Grb2 may induce a conformational change of the 
FGFR2 cytoplasmic domain. Therefore, we investigated the role of Grb2 in receptor 
phosphorylation. To find suitable conditions (concentrations and times) for testing the 
role of Grb2 in FGFR2 phosphorylation, various concentrations of the purified 
FGFR2 cytoplasmic domain were incubated with ATP/MgCl2 in a final volume of 
100 µl at 4°C for 15 minutes, 1 hour or overnight. The phosphorylation levels of the 
cytoplasmic domain were examined using an anti-phosphotyrosine antibody (Figure 
3.6 A, upper panel). The protein concentration of the FGFR2 cytoplasmic domain was 
confirmed using an anti-FGFR2 antibody (Figure 3.6 A, lower panel). We determined 
that 10 ng of the FGFR2 cytoplasmic domain was the best condition for investigating 
the role of Grb2 in FGFR2 activation and for understanding the mechanism of FGFR2 
activation enhanced by Grb2. Under this condition, the FGFR2 cytoplasmic domain is 
only phosphorylated at a low level. Therefore, if Grb2 enhances FGFR2 
phosphorylation, this condition would allow for comparisons between increased 
intensities of phosphorylation signals. 
 
First, to determine the role of Grb2 in FGFR2 cytoplasmic domain activation, 10 ng 
of FGFR2 cytoplasmic domain was mixed with various amounts of Grb2 and 
ATP/MgCl2 in a final volume of 100 µl at 4°C for 15 minutes. 
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Activation/phosphorylation levels of the FGFR2 cytoplasmic domain were detected 
using an anti-phosphotyrosine antibody. The phosphotyrosine signal was significantly 
increased by Grb2 in a concentration-dependent manner (Figure 3.6 C, upper blot). 
These data suggest that Grb2 binds to FGFR2, thereby altering the receptor 
conformation and enabling FGFR2 cytoplasmic domain auto-phosphorylation.  
 
However, the same experiment was repeated using purified FGFR2 kinase domain, 
which does not have the C-terminal tail (Figure 3.6 B). The result shows that Grb2 
has no effect in enhancing FGFR2 kinase domain phosphorylation (Figure 3.6 D, 
upper blot). Because we have previously shown that Grb2 binds to the FGFR2 
C-terminal tail, we propose that the direct binding of Grb2 to the FGFR2 C-terminal 
tail changes the FGFR2 conformation to favour its kinase activity.  Thus, Grb2 
binding enhances FGFR2 auto-phosphorylation. 
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Figure 3.6: Grb2 enhances the tyrosine kinase activity of the FGFR2 cytoplasmic 
domain, but not the FGFR2 kinase domain. To optimise the experimental conditions, 
different concentrations of purified FGFR2 cytoplasmic domains were incubated with 
ATP/MgCl2 for 15 min, 1 hour, or overnight. The phosphorylation levels of the 
auto-phosphorylated FGFR2 cytoplasmic domains were examined using a general 
anti-phosphotyrosine antibody. To compare the effects of Grb2 on the phosphorylation of the 
FGFR2 cytoplasmic and kinase domains, 10 ng of purified FGFR2 cytoplasmic domain or 
FGFR2 kinase domain was mixed with different amounts of Grb2 with/without ATP/MgCl2 and 
incubated for 15 minutes. The amount of phosphorylation was detected by immunoblotting 
with an anti-phosphotyrosine antibody. (A) Different amounts of FGFR2 cytoplasmic domain, 
and different incubation times were used to determine the ideal conditions for further studies. 
Ultimately, 10 ng of FGFR2 cytoplasmic domain with ATP/MgCl2 in a final volume of 100 µl for 
15 minutes was chosen. (B) Illustration of the FGFR2 cytoplasmic (residues 309–821) and 
kinase (residues 412–760) domains. (C) Addition of Grb2 in the presence of ATP/MgCl2 
increases the level of FGFR2 cytoplasmic domain phosphorylation in a 
concentration-dependent manner. (D) Addition of Grb2 has no effect on enhancing FGFR2 
kinase domain phosphorylation in the presence of ATP/MgCl2. The tyrosine phosphorylation 
levels were detected using a general anti-phosphotyrosine antibody. To assess equal loading 
of the FGFR2 cytoplasmic domain, blots were stripped and re-probed with anti-FGFR2 
antibody; however, there is no suitable antibody for FGFR2 kinase domain detection (Figure 
3.6 B.; as opposed to the cytoplasmic domain, the kinase domain lacks the C-terminal tail and 
therefore cannot be detected by FGFR2 antibodies). The increased amount of Grb2 was 
confirmed using an anti-Grb2 antibody. The results are representative of at least two 
independent experiments. 
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3.2.3 The enhanced kinase activity of the FGFR2 cytoplasmic domain 
is mediated by the Grb2 C-SH3 domain 
We conducted several experiments to characterise the mechanism by which direct 
binding of Grb2 enhances FGFR2 activation. First, several Grb2 constructs were 
created (Figure 3.7 A) and the recombinant proteins were purified. The role of these 
different Grb2 domains was examined as described above. Briefly, 10 ng of 
recombinant FGFR2 cytoplasmic domain was incubated with or without ATP/MgCl2 
and with or without Grb2 domains at various concentrations ranging from 1 ng to 
1000 ng. All reactions had a final volume of 100 µl and were incubated on ice for 15 
minutes. SDS-PAGE and western blotting were used to determine the FGFR2 
cytoplasmic domain phosphorylation levels from all reactions (Figure 3.7 B–H).  
 
The Grb2 R86A mutant (Arg-86 is conserved in the canonical SH2 FLI/VRES motif) 
caused an increase in the phosphorylation of FGFR2 cytoplasmic domain, with its 
maximal effect at its maximum at 10 ng protein, whereas the wild-type Grb2 
augmented FGFR2 kinase activity in a concentration-dependent manner up to 1000 ng 
in a 100 µl solution volume (Figure 3.7 B). The Grb2 N-SH3 domain alone and the 
SH2 domain alone had no effects on the phosphorylation of FGFR2 cytoplasmic 
domain (Figure 3.7 C and D, respectively). The Grb2 C-SH3 domain alone enhanced 
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the phosphorylation of FGFR2 cytoplasmic domain and had its maximum effect at 10 
ng (Figure 3.7 E). Therefore, we concluded that the Grb2-enhanced the 
phosphorylation of FGFR2 cytoplasmic domain is mediated by the Grb2 C-SH3 
domain. A truncated polypeptide was also expressed, which included the Grb2 SH2 
domain with either the N-SH3 domain or the C-SH3 domain, to test if the SH2 and 
SH3 domains cooperatively regulate the FGFR2 kinase activity. The NSH3-SH2 
domain (500 ng of protein) slightly enhanced the phosphorylation of FGFR2 
cytoplasmic domain, even though the N-SH3 domain alone and the SH2 domain alone 
had no effect. When the SH2-CSH3 domain was used, enhanced phosphorylation of 
FGFR2 cytoplasmic domain was observed, similar to the wild-type Grb2 or the 
C-SH3 domain alone. 
 
We hypothesised that the Grb2 interaction with the cytoplasmic domain of FGFR2 
occurs via the C-SH3 domain but is enhanced by the presence of the SH2 domain or 
another domain in the case of the NSH3-CSH3 polypeptide. 
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Figure 3.7: Effects of Grb2 and its various domains on the phosphorylation of FGFR2 
cytoplasmic domain. Purified FGFR2 cytoplasmic domain (10 ng) was mixed with different 
amounts of individual domains of Grb2 with/without ATP/MgCl2 and incubated for 15 minutes. 
The amount of phosphorylation was detected by immunoblotting with an anti-phosphotyrosine 
antibody.  (A) Illustration of the different Grb2 domains used in this study. (B) Enhanced 
phosphorylation of FGFR2 cytoplasmic domain by the Grb2 R86A mutant. (C) The N-SH3 
domain alone has no effect on enhancing phosphorylation of FGFR2 cytoplasmic domain. (D) 
The SH2 domain alone has no effect on enhancing phosphorylation of FGFR2 cytoplasmic 
domain. (E) Enhanced phosphorylation of FGFR2 cytoplasmic domain by the Grb2 C-SH3 
domain alone. (F) Enhanced phosphorylation of FGFR2 cytoplasmic domain by the Grb2 
NSH3-SH2 domain. (G) Enhanced phosphorylation of FGFR2 cytoplasmic domain by the 
Grb2 SH2-CSH3 domain. (H) Enhanced phosphorylation of FGFR2 cytoplasmic domain by 
Grb2 NSH3-C-SH3 domain. The phosphorylation of the FGFR2 cytoplasmic domain was 
monitored by anti-phosphotyrosine antibody. As a control, an anti-FGFR2 antibody was used 
to confirm that an equal amount of the FGFR2 cytoplasmic domain was used in all 
experiments. Increasing amounts of Grb2 and various domains were confirmed using 
anti-Grb2 antibodies against the N-SH3 domain (anti-Grb2 (F-9)), SH2 domain (anti-Grb2 
(C-7)), and C-SH3 domain (anti-Grb2 (C-23)). The amounts of FGFR2 phosphorylation were 
quantified using densitometry and are represented graphically. The results are representative 
of at least two independent experiments. 
    
These data suggest that the SH2 domain alone has no effect on FGFR2 cytoplasmic 
domain activity, but it enables the N-SH3 and C-SH3 domains to more efficiently 
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enhance the FGFR2 cytoplasmic domain activity by keeping the conformation of the 
N-SH3 and C-SH3 domains stable. The same theory can be applied to the N-SH3 and 
C-SH3 domains. Grb2 with the SH2 domain deletion (NSH3-CSH3) was also used to 
examine this protein’s ability to enhance FGFR2 cytoplasmic domain activity. 
Notably, this construct enhanced FGFR2 cytoplasmic domain activity at a 
concentration of 10 ng (Figure 3.7 F), which is similar to the effect observed for 
wild-type Grb2 and the Grb2 R86A mutant. Together with the in vitro Grb2-enhanced 
FGFR2 cytoplasmic domain activity, these data suggest that all of the Grb2 domains 
are important in enhancing the FGFR2 cytoplasmic domain activity by stabilising the 
Grb2 conformation.  
 
3.2.4 FGFR2 binding to Grb2 
A previous study investigated the interaction between Grb2 and the FGFR2 
C-terminal tail. Isothermal titration calorimetry (ITC) studies have shown direct 
binding of Grb2 to an unphosphorylated FGFR2 peptide corresponding to the last 15 
amino acid residues with an affinity dissociation constant (KD) of 4 µM and to a 
phosphorylated FGFR2 peptide corresponding to the same region with a binding 
affinity of 2 µM. The Grb2 C-SH3 domain binds to the same unphosphorylated and 
phosphorylated FGFR2 peptides with affinities between 10 to 100 µM173. Full-length 
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FGFR2 cytoplasmic domains (dephosphorylated and re-phosphorylated) and 
full-length Grb2 were used to investigate the FGFR2–Grb2 binding mechanism in 
vitro by biophysical methods. Both the FGFR2 cytoplasmic domain and Grb2 were 
expressed and purified from E. coli. All of the proteins exhibited purities above 98% 
as determined by SDS-PAGE with Coomassie blue staining. We used ITC to 
determine the affinity and stoichiometry of the full-length dephosphorylated FGFR2 
cytoplasmic domain binding to full-length Grb2 (Figure 3.8). Grb2 was present in the 
calorimeter cell, and dephosphorylated FGFR2 cytoplasmic domain was loaded in the 
syringe. The data fit to a model corresponding to a two-site binding event, with two 
Grb2 molecules binding to one dephosphorylated FGFR2 cytoplasmic domain with a 
first dissociation constant of 0.1 µM and a second dissociation constant of 27 µM. 
The initial binding event had a stoichiometry of 0:5, corresponding to one molecule of 
FGFR2 binding to two Grb2 molecules. The second binding event had a 
stoichiometry of 1:1, corresponding to equal numbers of molecules interacting. 
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Figure 3.8: ITC measurement of the interaction between the dephosphorylated FGFR2 
cytoplasmic domain with Grb2. Purified FGFR2 cytoplasmic domain was dephosphorylated 
using CIP. Twenty-eight 10-µl injections of dephosphorylated FGFR2 cytoplasmic domain 
were titrated into Grb2 at 15°C. The top panel show s the data for the baseline-corrected power 
versus time at 15°C, while the bottom panel shows t he integrated heats and the molar ratio of 
the dephosphorylated FGFR2 cytoplasmic domain to Grb2. The data were corrected for the 
heats of dilution of the dephosphorylated FGFR2 cytoplasmic domain and fit to a two-site 
binding model. The results are representative of four independent experiments. 
 
Four possible 2:1 Grb2-FGFR2 binding models can be proposed based on the ITC 
results (Figure 3.9). In model A, two monomeric Grb2 molecules bind to one FGFR2 
molecule on two different proline-rich regions via the Grb2 C-SH3 domain. This 
model is plausible because the FGFR2 C-terminal tail is proline-rich and has four 
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PXXP motifs for SH3 domain binding (see Figure 3.9; the proline-rich regions are 
shown in pink, and the PXXP motifs are underlined). Moreover, our data presented 
above and the pull-down results indicate that the Grb2 C-SH3 domain is the major 
region of Grb2 involved in the Grb2–FGFR2 interaction173. The first Grb2 molecule 
binds to the proline-rich region located in the last 15 residues with a higher binding 
affinity, whereas the second Grb2 molecule binds to another unidentified proline-rich 
region with a lower binding affinity. In model B, one Grb2 molecule binds to one 
FGFR2 molecule at the first proline-rich region via its C-SH3 domain, and another 
Grb2 molecule binds to the same FGFR2 molecule at the second proline-rich region 
via its N-SH3 domain. This model is based on the in vitro GST pull-down experiment, 
which indicated the N-SH3 domain of Grb2 can also precipitate FGFR2 in the HEK 
293 cell line expressing wild-type FGFR2, even though the same result could not be 
obtained using the NIH-3T3 cell line expressing endogenous FGFR2. Moreover, 
FLIM data have provided clear evidence that both the N-SH3 and C-SH3 domains of 
Grb2 bind to FGFR2 in both stimulated and unstimulated cells173. Altogether these 
results suggest a low-affinity binding of the Grb2 N-SH3 domain to FGFR2. 
McDonald et al. proposed that Grb2 may form a dimer251. Therefore, in models C and 
D, we propose that Grb2 forms a dimer and the dimeric Grb2 binds to one FGFR2 
molecule via its SH3 domains. 
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Figure 3.9: The four potential models of 2:1 Grb2-FGFR2 binding. The C-terminal tail of 
FGFR2 has four proline-rich regions, which could serve as binding sites for the Grb2 N-SH3 
and C-SH3 domains. (A) Two Grb2 molecules bind to one FGFR2 molecule on two different 
proline-rich regions via their C-SH3 domains. (B) One Grb2 molecule binds to one FGFR2 
molecule at the first proline-rich region via its C-SH3 domain, and another Grb2 molecule 
binds to the same FGFR2 molecule at the second proline-rich region via its N-SH3 domain. (C) 
and (D) Two Grb2 molecules form a dimer and bind to the C-terminal loop of FGFR2 via the 
N-SH3 domain or C-SH3 domain. 
 
Additional studies are still needed to understand the detailed mechanism of Grb2 
binding to FGFR2. First, no biophysical data support the direct binding of the N-SH3 
domain to FGFR2. If such binding occurs, it would be important to determine the 
binding site on FGFR2 and the binding affinity of the N-SH3 domain to the 
full-length FGFR2 cytoplasmic domain. The C-SH3 domain interacts with FGFR2 
directly in vivo, and an ITC binding study using purified C-SH3 domain and FGFR2 
peptides also showed a binding affinity above 10 µM173. Second, it is unclear if the 
affinity of the full-length FGFR2 cytoplasmic domain will be similar to that of 
FGFR2 peptides. Third, the SH2 domain does not interact with FGFR2 in basal or 
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ligand-stimulated cells. Therefore, one of the SH2 domains might function to stabilise 
either the N-SH3 or C-SH3 domain structure. To examine this possibility, we tested 
the interactions of the NSH3-SH2 and SH2-CSH3 domains with the FGFR2 
cytoplasmic domain using surface plasmon resonance (SPR) technology.  
 
Moreover, to examine whether the SH2 domain can enhance the binding affinity to 
the FGFR2 cytoplasmic domain by stabilising the N-SH3 and C-SH3 domain 
conformations, we prepared the NSH3-SH2 and SH2-CSH3 domains for SPR studies. 
The NSH3-CSH3 domain was also prepared, to compare the binding status with the 
N-SH3 or C-SH3 domain alone. Purified dephosphorylated FGFR2 cytoplasmic 
domain was covalently immobilised on a CM5 chip, and different concentrations of 
Grb2 N-SH3, C-SH3, NSH3-SH2, SH2-CSH3 and NSH3-CSH3 domains were used 
as the analytes. 
 
A range of concentrations of the Grb2 N-SH3 domain (1 µM to 400 µM) were flowed 
across the immobilised FGFR2 cytoplasmic domain, and direct binding was detected 
only at 400 µM. This may have been due to non-specific interactions, and such high 
concentration is probably not physiologically relevant (Figure 3.10 A).   
168 
 
Various concentrations of the Grb2 C-SH3 domain (1 µM to 1000 µM) showed weak 
binding (binding affinity above 500 µM) to immobilised FGFR2 cytoplasmic domain 
(Figure 3.10 B).  Notably, various concentrations of the Grb2 NSH3-SH2 domain (1 
µM to 753 µM) or SH2-CSH3 domain (1 µM to 471 µM) bound to the immobilised 
FGFR2 cytoplasmic domain exhibited binding affinities of 349 µM (Figure 3.10 C) or 
135 µM (Figure 3.10 D), respectively. The SH2-deleted NSH3-CSH3 polypeptide 
also interacted directly with the immobilised FGFR2 cytoplasmic domain with a 
binding affinity of 296 µM (Figure 3.10 E). The SPR results suggest that NSH3-SH2, 
SH2-CSH3 and NSH3-CSH3 have stronger binding affinities for FGFR2 than the 
N-SH3 or C-SH3 domain alone. 
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Figure 3.10: Surface plasmon resonance analysis of dephosphorylated FGFR2–Grb2 
interactions. Purified FGFR2 cytoplasmic domain was dephosphorylated by CIP and 
immobilised on a CM5 chip. Different Grb2 domains were purified, and various concentrations 
of the Grb2 proteins were flowed over the chip. (A) Sensorgrams of the Grb2 N-SH3 domain 
binding to dephosphorylated FGFR2 cytoplasmic domain. (B) Sensorgrams of the Grb2 
C-SH3 domain binding to dephosphorylated FGFR2 cytoplasmic domain. (C) Sensorgrams of 
the Grb2 NSH3-SH2 domain binding to dephosphorylated FGFR2 cytoplasmic domain. (D) 
Sensorgrams of the Grb2 SH2-CSH3 domain binding to dephosphorylated FGFR2 
cytoplasmic domain. (E) Sensorgrams of the Grb2 NSH3-CSH3 domain binding to 
dephosphorylated FGFR2 cytoplasmic domain. (F) Summary of the binding affinities of 
dephosphorylated cytoplasmic domain for various Grb2 domains. The N-SH3 domain does not 
bind to the FGFR2 cytoplasmic domain. The C-SH3 domain binds to the FGFR2 cytoplasmic 
domain with a KD>500 µM, the NSH3-SH2 domain binds to the FGFR2 cytoplasmic domain 
with a KD=349 µM, the SH2-CSH3 domain binds to the FGFR2 cytoplasmic domain with a 
KD=135 µM, and the NSH3-CSH3 domain binds to the FGFR2 cytoplasmic domain with a 
KD=296 µM. These data suggest that direct binding of the Grb2 N-SH3 domain or C-SH3 
domain to dephosphorylated FGFR2 cytoplasmic domain can be enhanced by another Grb2 
domain. The biosensor chip response is shown on the y-axis (RU) as a function of time (x-axis) 
at 20°C. The results are representative of at least  two independent experiments. 
170 
 
The two-site binding of Grb2 to dephosphorylated FGFR2 cytoplasmic domain and 
the role of Grb2 in FGFR2 activation have been investigated and are discussed above. 
In vitro FGFR2 phosphorylation studies, ITC measurements and SPR binding studies 
suggest a model in which the binding of Grb2 to the dephosphorylated (inactive) 
FGFR2 cytoplasmic domain enhances FGFR2 activity by altering the receptor 
conformation. 
 
In addition, an earlier study indicates that Grb2 binds to a phosphorylated FGFR2 
C-terminal peptide with a 2 µM binding affinity. Moreover, GST pull-down, 
immunoprecipitation, fluorescent confocal microscopy and FLIM experiments also 
indicate that Grb2 associates with FGF-stimulated FGFR2 both in vitro and in vivo173. 
Thus, studies in this section focused on exploring the interaction between 
phosphorylated (activated) FGFR2 and Grb2, using the full-length FGFR2 
cytoplasmic domain rather than the phosphopeptide. To mimic the early signalling 
process in vivo, the purified FGFR2 cytoplasmic domain was autophosphorylated in 
the presence of ATP/MgCl2 for 15 to 30 minutes. The phosphorylation reaction was 
quenched by the addition of EDTA, followed by size-exclusion chromatography to 
achieve complete buffer exchange and remove any contamination.  
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The interaction between the phosphorylated FGFR2 cytoplasmic domain and Grb2 
was analysed by SPR. To identify whether Grb2 can bind to phosphorylated FGFR2 
cytoplasmic domain via its C-SH3 domain, three different Grb2 constructs were 
purified: Grb2 C-SH3 domain, Grb2 R86A mutant (a conserved arginine-to-alanine 
mutation in the SH2 domain) and Grb2 NSH3-CSH3 domains with the deletion of the 
SH2 domain. The phosphorylated FGFR2 cytoplasmic domain was covalently 
immobilised to a CM5 sensor chip via its primary amine at about 300 RU. The Grb2 
C-SH3 domain, Grb2 R86A mutant or Grb2 NSH3-CSH2 domains were passed over 
the chip in solution. We used sample injections of 45 µl at a flow rate of 30 µl/min. 
The application of a range of concentrations of Grb2 C-SH3 domain (1 µM to 1 mM), 
Grb2 R86A mutant protein (1 µM to 400 µM) or Grb2 NSH3-CSH3 domains (1 µM 
to 200 µM) to the immobilised phosphorylated FGFR2 cytoplasmic domain yielded 
an increase in signal resulting from specific binding of ligands, followed by a 
decrease in signal upon dissociation of the ligands (Figure 3.11 A, B and C). Grb2 
C-SH3 bound to the phosphorylated FGFR2 cytoplasmic domain with an affinity of 
104 µM (Figure 3.11 A), whereas the Grb2 R86A mutant and Grb2 NSH3-CSH3 
domains bound to the phosphorylated FGFR2 cytoplasmic domain with similar 
binding affinities: 2.65 µM for Grb2 R86A (Figure 3.11 B) and 15.4 µM for the Grb2 
NSH3-CSH3 domains (Figure 3.11 C). This SPR binding study not only shows the 
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direct binding of Grb2 to the phosphorylated FGFR2 cytoplasmic domain via the 
Grb2 SH3 domains but also supports the hypothesis that the N-SH3 domain, and 
probably also the SH2 domain, is important in enhancing the C-SH3 domain binding 
affinity toward the phosphorylated FGFR2 cytoplasmic domain by stabilising the SH3 
domain structure.   
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Figure 3.11: Surface plasmon resonance analysis of phosphorylated FGFR2–Grb2 
interactions. Purified FGFR2 cytoplasmic domain was phosphorylated by adding ATP/MgCl2, 
followed by gel-filtration chromatography to remove any extra ATP. Phosphorylated FGFR2 
cytoplasmic domain was immobilised on a CM5 chip. Different Grb2 domains were purified, 
and various concentrations of the Grb2 proteins were flowed over the chip. (A) Sensorgrams of 
the Grb2 C-SH3 domain binding to the phosphorylated FGFR2 cytoplasmic domain. (B) 
Sensorgrams of the Grb2 R86A mutant binding to the phosphorylated FGFR2 cytoplasmic 
domain. (C) Sensorgrams of the Grb2 NSH3-CSH3 domains binding to the phosphorylated 
FGFR2 cytoplasmic domain. (D) Summary of the binding affinities of phosphorylated 
cytoplasmic domain for various Grb2 proteins. The C-SH3 domain binds to the FGFR2 
cytoplasmic domain with a KD=104 µM, the Grb2 R/A mutant binds to the FGFR2 cytoplasmic 
domain with a KD=2.65 µM, and the NSH3-CSH3 domain binds to the FGFR2 cytoplasmic 
domain with a KD=15.4 µM. These data show the direct binding of Grb2 to the phosphorylated 
FGFR2 cytoplasmic domain without the Grb2 SH2 domain. The biosensor chip response is 
shown on the y-axis (RU) as a function of time (x-axis) at 20°C. The results are representative 
of two independent experiments. 
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3.3 Discussion – The Grb2-mediated FGFR2 
phosphorylation and regulation model  
The direct binding of Grb2 to FGFR2 and its function in the SHP2 regulation of 
FGFR2 activation have been previously described173. In this chapter, we investigated 
the role of Grb2 in FGFR2 activation and the mechanistic details of the Grb2-FGFR2 
interaction.  
 
The dot blot results suggest that Grb2 may alter the FGFR2 conformation, leading to 
the exposure of buried phosphotyrosine(s) (Figure 3.5). The in vitro FGFR2 
cytoplasmic domain phosphorylation can be enhanced by Grb2 (Figure 3.6), and this 
activity is mediated by direct binding of Grb2 to the C-terminal tail of FGFR2 
because Grb2 could not enhance FGFR2 kinase domain activation in the absence of 
the C-terminal tail (Figure 3.6). The investigation of how the individual domains of 
Grb2 affect FGFR2 phosphorylation further suggests that the FGFR2 phosphorylation 
enhanced by Grb2 is mainly mediated by the Grb2 C-SH3 domain (Figure 3.7), 
whereas the Grb2 N-SH3 and SH2 domains alone have no effect on FGFR2 
phosphorylation. However, their presence helps to enhance the C-SH3 
domain–mediated FGFR2 activation/phosphorylation (Figure 3.7). NMR structural 
studies indicate that Grb2 is dynamic in solution208; CD and SAXS studies also show 
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the flexibility of Grb2 in solution (Loren Stagg, unpublished data). Therefore, the 
effect of the C-SH3 domain is enhanced in the presence of N-SH3 or SH2, which 
might be achieved by stabilising the C-SH3 structure and thereby increasing its 
binding affinity for FGFR2.  
 
We used SPR to test this hypothesis. A previous study carried out by Ahmed et 
al.173showed that the Grb2 C-SH3 domain alone exhibits low binding affinities for 
FGFR2 peptides (above 10 µM). Our SPR data also indicate that the C-SH3 domain 
alone has a low affinity for the dephosphorylated FGFR2 cytoplasmic domain. The 
observed binding between the N-SH3 domain alone and the dephosphorylated FGFR2 
cytoplasmic domain may not be physiologically relevant. The inclusion of either the 
N-SH3 or SH2 domain with the C-SH3 domain increases the binding affinity of the 
C-SH3 domain (also the N-SH3 domain) toward the dephosphorylated FGFR2 
cytoplasmic domain (Figure 3.10). The ITC data indicate a 2:1 stoichiometry for the 
Grb2:dephosphorylated FGFR2 binding model (Figure 3.8). Moreover, SPR data also 
demonstrate that phosphorylated FGFR2 cytoplasmic domain binds to Grb2 and that 
this interaction is mediated by the C-SH3 domain (Figure 3.11). 
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Based on these findings, we propose a mechanism of Grb2-enhanced FGFR2 
activation. The binding of Grb2 to inactive/unphosphorylated FGFR2 may cause a 
conformational change in FGFR2, which increases the FGFR2 tyrosine kinase activity. 
The ITC data suggest that Grb2 also might induce FGFR2 dimerisation by bringing 
two FGFR2 molecules together, thereby increasing FGFR2 activity (Figure 3.12). 
Several Grb2 knock-out cell lines have been generated in our group to further 
investigate the role of Grb2 in FGFR2 signalling pathway regulation. In conclusion, 
this chapter presents our investigation of the role of Grb2 in the regulation of FGFR2 
phosphorylation. 
 
 
Figure 3.12: Two-site binding model of Grb2-medaited FGFR2 phosphorylation. When 
Grb2 is present, direct binding of Grb2 to FGFR2 is a two-site binding event; binding not only 
enhances the dimerisation process but also causes a conformational change in FGFR2, which 
leads to enhanced phosphorylation of FGFR2. 
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Chapter 4 
 
 
Grb2 phosphorylation and its role 
in recruitment 
of the FGFR2 signalling complex  
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4.1 Introduction 
Adaptor proteins, such as Shc, can be tyrosine-phosphorylated by tyrosine kinases.  
These residues provide additional binding sites for the recruitment of other signalling 
proteins, enabling the formation of protein complexes252. Grb2 plays an important role 
in the RTK-mediated signalling pathway253. To date, tyrosine phosphorylation of 
Grb2 and its function in cell signalling have not been investigated thoroughly. An 
early study indicated that Grb2 is not tyrosine-phosphorylated in vivo when 
fibroblasts are stimulated with EGF or PDGF; however, Grb2 tyrosine 
phosphorylation can be detected when HEK 293 cells transiently overexpress both 
PDGFR and Grb254.  
 
Jones et al. reported the first clear evidence for Grb2 tyrosine phosphorylation: 
pp60c-src (Src) kinase targets Grb2 as its substrate and phosphorylates Grb2 on 
tyrosine 160 in vitro. In vivo experiments also show that Grb2 is 
tyrosine-phosphorylated by pp60c-src in response to PDGF stimulation254. A later study 
not only showed Grb2 can be tyrosine-phosphorylated at tyrosine 209 by a tyrosine 
kinase, Bcr/Abl (an oncogenic tyrosine kinase that induces chronic myeloid 
leukaemia (CML)-like disease in mice)255, but also provided information about the 
role of phospho-Grb2 in tyrosine kinase signalling pathways. This report showed that 
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overexpressing Grb2 in Bcr/Abl-expressing cells causes Grb2 tyrosine 
phosphorylation. Moreover, Grb2 phosphorylation requires direct binding of Grb2 to 
Bcr/Abl. Tyrosine phosphorylation of Grb2 reduces Grb2 SH3 domain–dependent 
binding to Sos, but not Grb2 SH2 domain–dependent binding to Bcr/Abl. One study 
suggests a negative regulatory role of tyrosine-phosphorylated Grb2 in tyrosine kinase 
signalling256.  
 
Grb2 has been shown to interact with SHP2 on tyrosines 546 and 584 in 293 LA cells. 
A highly phosphorylated 29-kDa protein present in Grb2 immunoprecipitates in 
response to prolactin receptor (PRLR)–mediated JAK2 activation and is a substrate of 
SHP2257. Haines et al. further confirmed the identity of this phosphorylated 29-kDa 
protein as Grb2. Their study showed that overexpression of catalytically inactive 
SHP2 and activation of PRLR/JAK results in Grb2 phosphorylation258. Additionally, 
tyrosine-phosphorylated Grb2 inhibits EGF-induced MAPK activity and cell 
proliferation. 
 
In this study, the first evidence of Grb2 phosphorylation by FGFR2 is reported. In 
addition, the docking site for Grb2 on FGFR2 appears distinct from the kinase domain. 
The phosphorylation sites on Grb2 are also identified. Furthermore, an in vitro study 
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using Grb2 Y/F mutants suggests that Grb2 phosphorylation may augment ERK1/2 
activation upon stimulation of the FGFR2 signalling pathway. Finally, expression of 
FGFR2 in HEK 293 cells is shown to cause Grb2 phosphorylation; in addition, 
stimulation by FGF ligands leads to the dephosphorylation of Grb2, which is probably 
due to the FGF stimulation-dependent SHP2 activation.   
 
The two-site binding model of Grb2 binding to inactive FGFR2 and the role of Grb2 
in the regulation of FGFR2 activation has been discussed in Chapter 3. In this chapter, 
the interactions between FGFR2 and phosphorylated Grb2 are explored. We show that 
phospho-Grb2 is released from activated FGFR2, suggesting a mechanism of 
Grb2-regulated FGFR2 signalling. We also characterised the role of SHP2 in FGFR2 
signalling complex recruitment. A previous study reported the site-specific 
dephosphorylation of FGFR2 by SHP2173, demonstrating that binding of Grb2 to 
inactive FGFR2 inhibits SHP2 binding to FGFR2. Herein, we report the direct 
binding of SHP2 to activated FGFR2 on the receptor’s C-terminal tail. SHP2 is also 
shown to directly interact with and dephosphorylate phospho-Grb2 in vitro. 
 
O’Rourke and Ladbury have indicated that the formation of a signalling complex is 
necessary to create specificity in protein–protein interactions that transmit specific 
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cellular signals43. Results from Chapter 3 and Chapter 4 provide a detailed model of 
the recruitment of the FGFR2 signalling complex, and a mechanism for FGFR2 
regulation is proposed.  
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4.2 Results 
4.2.1 Grb2 tyrosine phosphorylation by FGFR2 
Although Grb2 is tyrosine-phosphorylated by Bcr/Abl, EGFR256 and pp60c-src 254, it is 
unknown if tyrosine phosphorylation of Grb2 occurs in the FGFR signalling pathway.  
 
To determine the ability of FGFR2 to phosphorylate Grb2, purified Grb2 and the 
FGFR2 cytoplasmic domain were mixed in a 2:1 molar ratio and incubated with 5 
mM ATP and 10 mM MgCl2 overnight. Samples were denatured and analysed by 
SDS-PAGE, followed by immunoblotting with an anti-phosphotyrosine antibody to 
investigate the phosphorylation state of Grb2. A major species of Grb2 migrated at the 
expected molecular weight of 28 kDa (Figure 4.1 A, lane 2). The presence of the 
FGFR2 cytoplasmic domain alone without ATP/MgCl2 did not change the migration 
pattern or rate of Grb2 (Figure 4.1 A, lane 3). No phosphotyrosine signal was detected 
on E. coli–expressed Grb2 or on Grb2 incubated with the FGFR2 cytoplasmic domain 
alone without ATP/MgCl2 (Figure 4.1 A, lane 2 and 3; Figure 4.1 B, lane 1). These 
results confirm that these Grb2 samples were unphosphorylated. In the presence of 
ATP/MgCl2 and FGFR2, a Grb2 species with lower mobility appeared on a 
Coomassie blue–stained gel (Figure 4.1 A, lane 4) and cross-reacted with an 
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anti-phosphotyrosine antibody (Figure 4.1 B, lane 3), suggesting that the FGFR2 
cytoplasmic domain phosphorylates Grb2 on more than one tyrosine residue.  
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Figure 4.1: Grb2 tyrosine phosphorylation by the FGFR2 cytoplasmic domain in vitro.  
Purified FGFR2 cytoplasmic domain was used to phosphorylate Grb2 in vitro. Proteins were 
mixed in a 2:1 molar ratio and incubated with/without ATP/MgCl2 overnight. Samples were 
denatured and analysed using SDS-PAGE followed by Coomassie blue staining or 
immunoblotting. Grb2 appears to form multiple bands on Coomassie blue–stained SDS-PAGE 
gels when mixed with the FGFR2 cytoplasmic domain in the presence of ATP/MgCl2. Western 
blot probed with an anti-phosphotyrosine antibody confirms that these bands are 
tyrosine-phosphorylated. The results are representative of at least three independent 
experiments.  
 
4.2.2 Direct binding of Grb2 to FGFR2 facilitates Grb2 
phosphorylation 
We have previously shown direct binding of Grb2 to FGFR2 via the Grb2 C-SH3 
domain. The deletion of the last 10 residues in FGFR2 abolishes Grb2 binding to 
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FGFR2173. To test if direct binding of Grb2 and FGFR2 is required for Grb2 tyrosine 
phosphorylation, the FGFR2 cytoplasmic domain (residues 309–821) and the FGFR2 
kinase domain (residues 412–760) without the C-terminal tail (Figure 4.2) were used 
to compare the effect on Grb2 phosphorylation in vitro. To avoid non-specific 
tyrosine phosphorylation due to protein overloading and non-physiologically relevant 
Grb2 phosphorylation due to long incubation times, different amounts (0.01–4 nM) of 
purified FGFR2 cytoplasmic and kinase domains were incubated with a constant 
amount of Grb2 in the presence of ATP/MgCl2. All phosphorylation reactions were 
stopped at 15 minutes to mimic early FGFR2 signalling pathway activation in vivo.  
 
The phosphorylation level of Grb2 was significantly increased in the presence of the 
cytoplasmic domain (2 nM and 4 nM) and ATP/MgCl2 (Figure 4.2, lane 6 and 7). The 
minimal amount of cytoplasmic domain required to phosphorylate 500 ng of Grb2 in 
a 100 µl solution volume (170 nM) in the presence of ATP/MgCl2 was 2 nM. Notably, 
the same concentration of the FGFR2 kinase domain lacking the C-terminal tail 
(either 2 nM or 4 nM) failed to phosphorylate Grb2 in vitro. The data preasented in 
Chapter 3 show that the interaction between FGFR2 and Grb2 occurs through the 
FGFR2 C-terminal tail and the Grb2 C-SH3 domain. Therefore, this result implies 
that binding through the C-terminal tail of FGFR2 is important for Grb2 
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phosphorylation. Together with previous binding results, these results suggest that 
Grb2 phosphorylation occurs by direct binding to FGFR2. 
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Figure 4.2: Grb2 phosphorylation requires direct binding to FGFR2. Both purified FGFR2 
cytoplasmic (residues 309–821) and kinase (residues 412–760) domains were tested for their 
effects on Grb2 phosphorylation. Different amounts (0.01–4 nM) of FGFR2 cytoplasmic and 
kinase domains were mixed with 500 ng of Grb2 protein with/without ATP/MgCl2 in 100 µl 
solution. Reactions were incubated on ice for 15 min, and samples were denatured and 
analysed using immunoblotting. The results show that the FGFR2 cytoplasmic domain can 
phosphorylate Grb2 (lane 6 and 7), whereas the FGFR2 kinase domain cannot phosphorylate 
Grb2 under the same conditions (lane 13 and 14), suggesting that a direct interaction via the 
SH3 domain of Grb2 and the FGFR2 C-terminal tail is required for Grb2 phosphorylation. The 
results were analysed by immunoblotting with an anti-phosphotyrosine antibody (first panel) 
and an anti-Grb2 antibody as the Grb2 loading control (second panel). The results are 
representative of two independent experiments. 
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Human Grb2 has seven tyrosines: residues 7, 37 and 52 in the N-terminal SH3 
domain; 118 and 134 in the SH2 domain; 160 in the linker between SH2 and the 
C-terminal SH3 domain; and 209 in the C-terminal SH3 domain (Figure 4.3A). To 
characterise the nature of Grb2 phosphorylation, individual domains of Grb2 were 
purified and incubated with 4 nM of cytoplasmic domain with ATP/MgCl2. All 
phosphorylation reactions were quenched at 15 minutes.  
 
Figure 4.3A illustrates the constructs used in this part of the study. Western blotting 
using an anti-phosphotyrosine antibody showed that both Grb2 N-SH3 and C-SH3 
domains (2000 ng/2.5 nM of each protein) were tyrosine-phosphorylated by 4 nM 
FGFR2 cytoplasmic domain in the presence of ATP/MgCl2, whereas no tyrosine 
phosphorylation could be detected on the SH2 domain alone under the same 
conditions (Figure 4.3 B, lanes 6, 7 and 8). Notably, the phosphotyrosine signal from 
the C-SH3 construct was much higher than that of the N-SH3 construct (Figure 4.3 B, 
lower panel; the membrane was Ponceau-stained after transfer to show equal loading 
of the various proteins). Both of the tyrosine residues (Tyr 160 and 209) on the C-SH3 
construct could have been phosphorylated, whereas only one tyrosine residue on (one 
of Tyr 7, 37 or 52) the N-SH3 domain was phosphorylated. Alternatively, the C-SH3 
domain might have a higher binding affinity to the FGFR2 cytoplasmic domain than 
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the N-SH3 domain does. The C-SH3 domain binds to the FGFR2 cytoplasmic domain 
with a higher affinity, thus making it the preferred substrate. 
N-SH3 SH2 C-SH3
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C-SH3
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Figure 4.3: Phosphorylation of the individual domains of Grb2. Purified FGFR2 
cytoplasmic domain and the Grb2 N-SH3, SH2 and C-SH3 domains were used to identify the 
phosphorylation status of Grb2. The FGFR2 cytoplasmic domain (4 nM) was mixed with 200 
ng of the individual domains of Grb2 with/without ATP/MgCl2 in 100 µl solution Reactions were 
incubated on ice for 15 min, and samples were denatured and analysed using immunoblotting. 
(A) Constructs used in this experiment. Tyrosines are indicated as stars, with the residue 
numbers listed. (B) Both the N-SH3 and C-SH3 domains can be phosphorylated by FGFR2 in 
15 minutes in the presence of ATP/MgCl2 (middle panel, lanes 6 and 8), whereas the SH2 
domain is not tyrosine-phosphorylated (middle panel, lane 7). The results were analysed by 
immunoblotting with an anti-phosphotyrosine antibody (first and second panels). The loading 
control was carried out with Ponceau staining because no antibody can detect all of the 
constructs. The results are representative of two independent experiments. 
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4.2.3 Identification of the Grb2 phosphorylation sites 
To identify the sites of Grb2 phosphorylation by FGFR2, two incubation times 
determined by preliminary studies were selected for the generation of phospho-Grb2 
for mass-spectrometric analysis (Proteomics Facilities, University of Texas, MD 
Anderson Cancer Center). Purified Grb2 was incubated with purified FGFR2 
cytoplasmic domain in the presence of ATP/MgCl2, for either 15 minutes or overnight, 
to compare the effects of different reaction times on Grb2 phosphorylation.  
 
Four phosphopeptides were identified from the 15-minute incubation sample, 
indicating that tyrosine residues 7, 52 and 160 were phosphorylated (Table 4.1). 
Tyrosines 7 and 52 are located in the N-SH3 domain, and tyrosine 160 is found at the 
linker between the SH2 and C-SH3 domains. These results further corroborate the in 
vitro domain phosphorylation experiment (Figure 4.3). On the other hand, six 
phosphopeptides were identified in the overnight-incubation sample, revealing that 
tyrosine residues 7, 37, 52, 134, and 160 were phosphorylated (Table 4.1).    
 
An early study by our group that focused on the time-dependent FGFR2 and ERK1/2 
activation indicated that FGFR2 phosphorylation/activation reaches a maximum 
between 5 and 30 minutes of FGF9 stimulation in HEK 293 cells expressing 
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wild-type FGFR2, whereas ERK1/2 phosphorylation reaches a maximum within 10 
minutes of FGF2 stimulation in PC12 cells249. Therefore, it is reasonable to assume 
that the phospho-Grb2 samples from the 15-minute incubation more closely reflect 
the cellular reaction. Two tyrosine phosphorylation sites (phosphotyrosines 37 and 
134) are suspected not to be physiologically relevant because they required prolonged 
exposure to the kinase.  
  
Importantly, Bcr/Abl and pp60c-src phosphorylate Grb2 on tyrosines 209 and 160, 
respectively, whereas FGFR2 phosphorylates Grb2 on tyrosines 7, 52 and 160254, 255.  
Therefore, the phosphorylation sites of Grb2 are tyrosine kinase–specific, and these 
sites may play important roles in the FGFR2 signalling pathway. 
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Table 4.1: Mass spectrometry results for Grb2 phosphorylation sites. Grb2 protein 
samples were phosphorylated by the FGFR2 cytoplasmic domain in the presence of 
ATP/MgCl2 on ice for 15 minutes or overnight. Phosphorylated Grb2 samples were denatured 
and separated by SDS-PAGE. Protein bands were cut and digested by trypsin, and 
mass-spectrometric analysis was performed by the proteomics facilities services (Proteomics 
Facilities, University of Texas, MD Anderson Cancer Center).  We identified three 
phosphorylated tyrosines when Grb2 was incubated with FGFR2 in the presence of 
ATP/MgCl2 for 15 minutes. However, five phosphotyrosines were identified when the 
incubation time was increased to overnight. 
Phosphorylated peptide identified Phosphorylation sites identified
KY*DFKATADDELSFKR
KNY*IEMKPHPWFFGKI
KDGFIPKNY*IEMKPHPWFFGKI
RDIEQVPQQPTY*VQALFDFDPQEDGELGFRR
Tyr 7
Tyr 52
Tyr 52
Tyr 160
* Phosphorylation
Sample incubation time: 15 minutes
 
 
Phosphorylated peptide identified Phosphorylation sites identified
Tyr 7
Tyr 7
Tyr 37
Tyr 52
* Phosphorylation
KY*DFKATADDELSFKR 
KY*DFKATADDELSFKRG
KVLNEECDQNWY*KAELNGKD
KNY*IEMKPHPWFFGKI
KFNSLNELVDY*HRS
RDIEQVPQQPTY*VQALFDFDPQEDGELGFRR
Tyr 134
Tyr 160
Sample incubation time: overnight
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4.2.4 Phosphorylation of Grb2 may occur in a certain order 
The order of phosphorylation of the FGFR1 kinase domain has been identified163 and 
may be important in the regulation of a FGFR1 downstream signalling pathway163, 250, 
259
. As shown in Figures 4.1 and 4.2, different incubation times of Grb2 
phosphorylation reactions with the FGFR2 cytoplasmic domain result in 
phospho-Grb2 species that migrate differently on denaturing gels: overnight 
incubations produce multiple bands, and 15 minute incubations yield only two bands. 
To investigate the relationship between the Grb2 phosphorylation level and incubation 
time, purified Grb2 was incubated with purified FGFR2 cytoplasmic domain in the 
presence of ATP/MgCl2; EDTA was added to quench the phosphorylation reactions at 
different time points between 5 minutes and overnight. These samples were either 
denatured or kept in their native state.  
 
To characterise the phosphorylation states of Grb2 at different time points, the 
denatured samples were separated by SDS-PAGE and analysed by immunoblotting 
with a general anti-phosphotyrosine antibody. The anti-phosphorylation blot shows 
that the Grb2 phosphotyrosine signal could be detected with only a 5-minute 
incubation period; however, two species were present at 10 minutes, suggesting that 
two tyrosines were phosphorylated. The number of phospho-Grb2 species with 
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different mobilities increased as the incubation time increased (Figure 4.4, upper 
panel). Six species with different mobilities were present in the overnight incubation 
sample. These results support the mass spectrometry observation that Grb2 possesses 
more tyrosine phosphorylation sites than the two that have been previously reported 
by other groups. Immunoblotting with an anti-Grb2 antibody confirmed that all of the 
phosphorylated species present were indeed Grb2 (Figure 4.4, lower panel). Because 
these data and the mass spectrometry results indicate that FGFR2 can phosphorylate 
Grb2 on at least five distinct tyrosine sites in a time-dependent manner, we 
investigated the possibility of these sites being phosphorylated sequentially. 
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Figure 4.4: Time-dependent Grb2 phosphorylation by the FGFR2 cytoplasmic domain. 
Purified Grb2 was incubated with purified FGFR2 cytoplasmic domain in the presence of 
ATP/MgCl2; EDTA was added to quench the phosphorylation reactions at different time points 
between 5 minutes and overnight. These samples were denatured and analysed using 
SDS-PAGE followed by immunoblotting. The number of Grb2 bands with different 
phosphorylation states increased with increasing incubation time. Activated FGFR2 
cytoplasmic domain and phosphorylated Grb2 are indicated. Their phosphorylation states 
were detected using a general anti-phosphotyrosine antibody (upper panel). The anti-Grb2 
antibody was used as the loading control and to identify Grb2 (lower panel, indicated by 
arrows). These results indicate that the number of phosphorylated tyrosine residues is 
phosphorylation time-dependent.  
 
To investigate if FGFR2 phosphorylates Grb2 tyrosines in a certain order, we 
separated proteins based on their charge/mass ratios in native gels to separate 
phospho-Grb2 proteins with different phosphorylation levels. Native Tris-glycine (6%) 
gels and the above-described native phospho-Grb2 proteins were used. The reaction 
time course for Grb2 phosphorylation by FGFR2 was determined as shown in Figure 
4.5. Notably, the phospho-Grb2 separation patterns in the native gel were similar to 
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the FGFR2 kinase domain phosphorylation order pattern separated in a native gel163. 
Because phosphate groups increase the net negative charge on the protein, the five 
resolved bands might represent Grb2 proteins with different phosphorylation states, 
with the most phosphorylated migrating the furthest. 
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Figure 4.5: Analysis of Grb2 phosphorylation in a native gel. Purified Grb2 was mixed with 
purified FGFR2 cytoplasmic domain in the presence of ATP/MgCl2. The phosphorylation 
reactions were quenched by EDTA at different time points. Samples were run for 45 minutes at 
120 V. Coomassie blue staining was used to detect proteins. Bands chosen for mass 
spectrometry are indicated by red squares. 
 
To identify the phosphorylation states of phospho-Grb2 in the native gel, five bands 
were chosen, and mass-spectrometric analysis was conducted to identify the 
phosphorylation states and specific residues (Figure 4.5, the chosen samples are 
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indicated by red squares). The mass-spectrometric data are shown in Table 4.2. Five 
phosphopeptides were identified in total from all five protein bands used for mass 
spectrometry. Three tyrosine residues, 7, 52 and 160, were confirmed to be 
phosphorylated, supporting previously reported mass-spectrometric data.   
 
Table 4.2: Mass spectrometry results. Five phosphopeptides were identified in total from all 
five protein bands. However, only three phosphorylated tyrosines were identified. 
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To supplement the mass-spectrometric analysis, another FGFR2/Grb2 
phosphorylation experiment was carried out. Native proteins were separated in a 
native gel.  Certain protein bands were recovered from the native gel and denatured. 
SDS-PAGE and western blots were performed to characterise the components of the 
individual bands.  
 
Figure 4.6 A shows the migration patterns of FGFR2, Grb2 and phospho-Grb2 in the 
native gel. Proteins chosen for further analysis are indicated by arrows and numbers 
(Figure 4.6 A, number 1 to 9). The numbers correspond to the lanes of the denaturing 
gel (Figure 4.6 B, lane 1 to 9). As expected, multiple bands appeared when Grb2 was 
incubated with the FGFR2 cytoplasmic domain in the presence of ATP/MgCl2 (Figure 
4.6 A, arrows 6, 7, 8 and 9). Bands 6 to 9, which were separated by SDS-PAGE 
according to size and immunoblotted with the anti-Grb2 antibody, were confirmed to 
contain Grb2 (Figure 4.6 B, upper panel, lanes 6, 7, 8 and 9). There are three possible 
explanations for the presence of multiple Grb2 bands. First, each band may represent 
a Grb2 species with a certain number of phosphorylated tyrosine residues. This 
possibility is partially supported by immunoblotting with a general 
anti-phosphotyrosine antibody, showing that these bands contained 
tyrosine-phosphorylated Grb2 (Figure 4.6 B, lower panel, lanes 6, 7, 8 and 9, 
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indicated by a red box). However, because mass spectrometry did not clearly show a 
sequential order for the phosphorylation of the different tyrosine residues, other 
factors could account for the appearance of these multiple bands. Second, Grb2 might 
form multimers. Because the Grb2 SH2 domain can bind to phosphotyrosine residues, 
a Grb2–phospho-Grb2 or phospho-Grb2–phospho-Grb2 complex could form, produce 
different migration patterns, and still produce the same phosphotyrosine peptides 
overall in the mass spectrometry experiment. Finally, as shown in previous studies in 
Chapter 3, Grb2 binds to FGFR2 through the C-terminal tail. In addition, Grb2 can be 
tyrosine-phosphorylated by FGFR2 and ATP/MgCl2. Although these bands contain 
Grb2 proteins (Figure 4.6 B, upper panel, lanes 6, 7, 8 and 9), the FGFR2 cytoplasmic 
domain could also be detected in these bands when the immunoblot was stripped and 
re-probed with anti-FGFR2 antibody (Figure 4.6 B, second panel, lanes 6, 7, 8 and 9).  
Therefore, the multiple bands seen in the native gel contain (phospho-)Grb2 and the 
FGFR2 cytoplasmic domain. Even though the phosphotyrosine signal could be 
detected on the extracted Grb2 and FGFR2 proteins (Figure 4.6 B, lower panels, lanes 
6, 7, 8 and 9; the phospho-Grb2 proteins are indicated by a red box), it is not clear that 
phospho-Grb2 still binds to FGFR2. In summary, these multiple bands might be 
phospho-Grb2–bound and/or (phospho-)FGFR2–bound Grb2/phospho-Grb2. 
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Figure 4.6: Identification of the multiple bands shown in the native gel.  Purified Grb2 
was mixed with the FGFR2 cytoplasmic domain with/without ATP/MgCl2 for 3 hours. Samples 
were analysed in native gels. Coomassie blue staining was used to detect proteins. Selected 
bands were excised, and proteins were extracted for immunoblotting analysis. (A) All of the 
migration patterns of FGFR2, Grb2 and phospho-Grb2 are shown in the native gel. In the 
presence of the FGFR2 cytoplasmic domain and ATP/MgCl2, Grb2 forms multiple bands with 
different migration rates. Proteins were extracted (numbers 1 to 9; number 10 is protein 
contamination from the FGFR2 cytoplasmic domain and is shown with a black arrow) and 
denatured for immunoblotting analysis. (B) Immunoblotting results indicate that bands 6, 7, 8 
and 9 contain both Grb2 and the FGFR2 cytoplasmic domain (first and second panels, probed 
with anti-Grb2 antibody and anti-FGFR2 antibody, respectively.). Phosphotyrosine signal 
could be detected in bands 6, 7, 8 and 9 (third panel, lanes 6, 7, 8 and 9). However, the 
interaction of phospho-Grb2 and FGFR2 remains unclear. The results are representative of 
two independent experiments. 
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4.2.5 Tyrosine-phosphorylated Grb2 does not bind to the FGFR2 
cytoplasmic domain 
Direct binding of Grb2 to FGFR2 is necessary for Grb2 to be tyrosine-phosphorylated 
by FGFR2 (Figure 4.2); however, it remains unknown if FGFR2 and phospho-Grb2 
can form a stable complex. Therefore, we investigated the interaction between the 
FGFR2 cytoplasmic domain and phosphorylated Grb2 by ITC. Grb2 was 
tyrosine-phosphorylated by the cytoplasmic domain of FGFR2 cross-linked on 
agarose beads in the presence of ATP/MgCl2 for 15 minutes. No binding was detected 
by ITC when phosphorylated FGFR2 cytoplasmic domain was titrated with 
phospho-Grb2 (Figure 4.7 A), suggesting a mechanism in which phospho-Grb2 is 
released from activated FGFR2 after Grb2 is tyrosine-phosphorylated by FGFR2.  
However, Grb2 could also be tyrosine-phosphorylated by other cellular tyrosine 
kinases, even though only Bcr/Abl, EGFR and pp60src, which are not known to be 
involved in the FGFR2 pathway, have been identified to date.  
 
To understand if phosphorylated Grb2 can bind to inactivated 
(unphosphorylated/dephosphorylated) FGFR2 when phospho-Grb2 is released from 
the previously bound and activated FGFR2 or when Grb2 is tyrosine-phosphorylated 
by other cellular tyrosine kinases, ITC experiments were performed using 
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phospho-Grb2 and the dephosphorylated FGFR2 cytoplasmic domain. The results 
show that phospho-Grb2 did not bind to inactivated 
(unphosphorylated/dephosphorylated) FGFR2 (Figure 4.7 B). Therefore, we conclude 
that phospho-Grb2 cannot bind to either unphosphorylated or phosphorylated FGFR2.   
 
 
Figure 4.7: Phospho-Grb2 binding study using ITC, showing that phosphorylated Grb2 
does not bind to FGFR2. Grb2 was tyrosine-phosphorylated by the FGFR2 cytoplasmic 
domain in the presence of ATP/MgCl2 for 15 minutes. Phosphorylated FGFR2 cytoplasmic 
domain was prepared by adding ATP/MgCl2 and incubating on ice for 15 minutes, followed by 
buffer exchange. Dephosphorylated FGFR2 cytoplasmic domain was prepared by incubating 
with CIP overnight followed by buffer exchange. The FGFR2 cytoplasmic domain was loaded 
in the ITC syringe, and Grb2 was loaded in the ITC cell. All studies were done at 15°C.  (A) 
Tyrosine-phosphorylated FGFR2 cytoplasmic domain was titrated into 
tyrosine-phosphorylated Grb2. No binding event could be detected. (B) Dephosphorylated 
FGFR2 cytoplasmic domain was titrated into tyrosine-phosphorylated Grb2. No binding event 
could be detected. These ITC data suggest that the phosphorylated Grb2 is released from 
FGFR2 once Grb2 is tyrosine-phosphorylated by FGFR2. The results are representative of 
four independent experiments. 
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4.2.6 Grb2 is tyrosine-phosphorylated in FGFR2-expressing cells and 
is dephosphorylated upon FGF stimulation 
An earlier study carried out by Ahmed et al. indicated that Grb2 binds to FGFR2 but 
does not bind to FGFR1173. Figure 4.2 also shows that Grb2 is a substrate for FGFR2 
in vitro. To evaluate whether Grb2 is a substrate for FGFR2 in vivo and to examine 
whether Grb2 phosphorylation is specific for the FGFR2 pathway rather than the 
FGFR1 pathway, wild-type full-length Grb2 was transfected into both non-transfected 
HEK 293 cells and HEK 293 cells stably expressing wild-type FGFR2. The HEK 293 
cell line is ideal for this investigation as it lacks endogenous FGFR2 but possesses 
endogenous FGFR1.   
 
To ascertain whether Grb2 was phosphorylated by endogenous FGFR1, Grb2 was 
immunoprecipitated from either serum-starved or FGF2-stimulated HEK 293 cells 
transiently transfected with Grb2. Only a single population was detected when probed 
with the anti-Grb2 antibody. No phosphotyrosine signal could be detected, indicating 
that Grb2 is not tyrosine-phosphorylated in the basal or stimulated state (Figure 4.8).  
FGF9 was used as a control to confirm the absence of FGFR2. These data suggest that 
Grb2 cannot be phosphorylated by FGFR1 in vivo and support the previous finding by 
Ahmed et al. that Grb2 does not bind to FGFR1. 
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Figure 4.8: Grb2 is not tyrosine-phosphorylated in non-transfected HEK 293 cells. Grb2 
plasmid was transfected into HEK 293 cells by calcium phosphate precipitation. Forty-eight 
hours after transfection, FGF2 was used to stimulate endogenous FGFR1 to test for its ability 
to phosphorylate Grb2. FGF9 was used as the control. S, serum-starved HEK 293 cells. a, 20 
µl loading. b, 40 µl loading. Upon stimulation, cells were lysed in the presence of protease 
inhibitors and phosphatase inhibitors. Grb2 protein was immunoprecipitated, and the amount 
of Grb2 was detected by an anti-Grb2 antibody. The phosphorylation state was detected by an 
anti-phosphotyrosine antibody. No phosphorylation signal of Grb2 could be detected, 
suggesting that Grb2 is not phosphorylated in HEK 293 cells. The results are representative of 
two independent experiments. 
 
We used HEK 293 cells stably expressing wild-type FGFR2 to investigate Grb2 
phosphorylation by FGFR2 in vivo and the role of activated/inactivated FGFR2 in 
Grb2 phosphorylation. Cells were transiently transfected with wild-type Grb2 as 
previously described.  Cells were serum-starved for 16 hours, and 10 ng/ml of FGF9 
was used to stimulate FGFR2. An anti-phospho-FGFR2 (pFGFR2) antibody was used 
to confirm the activation of FGFR2 in response to FGF9 stimulation. An 
anti-phospho-ERK antibody (pERK) was used to detect the activation of FGFR2 
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downstream signalling upon FGF9 stimulation (Figure 4.9 A). The immunoblot was 
stripped and re-probed with anti-FGFR2 and anti-ERK antibodies to confirm equal 
loading. The transfected Grb2 was immunoprecipitated, and it appeared as multiple 
bands in both stimulated and unstimulated FGFR2-expressing cells. To confirm the 
phosphorylation states of Grb2 in these bands, a general anti-phosphotyrosine 
antibody (pY-99) was used. Grb2 phosphotyrosine signals could be detected in both 
the stimulated and unstimulated samples (Figure 4.9 B). The immunoblot was 
stripped and re-probed with an anti-Grb2 antibody to confirm the presence of equal 
amounts of Grb2. 
 
The Grb2 phosphorylation detected from the unstimulated HEK 293 cells stably 
expressing wild-type FGFR2 may have been due to the low level of FGFR2 activation 
in the serum-starved cells (Figure 4.9 A). Surprisingly, when the HEK 293 cells stably 
expressing wild-type FGFR2 were stimulated with FGF9 (to activate FGFR2), the 
phosphorylation level of Grb2 decreased (Figure 4.9 B, FGF9 +). Therefore, we 
hypothesise that Grb2 is tyrosine-phosphorylated by the weakly activated FGFR2 in 
vivo and that the fully activated FGFR2 leads to activation of a tyrosine phosphatase, 
which then dephosphorylates the phosphorylated Grb2. 
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Figure 4.9: Grb2 is tyrosine-phosphorylated in the FGFR2-expressing HEK 293 cells. 
Grb2 plasmid was transfected into FGFR2-expressing HEK 293 cells by calcium phosphate 
precipitation. Forty-eight hours after transfection, cells were starved overnight and FGF9 was 
used to stimulate FGFR2 for 15 minutes. Cells were lysed in the presence of protease 
inhibitors and phosphatase inhibitors. Grb2 protein was immunoprecipitated, and the amount 
of Grb2 was detected by an anti-Grb2 antibody. The phosphorylation state was detected by an 
anti-phosphotyrosine antibody. (A) Immunoblots probed with an anti-phospho-FGFR2 
antibody and an anti-phospho-ERK1/2 antibody show the activation levels of FGFR2 and ERK 
in the total cell lysates (Figure 4.9 A). Antibodies were used against total FGFR2 and ERK to 
confirm equal loading. (B) The immunoprecipitated Grb2 from both serum-starved and 
FGF9-stimulated cells show multiple bands. An anti-Grb2 antibody was used to confirm that 
these bands represent Grb2. Phosphorylation states of Grb2 species were examined using an 
anti-phosphotyrosine antibody. These data indicate that Grb2 is phosphorylated in 
FGFR2-expressing cells but might be dephosphorylated upon FGF ligand stimulation. The 
results are representative of two independent experiments. 
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4.2.7 Expression of Grb2 Y/F mutants may enhance FGFR2 
activation and down-regulate FGF-mediated ERK activation upon 
FGF ligand stimulation 
The biochemical consequences of Grb2 phosphorylation were studied by examining 
the effects of the expression of Grb2 Y/F mutants on FGF-stimulated FGFR2 
activation and ERK1/2 activation. The data in Section 3.2.2 show that FGFR2 
activation can be enhanced by direct binding of Grb2 to FGFR2, and the data in 
section 4.2.5 show that phospho-Grb2 does not bind to FGFR2. These data suggest 
that Grb2 phosphorylation plays a negative regulatory role in the activation of FGFR2; 
phosphorylation of Grb2 at tyrosines 7, 52 and/or 160 should reduce FGFR2 
phosphorylation at the basal state in cells. To test this hypothesis, we made Grb2 
constructs with mutations of tyrosine to phenylalanine at positions 7 and 52. HEK 293 
cells stably expressing FGFR2 were transfected with wild-type Grb2, Grb2 Y7F or 
Grb2 Y52F. Then, 10 ng/ml of FGF9 was used to stimulate the cells for 15 minutes. 
As seen in Figure 4.9, wild-type Grb2 and mutants appear as multiple bands in HEK 
293 cells stably expressing FGFR2 (Figure 4.10 A, fifth panel), suggesting that both 
wild-type Grb2 and mutants were phosphorylated when FGFR2 was expressed. 
Co-expression of FGFR2 and Grb2 Y/F mutants (Y7F and Y52F) resulted in a 
significant increase in the FGFR2 phosphorylation level in unstimulated cells (Figure 
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4.10 A, first panel and Figure 4.10 B), which may have been due to the Grb2 mutants 
having a higher binding affinity for FGFR2 compared with wild-type Grb2.  
 
To explore the biochemical effects of phosphorylation on tyrosines 7 and 52 of Grb2 
further, we examined the FGF-induced ERK1/2 activation. Stimulation of HEK 293 
cells stably expressing FGFR2 resulted in the activation of ERK1/2 (Figure 4.10 A, 
third and fourth panels). FGF-induced ERK1/2 activation was slightly reduced in cells 
expressing the Grb2 Y7F and Y52F mutants (Figure 4.10 A, third panel and Figure 
4.10 C). Because only a single experiment was done to study the effect of Grb2 
phosphorylation in FGFR2 signalling, it is hard to make a definitive conclusion. 
These data suggest that phosphorylation of Grb2 at Tyr 7 and 52 may be able to 
up-regulate ERK1/2 activation after FGF stimulation.  
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Figure 4.10: Mutation of Grb2 Tyr 7 and 52 and FGFR2 signalling pathway regulation.  
Grb2 mutant plasmids were transfected into FGFR2-expressing HEK 293 cells by calcium 
phosphate precipitation. Forty-eight hours after transfection, cells were starved overnight, and 
then FGF9 was used to stimulate FGFR2 for 15 minutes. Cells were lysed in the presence of 
protease inhibitors and phosphatase inhibitors. Total cell lysate was used to study the effect of 
expressing Grb2 mutants on FGFR2 signalling by probing with different antibodies. (A) FGFR2 
and ERK1/2 activation. HEK 293 cells co-expressing FGFR2 and either wild-type Grb2 or 
Grb2 Y/F mutants were starved (lanes 1, 3 and 5) or stimulated with FGF9 for 15 min (lanes 2, 
4 and 6). The lysates were analysed by immunoblotting with an anti-phospho-FGFR2 antibody 
(first panel), an anti-FGFR2 antibody (second panel), an anti-phospho-ERK1/2 antibody (third 
panel), an anti-ERK1/2 antibody (forth panel) and an anti-Grb2 antibody (fifth panel).  (B) The 
amounts of phosphorylated FGFR2 and phosphorylated ERK1/2 were quantified using 
densitometry and are represented graphically. Data were normalised by dividing the intensity 
of the phosphorylation signal by the intensity of the corresponding total signal. Co-expression 
of FGFR2 and Grb2 Y/F mutants (Y7F and Y52F) results in increased FGFR2 phosphorylation 
in unstimulated cells and slightly reduced FGF-induced ERK1/2 activation in cells expressing 
the Grb2 Y7F and Y52F mutants.  
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4.2.8 SHP2 can bind and dephosphorylate phospho-Grb2 
Previous studies173 have proposed a potential role of SHP2 in the FGFR2 signalling 
pathway. Results from the previous section (section 4.2.6, Figure 4.9) raise the 
possibility of Grb2 dephosphorylation by a tyrosine phosphatase, so we investigated if 
SHP2 acts as the phosphatase. Pull-down, in vitro dephosphorylation and ITC 
experiments were conducted to examine the (phospho-)Grb2–SHP2 interaction and 
the role of SHP2 in Grb2 dephosphorylation.  
 
First, various constructs of the SHP2 domains were created: the two SH2 domains 
(2SH2), N-SH2 domain (N-SH2), C-SH2 domain (C-SH2), 2SH2 with the conserved 
arginine-to-alanine mutation in the N-SH2 domain (2SH2-R32A in the FLI/VRES 
motif), 2SH2 with the conserved arginine-to-alanine mutation in the C-SH2 domain 
(2SH2-R138A) and 2SH2 with the conserved arginine-to-alanine mutation of both 
N-SH2 and C-SH2 domains (2SH2-R32/138A double mutant). These constructs were 
expressed as GST fusion proteins (Figure 4.11) for pull-down experiments. 
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Figure 4.11: Preparation of GST-fused SHP2 proteins. The two SH2 domains of SHP2 
(2SH2), N-SH2 domain (N-SH2), C-SH2 domain (C-SH2), 2SH2 with the conserved 
arginine-to-alanine mutation in the N-SH2 domain (2SH2-R32A), 2SH2 with the conserved 
arginine-to-alanine mutation in the C-SH2 domain (2SH2-R138A) and 2SH2 with the 
conserved arginine-to-alanine mutations in both N-SH2 and C-SH2 domains (2SH2-R32/138A) 
were cloned into a pGEX expression vector with N-terminally fused GST. The GST protein is 
not illustrated in this diagram. GST fusion proteins were expressed in E. coli. Cells were lysed, 
and the GST fusion proteins were immobilised on GST sepharose beads. Denaturing gels 
followed by Coomassie blue staining were used to verify protein expression and purity. 
 
A GST pull-down experiment was carried out to investigate the effect of Grb2 
phosphorylation on the Grb2–SHP2 interaction and to identify the domain required 
for these interactions. Grb2 was expressed in bacteria and purified; phospho-Grb2 was 
prepared as described in section 4.2.5. The various SHP2 constructs immobilised on 
agarose beads were incubated with an equal amount of either Grb2 or phosphorylated 
Grb2 overnight. The samples were then washed, denatured and analysed by 
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immunoblotting. Equal loading was verified by probing with the anti-GST antibody.  
The anti-Grb2 blot (Figure 4.12, first panel) shows that all constructs of the SHP2 
domains were able to bind to unphosphorylated Grb2, confirming that the binding is 
SHP2-specific. The amount of Grb2 pulled down by the C-SH2 domain alone was 
significantly less than that of the N-SH2 domain alone or the 2SH2 constructs, 
indicating that the interaction is mediated primarily by the N-SH2 domain. Because 
the R/A-mutant SHP2 proteins were able to pull down Grb2, the interaction was not 
phosphotyrosine-dependent. All of the SHP2 constructs were also able to pull down 
phosphorylated Grb2. However, when probed with the anti-phosphotyrosine antibody, 
only the N-SH2 domain was able to pull down a significant amount of phosphorylated 
Grb2 (Figure 4.12, second and third panels). Taken together, these results suggest 
unphosphorylated Grb2 is able to bind to SHP2 in vitro, albeit very weakly, through 
the N-SH2 domain of SHP2 in a non-canonical mode. However, phosphorylated Grb2 
binds to the N-SH2 domain of SHP2 via the FLI/VRES motif, and this binding is 
phosphotyrosine dependent.   
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Figure 4.12: Using GST pull-down to evaluate the interactions of individual SHP2 SH2 
domains with Grb2 and phospho-Grb2. GST-2SH2, GST-NSH2, GST-CSH2, 
GST-2SH2-R32A, GST-2SH2-R138A and GST-2SH2-R32/138A on glutathione sepharose 
were incubated with purified Grb2 and phospho-Grb2 overnight. The beads were washed with 
buffer five times, and the precipitated proteins were subjected to SDS-PAGE and western blot 
with an anti-Grb2 antibody (upper panel), an anti-phosphotyrosine antibody (middle panel) and 
an anti-GST antibody (lower panel) after stripping and re-probing. All SHP2 domains can pull 
down Grb2, whereas only the N-SH2 domain can pull down the phospho-Grb2 significantly. 
Anti-GST antibody was used to confirm the amounts of GST-SHP2 domain fusion proteins 
used in each precipitation experiment. The results are representative of two independent 
experiments. 
 
ITC experiments were used to characterise the interactions between 
unphosphorylated/phosphorylated Grb2 and SHP2. The 2SH2 domain of SHP2 was 
titrated into full-length Grb2. No significant change in heats could be detected in the 
unphosphorylated Grb2–SHP2 ITC titration (Figure 4.13 A). However, when the 
2SH2 domain of SHP2 was titrated into phosphorylated Grb2, a clear binding event 
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was detected (Figure 4.13 B), even though the isotherm does not allow for a good fit 
with any binding model. Previous mass spectrometry results showed that three 
tyrosines on Grb2 can be phosphorylated by FGFR2 in 15 minutes. Therefore, SHP2 
might be able to bind to more than one phosphotyrosine residue on phospho-Grb2, 
which could also be an explanation for the isotherm not being a simple sigmoidal 
curve with a 1:1 stoichiometry.                   
 
A B C
Figure 4.13: ITC measurements of SHP2 2SH2 domain binding to Grb2 and 
phospho-Grb2. (A) Fourteen 20-µl injections of 466 µM SHP2 2SH2 domain were titrated into 
60 µM Grb2 at 15°C. (B) Thirty-five 7- µl injections of 150 µM SHP2 2SH2 domain were titrated 
into 15 µM phospho-Grb2 at 15°C. (C)  Fourteen 20-µl injections of 466 µM SHP2 2SH2 
domaindomains were titrated into buffer at 15°C. Th e top panel shows the baseline -corrected 
data collected at 15°C, while the bottom panel show s the integrated heats released and the 
molar ratio of the SHP2 2SH2 domain proteindomains to Grb2, the Grb2 N-SH3 domain, the 
Grb2 C-SH3 domain and phospho-Grb2. The results are representative of two independent 
experiments. 
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It is clear that SHP2 interacts with phospho-Grb2, whereas the interaction between 
SHP2 and unphosphorylated Grb2 is unclear. These experiments are limited because 
of the concentrations of proteins used. To obtain isotherms that could fit a 
mathematical model reasonably well, the concentration of the proteins must be at least 
5 times above the KD of the interaction for a 1:1 binding model. The interaction 
between unphosphorylated Grb2 and SHP2 did not result in an isotherm that clearly 
showed binding, which could mean that the protein concentration in the cell was well 
below the KD. However, the titration between phosphorylated Grb2 and SHP2 showed 
that the binding sites were saturated when the molar ratio of the two components 
reached about 1 in the cell. Although accurate determinations for the KD of the two 
events cannot be made, the KD of full-length unphosphorylated Grb2 binding to SHP2 
is well above 60 µM, whereas the KD of full-length phosphorylated Grb2 binding to 
SHP2 is below 15 µM. These values corroborate the pull-down result that 
unphosphorylated Grb2 is a weaker binding partner for SHP2 than phosphorylated 
Grb2. 
 
Another difficulty in these ITC experiments is that the change in heats of binding was 
too small to be detected accurately. Obtaining better biophysical parameters for these 
interactions will require further optimisation in conditions such as pH, buffers and 
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temperatures. Different constructs of the two proteins might also be helpful in better 
understanding the interactions. 
 
The significance of the interaction between SHP2 and phosphorylated Grb2 was 
explored by a phosphorylation/dephosphorylation experiment. Purified wild-type 
full-length SHP2 was incubated with phosphorylated Grb2. Phosphorylated Grb2 was 
prepared as described before. Analysis was performed by immunoblotting with a 
phosphotyrosine-specific antibody, followed by stripping and re-probing with an 
anti-Grb2 antibody as the control for total Grb2 protein loading. Figure 4.14 shows 
the dephosphorylation of phospho-Grb2 by SHP2.  
 
Taken together, the pull-down, ITC and dephosphorylation in vitro experiments 
suggest that activated FGFR2 activates SHP2 and phosphorylates Grb2 in a cellular 
environment; then, the activated SHP2 binds to and de-phosphorylates phosphorylated 
Grb2. Thus, the FGFR2 and SHP2 act as a kinase and phosphatase, respectively, for 
Grb2 and regulate its phosphorylation level in vivo. 
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Figure 4.14: Dephosphorylation of phospho-Grb2 by SHP2. Purified wild-type full-length 
SHP2 was incubated with phospho-Grb2 for 30 minutes. Protein samples were denatured and 
analysed by SDS-PAGE and immunoblotting. The phosphorylation level of untreated 
phospho-Grb2 is shown in lane 1. The phosphorylation level was detected by a general 
anti-phosphotyrosine antibody (upper panel, lane 1). Lane 3 shows that the amount of Grb2 
phosphorylation decreases when SHP2 is present (upper panel, lanes 3). An anti-Grb2 
antibody was used to show the amount of phospho-Grb2 proteins used in each lane (lower 
panel). The results are representative of two independent experiments. 
 
 
4.2.9 Interactions among FGFR2, Grb2 and SHP2 
To understand the mechanism of SHP2, Grb2 and FGFR2 signalling complex 
formation, the Grb2 and FGFR2 cytoplasmic domains were purified, and the 
GST-fused SHP2 2SH2 domains were immobilised on glutathione sepharose beads. 
Pull-down experiments were performed using different protein combinations in the 
absence or presence of ATP/MgCl2, as indicated in Figure 4.15. Lanes 1 and 2 show 
that both unphosphorylated Grb2 and dephosphorylated FGFR2 cytoplasmic domain 
can be precipitated by the SHP2 2SH2 domains. Although most of the SH2 
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domain–mediated binding was phosphotyrosine-specific, it is clear that the binding of 
unphosphorylated Grb2 and unphosphorylated FGFR2 cytoplasmic domain to the 
2SH2 domains was phosphotyrosine-independent. However, the nature of the 
interactions between unphosphorylated Grb2 and the 2SH2 domains of SHP2, as well 
as between unphosphorylated FGFR2 cytoplasmic domain and the 2SH2 domains of 
SHP2, remains to be determined. Notably, when both unphosphorylated Grb2 and the 
FGFR2 cytoplasmic domain were present in the reaction, the amount of FGFR2 
precipitated by the 2SH2 domains decreased (lane 3, first panel), whereas the 
presence of the unphosphorylated FGFR2 cytoplasmic domain had no effect on the 
amount of Grb2 precipitated by the SHP2 2SH2 domains (lane 3, third panel). The 
same effect was not observed when ATP was added to phosphorylated FGFR2 
cytoplasmic domain and Grb2 (lanes 4 and 5). Importantly, the pull-down results from 
lanes 4 and 5 also confirm the previous result that phosphorylated Grb2 does not bind 
to phosphorylated FGFR2 (Figure 4.7), as it cannot inhibit the SHP2 2SH2 domains. 
This pull-down experiment reveals a possible mechanism of FGFR2–Grb2–SHP2 
interaction.       
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Figure 4.15: Binding of SHP2 to inactivated FGFR2 is inhibited by Grb2. GST-SHP2 
2SH2 domains on glutathione sepharose were incubated with purified proteins overnight. The 
beads were washed with buffer five times, and the precipitated proteins were subjected to 
SDS-PAGE and western blot. GST-fused SHP2 2SH2 domains were used to precipitate Grb2 
(lane 1), dephosphorylated FGFR2 cytoplasmic domain (lane 2), and phosphorylated FGFR2 
cytoplasmic domain (lane 4). Grb2 was mixed with the dephosphorylated FGFR2 cytoplasmic 
domain; less dephosphorylated FGFR2 cytoplasmic domain was precipitated by the SHP2 
2SH2 domains (lane 3, compared with lane 2), whereas the precipitation of phosphorylated 
FGFR2 cytoplasmic domain by the SHP2 2SH2 domains was not affected by either Grb2 or 
phospho-Grb2 (lane 5, compared with lane 4). An anti-FGFR2 antibody and anti-Grb2 
antibody were used to measure the amount of FGFR2 and Grb2 precipitated by the SHP2 
2SH2 domains (first and third panels), an anti-phosphotyrosine antibody was used to confirm 
the phosphorylation states of the FGFR2 cytoplasmic domain and Grb2 (second and forth 
panels), and an anti-Grb2 antibody was used as the control to show that the same amount of 
GST-fused SHP2 2SH2 domains was used in each lane (fifth panel). The results are 
representative of at least three independent experiments. 
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The binding of Grb2 and phospho-Grb2 to the 2SH2 domains of SHP2 by ITC is 
described above. To confirm the interactions between FGFR2 and SHP2, both GST 
pull-down and ITC experiments were performed. 
 
GST pull-down data indicate that both phosphorylated and dephosphorylated FGFR2 
cytoplasmic domain can be precipitated by the GST-tagged SHP2 2SH2 domains. 
Figure 4.16 shows that the SHP2 2SH2 domain binding to the dephosphorylated 
FGFR2 cytoplasmic domain is phosphotyrosine-independent (Figure 4.16, right 
panels), confirming previous results (Figure 4.15). As in the binding of Grb2 to the 
SHP2 2SH2 domains (Figure 4.12 and Figure 4.13), this interaction is 
phosphotyrosine-independent, and the binding mechanism is unclear. However, our 
GST pull-down results indicate that the binding of the SHP2 2SH2 domains to either 
phosphorylated or dephosphorylated FGFR2 is mediated through the C-SH2 domain 
of SHP2. 
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Figure 4.16: GST pull-down to evaluate the interaction of SHP2 2SH2 domains with 
phosphorylated FGFR2 cytoplasmic domain and dephosphorylated FGFR2 cytoplasmic 
domain. GST-SHP2 2SH2 domains on glutathione sepharose were incubated with purified 
phosphorylated FGFR2 cytoplasmic domain and dephosphorylated FGFR2 cytoplasmic 
domain overnight. The beads were washed with buffer five times, and the precipitated proteins 
were subjected to SDS-PAGE and western blot with appropriate antibodies. Both 
phosphorylated FGFR2 cytoplasmic domain and dephosphorylated FGFR2 cytoplasmic 
domain were precipitated with the SHP2 2SH2 domains and the 2SH2 domains with the 
conserved arginine mutated in the N-terminal SH2 domain. By contrast, the C-terminal mutant 
and the double mutant precipitated less phosphorylated and dephosphorylated proteins (first 
panel, probed with anti-FGFR2 antibody). An anti-phosphotyrosine antibody was used to 
confirm the phosphorylation states of the precipitated FGFR2 proteins, and an anti-GST 
antibody was used to confirm the amounts of GST-SHP2 domains fusion proteins used in each 
precipitation experiment. The results are representative of at least three independent 
experiments. 
 
 
The GST pull-down results indicate that the binding site of SHP2 is located in the 
FGFR2 C-terminus. Therefore, ITC studies were performed to verify the interactions 
of the 2SH2 domains of SHP2 with an unphosphorylated FGFR2 C-terminal 
58-residue peptide (Figure 4.17 A and B; A: actual titration; B: heats of dilution) and 
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a phosphorylated FGFR2 C-terminal 58-residue peptide (Figure 4.17 C and D; C: 
actual titration; D: heats of dilution). The tyrosine-phosphorylated C58 peptide bound 
to the 2SH2 domains with an affinity of 8.3 µM (Figure 4.17 C), whereas the 
interaction between unphosphorylated C58 peptide and the 2SH2 domains was 
undetectable by ITC (Figure 4.17 A). 
A B C D
 
Figure 4.17: ITC measurements of SHP2 2SH2 domains binding to unphosphorylated 
FGFR2 C-terminal peptide (C58) (A) and phosphorylated FGFR2 C-terminal peptide (C58) 
(C). To examine unphosphorylated FGFR2 binding to SHP2, the 2SH2 domain peptide was 
loaded in the ITC syringe, whereas the unphosphorylated FGFR2 C-terminal C58 peptide was 
loaded in the cell. To examine phosphorylated FGFR2 binding to SHP2, the phosphorylated 
FGFR2 C-terminal peptide (C58) was loaded in the ITC syringe, whereas the 2SH2 domain 
peptide was loaded in the cell. The FGFR2 C58 peptide was expressed and purified from E. 
coli. The phosphorylated FGFR2 C58 peptide was prepared by mixing the FGFR2 cytoplasmic 
domain and C58 peptide in the presence of ATP/MgCl2 for 30 minutes. Gel filtration was used 
to remove the cytoplasmic domain and free ATP. ITC experiments were carried out at 15°C. 
The top panel shows the baseline-corrected data collected at 15°C, while the bottom panel 
shows the integrated heats released and the molar ratio of FGFR2 to Grb2. (A) The 2SH2 
domains were titrated into the unphosphorylated FGFR2 C-terminal peptide (C58). (B) The 
2SH2 domains were titrated into buffer to measure the heats of dilution. It cannot be 
definitively concluded that the 2SH2 domains bind to dephosphorylated FGFR2. (C) Direct 
binding was measured when phosphorylated FGFR2 C-terminal peptide (C58) was titrated 
into the 2SH2 domains. (D) The same concentration of phosphorylated FGFR2 C-terminal 
peptide (C58) was titrated into buffer to measure the heats of dilution. The results are 
representative of two independent experiments. 
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4.3 Discussion  
Grb2 plays an important role in RTK signalling pathways by coupling activated 
growth factor receptors to Sos. The Grb2–Sos complex activates the MAP kinase 
signal for RTKs when exposed to mitogens.  
 
The induction of RTK intracellular signalling by growth factor stimulation must be 
precisely controlled to prevent improper cellular responses. For example, 
GTPase-activating proteins stimulate the GTPase activity of GTP-bound Ras, 
resulting in GDP-bound Ras and thereby permitting the control of cellular responses 
with unlimited transduction. 
 
The C-terminal proline-rich domain of Sos has several MAP kinase consensus 
phosphorylation sites262, 263. ERK phosphorylates Sos both in vitro and in vivo264. 
Activation of insulin receptor results in the serine/threonine phosphorylation of Sos, 
followed by the dissociation of Sos–Grb2 complexes or the release of the Sos–Grb2 
binary complex from the RTKs265-267. Therefore, serine/threonine phosphorylation of 
Sos has been suggested to play a negative feedback role in the Ras pathway.   
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In contrast to Sos phosphorylation and its role in regulating RTK signalling, Grb2 
phosphorylation and its cellular function still remain largely unknown. Grb2 can be 
tyrosine-phosphorylated by activated RTKs in certain cell lines, and the 
phosphorylation of Grb2 may be another potential regulation mechanism in RTK 
signalling control. 
 
However, studies by our group show that direct binding of Grb2 to FGFR2 may have 
two functions in controlling the FGFR2 signalling pathway. First, direct binding is 
involved in regulating SHP2 function towards site-specific FGFR2 dephosphorylation. 
Second, direct binding is important in up-regulating FGFR2 activity.   
 
Therefore, we attempted to investigate the potency of FGFR2 in Grb2 
phosphorylation and to examine the role of Grb2 phosphorylation in FGFR2-specific 
downstream signalling. Biophysical approaches were also used to study the effect of 
Grb2 phosphorylation on its binding to FGFR2. Moreover, HEK 293T cells that 
stably expressed FGFR2 were used to transfect Grb2 Y/F mutants in order to 
understand the role of Grb2 phosphorylation in the FGFR2-mediated signalling 
pathway. Finally, we investigated the interaction between phosphorylated Grb2 and 
SHP2 and the relationship among SHP2, Grb2 and FGFR2. 
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Using bacterially expressed recombinant proteins, we show for the first time that 
FGFR2 phosphorylates Grb2 in vitro. We found that tyrosine phosphorylation of Grb2 
requires direct binding to FGFR2 via an SH3 domain–mediated interaction. Grb2 is 
not tyrosine-phosphorylated under the same conditions when the FGFR2 kinase 
domain (without the C-terminal tail, where Grb2 binds) was used instead of the whole 
FGFR2 cytoplasmic domain. Grb2 tyrosines 7, 52 and 160 were identified as the 
FGFR2 phosphorylation sites using mass spectrometry. These phosphorylation sites 
are different from those used by Bcr/Abl and prolactin receptor/EGF receptor, which 
mainly phosphorylate Grb2 on tyrosine 209. The difference in Grb2 phosphorylation 
sites suggests that Grb2 phosphorylation by different tyrosine kinases may have 
different roles in Grb2-mediated signalling pathways.   
 
Notably, when native gel electrophoresis and SDS-PAGE were used to analyse the 
phosphorylated Grb2 samples, the phosphorylated Grb2 migration patterns showed a 
dependence on time, suggesting that the FGFR2-mediated tyrosine phosphorylation of 
Grb2 may happen in a certain order. However, mass spectrometry did not show any 
significant phosphorylation order of Grb2 when the separated bands from the native 
gel were subjected to analysis. We propose that (phosphorylated) Grb2 may interact 
with (phosphorylated) Grb2 and/or FGFR2 because the SH2 domain of Grb2 can bind 
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phosphotyrosine residues, thus making this mass spectrometry result controversial. 
The best way to determine if Grb2 phosphorylation does happen in a sequential 
reaction is by resolving these denatured bands by SDS-PAGE.  
 
Grb2 binds to both phosphorylated and dephosphorylated FGFR2 directly (Chapter 3). 
The interactions between tyrosine-phosphorylated Grb2 and phosphorylated or 
dephosphorylated FGFR2 were investigated using ITC. The ITC studies did not detect 
any binding events with tyrosine-phosphorylated Grb2. It is possible that Grb2 
phosphorylation acts as a regulator of the FGFR2 signalling pathway. First, because 
Grb2 can bind and stimulate FGFR2 phosphorylation, the release of Grb2 after it is 
phosphorylated by FGFR2 may prevent constitutive phosphorylation of FGFR2. 
Second, GST pull-down experiments show that the direct binding of Grb2 to FGFR2 
prevents the interaction of SHP2 to FGFR2. A previous study by our group also 
indicated that the Grb2–FGFR2 interaction inhibits SHP2 site-specific 
dephosphorylation of FGFR2. Therefore, the release of phosphorylated Grb2 from 
FGFR2 allows SHP2 to regulate FGFR2 activation. Third, tyrosine phosphorylation 
of Grb2 may create sites for intermolecular binding and regulated Grb2 function 
and/or FGFR2 activation. However, the detailed role of Grb2 phosphorylation 
remains unclear. 
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Grb2 phosphorylation was examined in vivo. HEK 293 cells express endogenous 
FGFR1, and FGF2 is an FGFR1-specific ligand. Grb2 immunoprecipitated from HEK 
293 cells did not show any tyrosine phosphorylation signal in serum-starved cells, 
FGF2-stimulated, or FGF9-stimulated cells. These results show that FGFR1 is not 
able to phosphorylate Grb2. However, Grb2 immunoprecipitated from HEK 293 cells 
stably expressing FGFR2 showed a Grb2 phosphorylation signal upon 
phosphotyrosine immunoblotting. But, when the cells were stimulated with FGF9, the 
phosphotyrosine signal decreased, suggesting a potential protein that could be 
activated by FGF9 stimulation and therefore dephosphorylate Grb2. HEK 293 cells 
stably expressing FGFR2 were transfected with wild-type Grb2, Grb2 Y7F or Grb2 
Y52F mutant to understand the roles of Grb2 phosphorylation in FGFR2 and ERK 
phosphorylation. This experiment suggests that Grb2 Y7F and Y52F mutants could 
enhance FGFR2 phosphorylation and down-regulate FGF-induced ERK activation. 
This may due to altered binding affinity of Grb2 Y/F mutants towards FGFR2. 
However, the role of Grb2 Y/F mutants in FGFR2-mediated signalling pathway 
remains unknown and needs to be investigated thoroughly in the future. 
 
Furthermore, both Grb2 and phospho-Grb2 can directly interact with the two SH2 
domains of SHP2. In the unphosphorylated state of Grb2, the interaction between 
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Grb2 and SHP2 is mainly mediated by Grb2 SH3 domain(s) binding to the RXXK 
motif of the N-terminal SHP2 SH2 domain. This Grb2 SH3 domain–mediated 
interaction explains why all of the SH2 R/A mutants could still pull down Grb2. 
However, the N-terminal domain of SHP2 alone seems to play a major role in 
phospho-Grb2-SHP2 binding when Grb2 is phosphorylated. The ITC studies also 
confirm the direct interactions of Grb2 and phospho-Grb2 with SHP2, although the 
ideal titration curves were not obtained. Importantly, SHP2 dephosphorylated 
phospho-Grb2 in vitro, as shown by anti-phosphotyrosine immunoblot. Therefore, we 
propose that the dephosphorylation of Grb2 by SHP2 may play a role in recycling 
Grb2 in vivo. 
 
In conclusion, this chapter describes the mechanism of Grb2 phosphorylation and its 
role in FGFR2-mediated signalling. This finding is significant because Grb2 
phosphorylation may be important in regulating the FGFR2 signalling pathway. Some 
of the data are only based on preliminary studies, and the role of Grb2 
phosphorylation in cellular signalling remains unclear.  More detailed studies will be 
carried out to investigate the role of Grb2 phosphorylation in the FGFR2-mediated 
signalling pathway. 
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Chapter 5 
 
 
Summary 
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The aim of this study is to investigate the role of Grb2 in FGFR2 signalling using 
both in vivo and in vitro approaches. 
Grb2 regulates FGFR2 activation. Grb2, an adaptor protein, lacks enzymatic activity 
and is thought to be involved in signalling by mediating specific protein-protein 
interactions that lead to the formation of signalling complexes and prevent the 
corruption between two different signalling pathways. This study provides evidence 
that Grb2 not only takes part in the assembly of the early signalling complex upon 
FGFR2 stimulation but is also able to enhance FGFR2 phosphorylation by inducing a 
conformational change in FGFR2 and preventing phosphatase binding, suggesting a 
novel role for Grb2 in regulating FGFR2 activity.  
Few reports have shown that Grb2 can be phosphorylated by tyrosine kinases, and the 
effect of Grb2 phosphorylation on signalling remains unclear. Grb2 is phosphorylated 
on tyrosine 209 upon EGF stimulation256, and tyrosine 160 has been reported to be 
phosphorylated by pp60c-src 255.  The present study shows that Grb2 can be tyrosine 
phosphorylated by FGFR2 both in vivo and in vitro, dependent on the direct binding 
of Grb2 to the C-terminal tail of FGFR2. Three tyrosine phosphorylation sites on 
Grb2 have been identified: tyrosines 7, 52 and 160. These additional phosphorylation 
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sites suggest a different role for Grb2 phosphorylation in the FGFR2 signalling 
pathway compared to the EGFR signalling pathway. Exogenous expression of the 
Grb2 Y7F and Y52F mutants may be able to enhance the phosphorylation of FGFR2 
in serum-deprived HEK293T cells. Phosphorylation of Grb2 Y7F and Y52F may 
reduce FGF-stimulated ERK1/2 activation, which opposes the effect of the Grb2 
Y209F mutant in increasing EGF-stimulated ERK1/2 activation. These data indicate 
that variations in Grb2 phosphorylation may modulate different signalling pathways. 
However, the in vivo investigation of Grb2 phosphorylation and its effects on 
FGFR2-mediated signalling remain unclear. 
Biophysical studies were used to characterise the protein-protein interactions involved 
in the early signalling complex formation of FGFR2 signalling. The two-site binding 
model of Grb2 binding to FGFR2 is presented, which offers more details than the 
binding studies using peptides. Additionally, Grb2 binding to phosphorylated FGFR2 
in vitro is investigated using surface plasmon resonance (SPR), which also shows 
direct binding of Grb2 to phosphorylated FGFR2 via the SH3 domain of Grb2. 
Moreover, phospho-Grb2 has been shown to be unable to bind to FGFR2, which 
suggests a molecular switch mechanism for the Grb2-FGFR2 interaction. 
229 
 
Furthermore, we examined the role of SHP2 in FGFR2-Grb2 binding and FGFR2 
activation. This study shows the direct interaction of SHP2 with activated FGFR2 and 
phospho-Grb2 in vitro. Direct binding of the SHP2 C-SH2 domain to the C-terminal 
tail of activated FGFR2 is thought to be important in the repression of FGFR2 
activation, while direct binding of SHP2 to phospho-Grb2 is necessary for Grb2 
dephosphorylation.  
Taken together, this study provides new insights into the role of Grb2 in FGFR2 
signalling. We present a model for FGFR2 regulation through the dynamic formation 
of protein-protein interactions. 
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5.1 The FGFR2 early signal complex recruitment model  
O’Rourke and Ladbury have discussed the importance of signalling complex 
formation in the RTK signalling pathway43. Together with the studies carried out in 
Chapters 3 and 4, the following FGFR2 signalling complex formation and FGFR2 
signalling pathway activation model is proposed (Figure 5.1). Grb2 binds to inactive 
FGFR2 via its C-SH3 domain, resulting in a conformational change and an increase in 
FGFR2 activity (Figure 5.1 A). In this state, the direct binding of Grb2 to FGFR2 
inhibits the recruitment of SHP2 to FGFR2, which is important in preventing 
SHP2-mediated FGFR2 dephosphorylation (Figure 5.1 B). Early studies indicated that 
the dimerisation of the FGF receptor is due to the cooperation of the extracellular 
domain in binding to FGF ligands and heparan sulphate proteoglycans. However, our 
studies propose that Grb2 may also be able to cause the dimerisation of FGFR2. Once 
FGFR2 molecules begin to be activated and phosphorylated, the conformation of 
FGFR2 changes. The C-terminal tail of FGFR2 with Grb2 would loop back and bind 
to the kinase domain (unpublished data), bringing Grb2 to the kinase domain for 
subsequent phosphorylation (Figure 5.1 C). Phosphorylated Grb2 cannot bind to 
activated FGFR2 (Figure 5.1 D) and is therefore released. The SH2 
domain-containing phosphatase SHP2 is then recruited to the activated FGFR2, 
mediated by binding of the SHP2 C-SH2 domain to the phosphotyrosine residues on 
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the FGFR2 C-terminal tail, causing site-specific dephosphorylation of FGFR2 (Figure 
5.1 E). SHP2 can also bind to the released tyrosine-phosphorylated Grb2 via its 
N-SH2 domain and subsequently dephosphorylate Grb2. The SHP2-dephosphorylated 
Grb2 and FGFR2 are then ready for a new cycle of FGFR2 activation (Figure 5.1 F). 
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Figure 5.1: Diagrammatic representation of FGFR2 activation and the signalling 
complex recruitment. Grb2 binds to inactivated FGFR2 via SH3 domains, resulting in 
conformational change and preferential activation of FGFR2, this direct binding of Grb2 to 
FGFR2 also inhibits the recruitment of SHP2 to FGFR2. Grb2 is phoshporylated by the 
activated FGFR2, and the phosphorylated Grb2 no longer bind to the activated FGFR2. The 
SH2 domain-containing phosphatase SHP2 is recruited to the activated FGFR2 via binding of 
SHP2 C-SH2 domain to the phosphotyrosine residues on the FGFR2 C-terminal tail, and 
causes the site-specific dephosphorylation of FGFR. SHP2 can also binds to the released 
tyrosine phosphorylated Grb2 via SHP2 N-SH2 domain and dephosphorylates the 
phospho-Grb2. The SHP2-dephosphorylated Grb2 and FGFR2 therefore can restart the 
FGFR2 signalling pathway.  
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5.2 Future work 
5.2.1 Does Grb2 binding induce conformational changes in FGFR2? 
Both previous work by Ahmed et al.173 and this study show direct interaction between 
Grb2 and FGFR2. Dot-blot experiments suggest that binding of Grb2 to FGFR2 may 
expose the buried phosho-tyrosines of FGFR2. Additionally, this study provides 
evidence that Grb2 can enhance FGFR2 phosphorylation in vitro. Based on these 
findings, we propose that the direct binding of Grb2 to FGFR2 may cause a 
conformational change of FGFR2 that is preferential for phosphorylation.  
 
Direct evidence addressing a Grb2-induced FGFR2 conformational change will be 
dependent on structural studies. However, because there is no structural information 
currently available, different approaches may be used to investigate the 
conformational change. First, the small-angle X-ray scattering (SAXS) method will be 
employed to study the overall conformation of the FGFR2 cytoplasmic domain in the 
absence or presence of Grb2. Because the stability of Grb2-FGFR2 complexes has 
previously caused technical challenges, bis(sulfosuccinimidyl) suberate (BS3) will be 
used to cross-link Grb2 and FGFR2.  
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An alternative approach to determine the Grb2 binding-induced FGFR2 
conformational changes will be fluorescence-based. Fluorescence resonance energy 
transfer (FRET) has been demonstrated to be a powerful tool for studying protein 
structure268. Using fluorescent tags, such as N-terminal-tagged CFP and 
C-terminal-tagged YFP, conformational changes, including the distance and the 
orientation of biological macromolecules, have been successfully monitored. Recently, 
the remarkable development of single-molecule spectroscopy has provided an 
advantage in studying protein conformational changes within a single molecule 
range269. However, the use of fluorescent proteins as the FRET donor or acceptor may 
interfere with the native protein structure and function because of their large size270. 
Therefore, Kajihara et al. developed the position-specific incorporation of fluorescent 
amino acids that function as fluorescent donors and acceptors and have limited effects 
on protein structure and function271. Most recently, Santoso et al. used 
single-molecule FRET technology to study the conformational transitions in DNA 
polymerase I272.  
 
5.2.2 The detailed model of FGFR2- Grb2 binding 
Based on the two-site binding model presented in this study, it is necessary to identify 
the secondary binding site for Grb2 on FGFR2. Four PXXP motifs can be found on 
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the C-terminal tail of FGFR2; therefore, recombinant cytoplasmic domain constructs 
with different PXXP motif mutants (Pro to Ala mutations) will be generated for the 
identification of the secondary binding site.  
 
The detailed mechanism of FGFR2 binding to Grb2 still remains unclear. To date, we 
can only conclude that the Grb2 C-SH3 domain is the major contributor involved in 
binding to the PXXP motif of FGFR2, which is reflected in our two-site binding 
model. However, it is not clear whether the N-SH3 domain or the C-SH3 domain 
mediates the secondary binding event of the two-site binding model. In this study, 
both isothermal titration calorimetry (ITC) and SPR approaches did not detect any 
interaction between the N-SH3 domain and FGFR2. However, one of our earlier 
studies shows direct interaction between the N-terminal SH3 domain of Grb2 and 
FGFR2: the GST-tagged N-SH3 domain of Grb2 is able to pull down wild-type 
FGFR2 from HEK 293 cells both before and after stimulation. In contrast with HEK 
293 cells, the same result could not be duplicated using NIH-3T3 cells. Moreover, 
fluorescence lifetime imaging microscopy (FLIM) also shows direct interaction 
between the N-terminal SH3 domain of Grb2 and FGFR2 in unstimulated HEK 293 
cells. In vivo binding of the Grb2 N-SH3 domain to FGFR2 may be cell type–specific.  
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Once the secondary binding site has been identified, amino acid sequence–relevant 
peptides will be synthesised, and both N-SH3 and C-SH3 domain proteins or 
N-SH3/C-SH3 with Grb2 will be components in a competition-binding assay using 
both ITC and SPR technology or the alternative fluorescent-based assay. Hopefully, 
this study will allow us to provide a more detailed model of the interaction between 
FGFR2 and Grb2. 
 
5.2.3 The role of Grb2 phosphorylation in FGFR2-mediated 
signalling 
This study shows that Grb2 can be tyrosine phosphorylated by FGFR2 both in vitro 
and in vivo and identifies the phosphorylation sites on Grb2. Although this study has 
shown that Grb2 phosphorylation is the key mechanism controlling FGFR2 binding, 
the function of Grb2 phosphorylation in FGFR2 signalling remains unclear.  
 
In Chapter 3, we show that direct binding of Grb2 to FGFR2 is necessary for 
Grb2-mediated FGFR2 phosphorylation. However, in vitro binding studies provide 
clear evidence that Grb2 is released from FGFR2 once it is phosphorylated by FGFR2. 
Therefore, we propose a potential role for Grb2 phosphorylation in regulating FGFR2 
signalling.   
237 
 
Our in vivo study proposes that Grb2 phosphorylation may be involved in regulating 
FGFR2 and ERK1/2 phosphorylation. However, this hypothesis is based on a single 
experiment prior to checking reproducibility. To rigorously investigate the role of 
Grb2 phosphorylation in FGFR2-mediated signalling, several additional experiments 
are necessary.  
 
First, the experiment shown in Figure 4.10 needs to be repeated, and proper controls 
need to be employed to make a solid conclusion regarding the effects of Grb2 Y/F 
mutants on FGFR2 and ERK1/2 activation. The phosphorylation status of Grb2 Y/F 
mutants in response to FGF9 stimulation will also be examined.  
 
Second, we have shown that Grb2 is tyrosine phosphorylated in FGFR2-expressing 
HEK 293 cells. Interestingly, the phosphorylation level of Grb2 goes down in 
response to FGF9 stimulation. SHP2 may be activated by FGFR2 in response to 
FGF9, in which case activated SHP2 would dephosphorylate Grb2. In vitro 
experiments have demonstrated that SHP2 can bind to phospho-Grb2 directly and that 
SHP2 can dephopshorylate phospho-Grb2. However, the exact role of SHP2 in Grb2 
phosphorylation is still unclear. The SHP2 inhibitor NSC87877 will be included in 
this experiment to elucidate the role of SHP2 in Grb2 dephosphorylation. Both 
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serum-starved and FGF9-stimulated FGFR2-expressing cells will be treated with the 
SHP2 inhibitor NSC87877. Together with other NSC87877-free controls, 
immunoprecipitation will be carried out using an anti-Grb2 antibody, and different 
antibodies will be used to investigate the immunoprecipitated complex. 
SHP2-knockdown cell lines would be a useful material in this part of study. Both 
FGFR2-expressing cell lines and FGFR2-expressing/SHP2-knockdown cell lines will 
be used to compare the effects of SHP2 expression on Grb2 phosphorylation. 
Immunoprecipitation will be carried out using an anti-Grb2 antibody, and an 
anti-phosphotyrosine antibody will be used to illustrate the phosphorylation status of 
precipitated Grb2.  
  
Finally, Li et al.256 have shown that phosphorylation of Grb2 tyrosine 209 reduces its 
binding to Sos. Because Grb2 is phosphorylated by FGFR2 at tyrosines 7, 52 and 160, 
we will also examine the effects of these three tyrosine phosphorylation sites on 
Grb2-Sos complex formation. FGFR2-expressing cell lines transfected with different 
Grb2 mutants will be used to study Grb2-Sos complex formation. 
Immunoprecipitation will be carried out using an anti-Grb2 antibody and an anti-Sos 
antibody to understand the effects of variant Grb2 Y/F mutants on Grb2-Sos complex 
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formation. Lastly, we will examine possible contributions of Grb2 Y/F mutant 
expression to FGFR2-mediated signalling that lead to active Ras.  
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